{"title": "PDF", "author": "PDF", "url": "https://docs.house.gov/billsthisweek/20150706/CPRT-114-HPRT-RU00-HR6.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "JULY 2, 2015 RULES COMMITTEE PRINT 114-22 TEXT OF H.R. 6, 21 STCENTURY CURES ACT [Showing text based on H.R. 6 as ordered reported by the Committee on Energy and Commerce.] SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 1 (a) S HORT TITLE.\u2014This Act may be cited as the 2 ''21st Century Cures Act''. 3 (b) T ABLE OF CONTENTS .\u2014The table of contents for 4 this Act is as follows: 5 Sec. 1. Short title; table of contents. Sec. 2. NIH and Cures Innovation Fund. TITLE I\u2014DISCOVERY Subtitle A\u2014National Institutes of Health Funding Sec. 1001. National Institutes of Health reauthorization. Subtitle B\u2014National Institutes of Health Planning and Administration Sec. 1021. NIH research strategic plan. Sec. 1022. Increasing accountability at the National Institutes of Health. Sec. 1023. Reducing administrative burdens of researchers. Sec. 1024. Exemption for the National Institutes of Health from the Paper- work Reduction Act requirements. Sec. 1025. NIH travel. Sec. 1026. Other transactions authority. Sec. 1027. NCATS phase IIB restriction. Sec. 1028. High-risk, high-reward research. Sec. 1029. Sense of Congress on increased inclusion of underrepresented com- munities in clinical trials. Subtitle C\u2014Supporting Young Emerging Scientists Sec. 1041. Improvement of loan repayment programs of the National Institutes of Health. Sec. 1042. Report. Subtitle D\u2014Capstone Grant Program Sec. 1061. Capstone award. VerDate Nov 24 2008 11:47 Subtitle E\u2014Promoting Pediatric Research Through the National Institutes of Health Sec. 1081. National pediatric research network. Sec. 1082. Global pediatric clinical study network sense of Congress. Sec. 1083. Appropriate age groupings in clinical research. Subtitle F\u2014Advancement of the National Institutes of Health Research and Data Access Sec. 1101. Standardization of data in Clinical Trial Registry Data Bank on eli- gibility for clinical trials. Subtitle G\u2014Facilitating Collaborative Research Sec. 1121. Clinical trial data system. Sec. 1122. National neurological diseases surveillance system. Sec. 1123. Data on natural history of diseases. Sec. 1124. Accessing, sharing, and using health data for research purposes. Subtitle H\u2014Council for 21st Century Cures Sec. 1141. Council for 21st Century Cures. TITLE II\u2014DEVELOPMENT Subtitle A\u2014Patient-Focused Drug Development Sec. 2001. Development and use of patient experience data to enhance struc- tured risk-benefit assessment framework. Subtitle B\u2014Qualification and Use of Drug Development Tools Sec. 2021. Qualification of drug development tools. Sec. 2022. Accelerated approval development plan. Subtitle C\u2014FDA Advancement of Precision Medicine Sec. 2041. Precision medicine guidance and other programs of Food and Drug Administration. Subtitle D\u2014Modern Trial Design and Evidence Development Sec. 2061. Broader application of Bayesian statistics and adaptive trial designs. Sec. 2062. Utilizing evidence from clinical experience. Sec. 2063. Streamlined data review program. Subtitle E\u2014Expediting Patient Access Sec. 2081. Sense of Congress. Sec. 2082. Expanded access policy. Sec. 2083. Finalizing draft guidance on expanded access. Subtitle F\u2014Facilitating Responsible Manufacturer Communications Sec. 2101. Facilitating dissemination of health care economic information. Sec. 2102. Facilitating responsible communication of scientific and medical de- velopments. Subtitle G\u2014Antibiotic Drug Development VerDate Nov 24 2008 Sec. 2121. Approval of certain drugs for use in a limited population of patients. Sec. 2122. Susceptibility test interpretive criteria for microorganisms. Sec. 2123. Encouraging the development and use of DISARM drugs. Subtitle H\u2014Vaccine Access, Certainty, and Innovation Sec. 2141. Timely review of vaccines by the Advisory Committee on Immuniza- tion Practices. Sec. 2142. Review of processes and consistency of ACIP recommendations. Sec. 2143. Meetings between CDC and vaccine developers. Subtitle I\u2014Orphan Product Extensions Now; Incentives for Certain Products for Limited Populations Sec. 2151. Extension of exclusivity periods for a drug approved for a new indi- cation for a rare disease or condition. Sec. 2152. Reauthorization of rare pediatric disease priority review voucher in- centive program. Subtitle J\u2014Domestic Manufacturing and Export Efficiencies Sec. 2161. Grants for studying the process of continuous drug manufacturing. Sec. 2162. Re-exportation among members of the European Economic Area. Subtitle K\u2014Enhancing Combination Products Review Sec. 2181. Enhancing combination products review. Subtitle L\u2014Priority Review for Breakthrough Devices Sec. 2201. Priority review for breakthrough devices. Subtitle M\u2014Medical Device Regulatory Process Improvements Sec. 2221. Third-party quality system assessment. Sec. 2222. Valid scientific evidence. Sec. 2223. Training and oversight in least burdensome appropriate means con- cept. Sec. 2224. Recognition of standards. Sec. 2225. Easing regulatory burden with respect to certain class I and class II devices. Sec. 2226. Advisory committee process. Sec. 2227. Humanitarian device exemption application. Sec. 2228. CLIA waiver study design guidance for in vitro diagnostics. Subtitle N\u2014Sensible Oversight for Technology Which Advances Regulatory Efficiency Sec. 2241. Health software. Sec. 2242. Applicability and inapplicability of regulation. Sec. 2243. Exclusion from definition of device. Subtitle O\u2014Streamlining Clinical Trials Sec. 2261. Protection of human subjects in research; applicability of rules. Sec. 2262. Use of non-local institutional review boards for review of investiga- tional device exemptions and human device exemptions. Sec. 2263. Alteration or waiver of informed consent for clinical investigations. VerDate Nov 24 2008 11:47 Jul 02, P\u2014Improving Scientific Expertise and Outreach at FDA Sec. 2281. Silvio O. Conte Senior Biomedical Research Service. Sec. 2282. Enabling FDA scientific engagement. Sec. 2283. Reagan-Udall Foundation for the Food and Drug Administration. Sec. 2284. Collection of certain voluntary information exempted from Paper- work Reduction Act. Sec. 2285. Hiring authority for scientific, technical, and professional personnel. Subtitle Q\u2014Exempting From Sequestration Certain User Fees Sec. 2301. Exempting from sequestration certain user fees of Food and Drug Administration. TITLE III\u2014DELIVERY Subtitle A\u2014Interoperability Sec. 3001. Ensuring interoperability of health information technology. Subtitle B\u2014Telehealth Sec. 3021. Telehealth services under the Medicare program. Subtitle C\u2014Encouraging Continuing Medical Education for Physicians Sec. 3041. Exempting from manufacturer transparency reporting certain trans- fers used for educational purposes. Subtitle D\u2014Disposable Medical Technologies Sec. 3061. Treatment of certain items and devices. Subtitle E\u2014Local Coverage Decision Reforms Sec. 3081. Improvements in the Medicare local coverage determination (LCD) process. Subtitle F\u2014Medicare Pharmaceutical and Technology Ombudsman Sec. 3101. Medicare pharmaceutical and technology ombudsman. Subtitle G\u2014Medicare Site-of-Service Price Transparency Sec. 3121. Medicare site-of-Service price transparency. Subtitle H\u2014Medicare Part D Patient Safety and Drug Abuse Prevention Sec. 3141. Programs to prevent prescription drug abuse under Medicare parts C and D. TITLE IV\u2014MEDICAID, MEDICARE, AND OTHER REFORMS Subtitle A\u2014Medicaid and Medicare Reforms Sec. 4001. Limiting Federal Medicaid reimbursement to States for durable medical equipment (DME) to Medicare payment rates. Sec. 4002. Excluding authorized generics from calculation of average manufac- turer price. VerDate Nov 24 2008 11:47 Sec. 4003. Medicare payment incentive for the transition from traditional x-ray imaging to digital radiography and other Medicare imaging payment provision. Sec. 4004. Treatment of infusion drugs furnished through durable medical equipment. Sec. 4005. Extension and expansion of prior authorization for power mobility devices (PMDs) and accessories and prior authorization audit limitations. Sec. 4006. Civil monetary penalties for violations related to grants, contracts, and other agreements. Subtitle B\u2014Other Reforms Sec. 4041. SPR drawdown. Subtitle C\u2014Miscellaneous Sec. 4061. Lyme disease and other tick-borne diseases. SEC. 2. NIH AND CURES INNOVATION FUND. 1 (a) E STABLISHMENT .\u2014There is hereby established in 2 the Treasury of the United States a fund to be known 3 as the NIH and Cures Innovation Fund. 4 (b) A MOUNTS MADE AVAILABLE TO FUND.\u2014 5 (1) I N GENERAL .\u2014There is authorized to be 6 appropriated, and appropriated, to the NIH and 7 Cures Innovation Fund, out of any funds in the 8 Treasury not otherwise appropriated, 9 $1,860,000,000 for each of fiscal years 2016 10 through 2020. The amounts appropriated to the 11 NIH and Cures Innovation Fund by the preceding 12 sentence shall be in addition to any amounts other- 13 wise made available to the Department of Health 14 and Human Services. 15 VerDate Nov 24 2008 11:47 Jul 02, A LLOCATION OF AMOUNTS .\u2014Of the 1 amounts made available from the NIH and Cures 2 Innovation Fund for a fiscal year\u2014 3 (A) $1,750,000,000 shall be for biomedical 4 research of the National Institutes of Health 5 under subsection (c)(1), of which\u2014 6 (i) not less than $500,000,000 shall 7 be for the Accelerating Advancement Pro- 8 gram under subsection (d)(2); 9 (ii) not less than 35 percent of such 10 amounts remaining after subtracting the 11 allocation for the Accelerating Advance- 12 ment Program shall be for early stage in- 13 vestigators as defined in subsection (g); 14 (iii) not less than 20 percent of such 15 amounts remaining after subtracting the 16 allocation for the Accelerating Advance- 17 ment Program shall be for high-risk, high- 18 reward research under section 409K of the 19 Public Health Service Act, as added by 20 section 1028; and 21 (iv) not more than 10 percent of such 22 amounts (without subtracting the alloca- 23 tion for the Accelerating Advancement 24 VerDate Nov 24 2008 11:47 Jul 02, be for intramural research; 1 and 2 (B) $110,000,000 shall be for carrying out 3 the provisions listed in subsection (c)(2). 4 (3) I NAPPLICABILITY OF CERTAIN PROVI - 5 SIONS .\u2014Amounts in the NIH and Cures Innovation 6 Fund (including amounts made available to the Na- 7 tional Institutes of Health) shall not be subject to\u2014 8 (A) any transfer authority of the Secretary 9 of Health and Human Services or the Director 10 of the National Institutes of Health under sec- 11 tions 241, 402A(c), or 402A(d) of the Public 12 Health Service Act (42 U.S.C. 238j, 282a(c) 13 and (d)) or any other provision of law (other 14 than this section); or 15 (B) the Nonrecurring expenses fund under 16 section 223 of division G of the Consolidated 17 Appropriations Act, 2008 (42 U.S.C. 3514a). 18 (c) A UTHORIZED USES.\u2014 19 (1) NIH BIOMEDICAL RESEARCH .\u2014Amounts in 20 the NIH and Cures Innovation Fund that are allo- 21 cated pursuant to subsection (b)(2)(A) may only be 22 used for the purpose of conducting or supporting 23 biomedical research (including basic, translational, 24 and clinical research) through the following: 25 VerDate Nov 24 2008 11:47 Jul (A) Research in which\u2014 1 (i) a principal investigator has a spe- 2 cific project or specific objectives; and 3 (ii) funding is tied to pursuit of such 4 project or objectives. 5 (B) Research in which\u2014 6 (i) a principal investigator has shown 7 promise in biomedical research; and 8 (ii) funding is not tied to a specific 9 project or specific objectives. 10 (C) Research to be carried out by an early 11 stage investigator (as defined in subsection (g)). 12 (D) Research to be carried out by a small 13 business concern (as defined in section 3 of the 14 Small Business Act). 15 (E) The Accelerating Advancement Pro- 16 gram under subsection (d)(2). 17 (F) Development and implementation of 18 the strategic plan under subsection (d)(3). 19 (2) C URES DEVELOPMENT .\u2014Amounts in the 20 NIH and Cures Innovation Fund that are allocated 21 pursuant to subsection (b)(2)(B) may only be used 22 for the purpose of carrying out the following provi- 23 sions: 24 VerDate Nov 24 2008 11:47 (A) Section 229A of the Public Health 1 Service Act, as added by section 1123 (relating 2 to data on natural history of diseases). 3 (B) Section 2001 and the amendments 4 made by such section (relating to development 5 and use of patient experience data to enhance 6 structured risk-benefit assessment framework). 7 (C) Section 2021 and the amendments 8 made by such section (relating to qualification 9 of drug development tools). 10 (D) Section 2062 and the amendments 11 made by such section (relating to utilizing evi- 12 dence from clinical experience). 13 (E) Section 2161 (relating to grants for 14 studying the process of continuous drug manu- 15 facturing). 16 (F) Section 2201 and the amendments 17 made by such section (relating to priority re- 18 view for breakthrough devices). 19 (G) Section 2221 and the amendments 20 made by such section (relating to third-party 21 quality system assessments). 22 (H) Sections 2241, 2242, and 2243 and 23 the amendments made by such sections (relat- 24 ing to health software). 25 VerDate Nov 24 2008 11:47 Jul 02, (I) Section 513(j) of the Federal Food, 1 Drug, and Cosmetic Act, as added by section 2 2223 (relating to training and oversight in least 3 burdensome appropriate means concept). 4 (d) NIH I NNOVATION FUND.\u2014 5 (1) C OORDINATION .\u2014In conducting or sup- 6 porting biomedical research pursuant to funds allo- 7 cated pursuant to subsection (b)(2)(A), the Sec- 8 retary of Health and Human Services, acting 9 through the Director of the National Institutes of 10 Health, shall\u2014 11 (A) ensure coordination among the na- 12 tional research institutes, the national centers, 13 and other departments, agencies, and offices of 14 the Federal Government; and 15 (B) minimize unnecessary duplication. 16 (2) A CCELERATING ADVANCEMENT PROGRAM .\u2014 17 The Director of the National Institutes of Health 18 shall establish a program, to be known as the Accel- 19 erating Advancement Program, under which\u2014 20 (A) the Director partners with national re- 21 search institutes and national centers to accom- 22 plish important biomedical research objectives; 23 and 24 VerDate Nov 24 2008 11:47 Jul (B) for every $1 made available by the Di- 1 rector to a national research institute or na- 2 tional center for a research project, the insti- 3 tute or center makes $1 available for such 4 project from funds that are not derived from 5 the NIH and Cures Innovation Fund. 6 (3) S TRATEGIC PLAN .\u2014 7 (A) I N GENERAL .\u2014The Director of the 8 National Institutes of Health shall ensure that 9 scientifically based strategic planning is imple- 10 mented in support of research priorities, includ- 11 ing through development, use, and updating of 12 a research strategic plan that\u2014 13 (i) is designed to increase the efficient 14 and effective focus of biomedical research 15 in a manner that leverages the best sci- 16 entific opportunities through a deliberative 17 planning process; 18 (ii) identifies areas, to be known as 19 strategic focus areas, in which the re- 20 sources of the NIH and Cures Innovation 21 Fund can contribute to the goals of ex- 22 panding knowledge to address, and find 23 more effective treatments for, unmet med- 24 VerDate Nov 24 2008 11:47 Jul ical needs in the United States, including 1 the areas of\u2014 2 (I) biomarkers; 3 (II) precision medicine; 4 (III) infectious diseases, includ- 5 ing pathogens listed as a qualifying 6 pathogen under section 505E(f) of the 7 Federal Food, Drug, and Cosmetic 8 Act or listed or designated as a trop- 9 ical disease under section 524 of such 10 Act; and 11 (IV) antibiotics; 12 (iii) includes objectives for each such 13 strategic focus area; and 14 (iv) ensures that basic research re- 15 mains a priority. 16 (B) U PDATES AND REVIEWS .\u2014The Direc- 17 tor of the National Institutes of Health shall re- 18 view and, as appropriate, update the research 19 strategic plan under subparagraph (A) not less 20 than every 18 months. 21 (e) T RANSFER AUTHORITY .\u2014The Committee on Ap- 22 propriations of the Senate and the Committee on Appro-23 priations of the House of Representatives may provide for 24 VerDate Nov 24 2008 11:47 Jul 02, 13 the transfer of funds in the NIH and Cures Innovation 1 Fund for the purposes specified in subsection (c). 2 (f) S UPPLEMENT , NOTSUPPLANT ; LIMITATIONS .\u2014 3 Funds appropriated by subsection (b)\u2014 4 (1) shall be used to supplement, not supplant, 5 amounts otherwise made available to the Depart- 6 ment of Health and Human Services; 7 (2) are subject to the requirements and limita- 8 tions of the most recently enacted regular or full- 9 year continuing appropriation Act or resolution (as 10 of the date of obligation) for programs of the Na- 11 tional Institutes of Health or the Food and Drug 12 Administration, as applicable; and 13 (3) notwithstanding any transfer authority in 14 any appropriation Act, shall not be used for any 15 purpose other than the purposes specified in sub- 16 section (c). 17 (g) D EFINITION .\u2014In this subsection: 18 (1) The term ''early stage investigator'' means 19 an investigator who\u2014 20 (A) will be the principal investigator or the 21 program director of the proposed research; 22 (B) has never been awarded, or has been 23 awarded only once, a substantial, competing 24 VerDate Nov 24 2008 11:47 Jul 02, 14 grant by the National Institutes of Health for 1 independent research; and 2 (C) is within 10 years of having com- 3 pleted\u2014 4 (i) the investigator's terminal degree; 5 or 6 (ii) a medical residency (or the equiva- 7 lent). 8 (2) The terms ''national center'' and ''national 9 research institute'' have the meanings given to those 10 terms in section 401(g) of the Public Health Service 11 Act (42 U.S.C. 281(g)). 12 TITLE I\u2014DISCOVERY 13 Subtitle A\u2014National Institutes of 14 Health Funding 15 SEC. 1001. NATIONAL INSTITUTES OF HEALTH REAUTHOR-16 IZATION. 17 Section 402A(a)(1) of the Public Health Service Act 18 (42 U.S.C. 282a(a)(1)) is amended\u2014 19 (1) in subparagraph (B), by striking at the end 20 ''and''; 21 (2) in subparagraph (C), by striking at the end 22 the period and inserting a semicolon; and 23 (3) by adding at the end the following new sub- 24 paragraphs: 25 VerDate Nov 24 2008 11:47 2 ''(E) $33,331,000,000 for fiscal year 2017; 3 and 4 ''(F) $34,851,000,000 for fiscal year 5 2018.''. 6 Subtitle B\u2014National Institutes of 7 Health Planning and Adminis- 8 tration 9 SEC. 1021. NIH RESEARCH STRATEGIC PLAN. 10 Section 402 of the Public Health Service Act (42 11 U.S.C. 282) is amended\u2014 12 (1) in subsection (b), by amending paragraph 13 (5) to read as follows: 14 ''(5) shall ensure that scientifically based stra- 15 tegic planning is implemented in support of research 16 priorities as determined by the agencies of the Na- 17 tional Institutes of Health, including through devel- 18 opment, use, and updating of the research strategic 19 plan under subsection (m);''; and 20 (2) by adding at the end the following: 21 ''(m) R ESEARCH STRATEGIC PLAN.\u2014 22 ''(1) F IVE-YEAR PLANS FOR BIOMEDICAL RE - 23 SEARCH STRATEGY .\u2014 24 VerDate Nov 24 2008 11:47 Jul 02, N GENERAL .\u2014For each successive 1 five-year period beginning with the period of fis- 2 cal years 2016 through 2020, the Director of 3 NIH, in consultation with the entities described 4 in subparagraph (B), shall develop and main- 5 tain a biomedical research strategic plan that\u2014 6 ''(i) is designed to increase the effi- 7 cient and effective focus of biomedical re- 8 search in a manner that leverages the best 9 scientific opportunities through a delibera- 10 tive planning process; 11 ''(ii) identifies areas, to be known as 12 strategic focus areas, in which the re- 13 sources of the National Institutes of 14 Health can best contribute to the goal of 15 expanding knowledge on human health in 16 the United States through biomedical re- 17 search; and 18 ''(iii) includes objectives for each such 19 strategic focus area. 20 ''(B) E NTITIES DESCRIBED .\u2014The entities 21 described in this subparagraph are the directors 22 of the national research institutes and national 23 centers, researchers, patient advocacy groups, 24 and industry leaders. 25 VerDate Nov 24 2008 11:47 Jul 02, U SE OF PLAN .\u2014The Director of NIH and 1 the directors of the national research institutes and 2 national centers shall use the strategic plan\u2014 3 ''(A) to identify research opportunities; 4 and 5 ''(B) to develop individual strategic plans 6 for the research activities of each of the na- 7 tional research institutes and national centers 8 that\u2014 9 ''(i) have a common template; and 10 ''(ii) identify strategic focus areas in 11 which the resources of the national re- 12 search institutes and national centers can 13 best contribute to the goal of expanding 14 knowledge on human health in the United 15 States through biomedical research. 16 ''(3) C ONTENTS OF PLANS .\u2014 17 ''(A) S TRATEGIC FOCUS AREAS .\u2014The stra- 18 tegic focus areas identified pursuant to para- 19 graph (1)(A)(ii) shall\u2014 20 ''(i) be identified in a manner that\u2014 21 ''(I) considers the return on in- 22 vestment to the United States public 23 through the investments of the Na- 24 VerDate Nov 24 2008 11:47 Jul 02, Health in bio- 1 medical research; and 2 ''(II) contributes to expanding 3 knowledge to improve the United 4 States public's health through bio- 5 medical research; and 6 ''(ii) include overarching and trans- 7 National Institutes of Health strategic 8 focus areas, to be known as Mission Pri- 9 ority Focus Areas, which best serve the 10 goals of preventing or eliminating the bur- 11 den of a disease or condition and scientif- 12 ically merit enhanced and focused research 13 over the next 5 years. 14 ''(B) R ARE AND PEDIATRIC DISEASES AND 15 CONDITIONS .\u2014In developing and maintaining a 16 strategic plan under this subsection, the Direc- 17 tor of NIH shall ensure that rare and pediatric 18 diseases and conditions remain a priority. 19 ''(C) W ORKFORCE .\u2014In developing and 20 maintaining a strategic plan under this sub- 21 section, the Director of NIH shall ensure that 22 maintaining the biomedical workforce of the fu- 23 ture, including the participation by scientists 24 VerDate Nov 24 2008 11:47 Jul 02, 19 from groups traditionally underrepresented in 1 the scientific workforce, remains a priority. 2 ''(4) I NITIAL PLAN .\u2014Not later than 270 days 3 after the date of enactment of this subsection, the 4 Director of NIH and the directors of the national re- 5 search institutes and national centers shall\u2014 6 ''(A) complete the initial strategic plan re- 7 quired by paragraphs (1) and (2); and 8 ''(B) make such initial strategic plan pub- 9 licly available on the website of the National In- 10 stitutes of Health. 11 ''(5) R EVIEW ; UPDATES .\u2014 12 ''(A) P ROGRESS REVIEWS .\u2014Not less than 13 annually, the Director of NIH, in consultation 14 with the directors of the national research insti- 15 tutes and national centers, shall conduct 16 progress reviews for each strategic focus area 17 identified under paragraph (1)(A)(ii). 18 ''(B) U PDATES .\u2014Not later than the end of 19 the 5-year period covered by the initial strategic 20 plan under this subsection, and every 5 years 21 thereafter, the Director of NIH, in consultation 22 with the directors of the national research insti- 23 tutes and national centers, stakeholders in the 24 VerDate Nov 24 2008 11:47 Jul 02, 20 scientific field, advocates, and the public at 1 large, shall\u2014 2 ''(i) conduct a review of the plan, in- 3 cluding each strategic focus area identified 4 under paragraph (2)(B); and 5 ''(ii) update such plan in accordance 6 with this section.''. 7 SEC. 1022. INCREASING ACCOUNTABILITY AT THE NA-8 TIONAL INSTITUTES OF HEALTH. 9 (a) A PPOINTMENT AND TERMS OF DIRECTORS OF 10 NATIONAL RESEARCH INSTITUTES AND NATIONAL CEN- 11 TERS .\u2014Subsection (a) of section 405 of the Public Health 12 Service Act (42 U.S.C. 284) is amended to read as follows: 13 ''(a) A PPOINTMENT ; TERMS .\u2014 14 ''(1) A PPOINTMENT .\u2014The Director of the Na- 15 tional Cancer Institute shall be appointed by the 16 President and the directors of the other national re- 17 search institutes, as well as the directors of the na- 18 tional centers, shall be appointed by the Director of 19 NIH. The directors of the national research insti- 20 tutes, as well as national centers, shall report di- 21 rectly to the Director of NIH. 22 ''(2) T ERMS .\u2014 23 VerDate Nov 24 2008 11:47 I N GENERAL .\u2014The term of office of 1 a director of a national research institute or na- 2 tional center shall be 5 years. 3 ''(B) R EMOVAL .\u2014The director of a na- 4 tional research institute or national center may 5 be removed from office by the Director of NIH 6 prior to the expiration of such director's 5-year 7 term. 8 ''(C) R EAPPOINTMENT .\u2014At the end of the 9 term of a director of a national research insti- 10 tute or national center, the director may be re- 11 appointed. There is no limit on the number of 12 terms a director may serve. 13 ''(D) V ACANCIES .\u2014If the office of a direc- 14 tor of a national research institute or national 15 center becomes vacant before the end of such 16 director's term, the director appointed to fill the 17 vacancy shall be appointed for a 5-year term 18 starting on the date of such appointment. 19 ''(E) T RANSITIONAL PROVISION .\u2014Each di- 20 rector of a national research institute or na- 21 tional center serving on the date of enactment 22 of the 21st Century Cures Act is deemed to be 23 appointed for a 5-year term under this sub- 24 section starting on such date of enactment.''. 25 VerDate Nov 24 2008 11:47 Jul TO CONSULTANTS OR INDI- 1 VIDUAL SCIENTISTS .\u2014Section 202 of the Departments of 2 Labor, Health and Human Services, and Education, and 3 Related Agencies Appropriations Act, 1993 (Public Law 4 102-394; 42 U.S.C. 238f note) is amended by striking 5 ''portable structures;'' and all that follows and inserting 6 ''portable structures.''. 7 (c) R EVIEW OF CERTAIN AWARDS BY DIRECTORS .\u2014 8 Section 405(b) of the Public Health Service Act (42 9 U.S.C. 284(b)) is amended by adding at the end the fol-10 lowing: 11 ''(3) Before an award is made by a national research 12 institute or by a national center for a grant for a research 13 program or project (commonly referred to as an 'R-series 14 grant'), other than an award constituting a noncompeting 15 renewal of such grant, or a noncompeting administrative 16 supplement to such grant, the director of such national 17 research institute or national center\u2014 18 ''(A) shall review and approve the award; and 19 ''(B) shall take into consideration\u2014 20 ''(i) the mission of the national research 21 institute or national center and the scientific 22 priorities identified in the strategic plan under 23 section 402(m); and 24 VerDate Nov 24 2008 11:47 Jul ''(ii) whether other agencies are funding 1 programs or projects to accomplish the same 2 goal.''. 3 (d) IOM S TUDY ON DUPLICATION IN FEDERAL BIO- 4 MEDICAL RESEARCH .\u2014The Secretary of Health and 5 Human Services shall enter into an arrangement with the 6 Institute of Medicine of the National Academies (or, if the 7 Institute declines, another appropriate entity) under which 8 the Institute (or other appropriate entity) not later than 9 2 years after the date of enactment of this Act will\u2014 10 (1) complete a study on the extent to which bio- 11 medical research conducted or supported by Federal 12 agencies is duplicative; and 13 (2) submit a report to the Congress on the re- 14 sults of such study, including recommendations on 15 how to prevent such duplication. 16 SEC. 1023. REDUCING ADMINISTRATIVE BURDENS OF RE-17 SEARCHERS. 18 (a) P LAN PREPARATION AND IMPLEMENTATION OF 19 MEASURES TOREDUCE ADMINISTRATIVE BURDENS .\u2014 20 The Director of the National Institutes of Health shall 21 prepare a plan, including time frames, and implement 22 measures to reduce the administrative burdens of re-23 searchers funded by the National Institutes of Health, 24 VerDate Nov 24 2008 11:47 Jul 02, 24 taking into account the recommendations, evaluations, 1 and plans researched by the following entities: 2 (1) The Scientific Management Review Board. 3 (2) The National Academy of Sciences. 4 (3) The 2007 and 2012 Faculty Burden Survey 5 conducted by The Federal Demonstration Partner- 6 ship. 7 (4) Relevant recommendations from the Re- 8 search Business Models Working Group. 9 (b) R EPORT .\u2014Not later than two years after the date 10 of enactment of this Act, the Director of the National In-11 stitutes of Health shall submit to Congress a report on 12 the extent to which the Director has implemented meas-13 ures pursuant to subsection (a). 14 SEC. 1024. EXEMPTION FOR THE NATIONAL INSTITUTES OF 15 HEALTH FROM THE PAPERWORK REDUCTION 16 ACT REQUIREMENTS. 17 Section 3518(c)(1) of title 44, United States Code, 18 is amended\u2014 19 (1) in subparagraph (C), by striking ''; or'' and 20 inserting a semicolon; 21 (2) in subparagraph (D), by striking the period 22 at the end and inserting ''; or''; and 23 (3) by inserting at the end the following new 24 subparagraph: 25 VerDate Nov 24 2008 11:47 Jul ''(E) during the conduct of research by the Na- 1 tional Institutes of Health.''. 2 SEC. 1025. NIH TRAVEL. 3 It is the sense of Congress that participation in or 4 sponsorship of scientific conferences and meetings is es-5 sential to the mission of the National Institutes of Health. 6 SEC. 1026. OTHER TRANSACTIONS AUTHORITY. 7 Section 480 of the Public Health Service Act (42 8 U.S.C. 287a) is amended\u2014 9 (1) in subsection (b), by striking ''the appro- 10 priation of funds as described in subsection (g)'' and 11 inserting ''the availability of funds as described in 12 subsection (f)''; 13 (2) in subsection (e)(3), by amending subpara- 14 graph (C) to read as follows: 15 ''(C) O THER TRANSACTIONS AUTHORITY .\u2014 16 The Director of the Center shall have other 17 transactions authority in entering into trans- 18 actions to fund projects in accordance with the 19 terms and conditions of this section.''; 20 (3) by striking subsection (f); and 21 (4) by redesignating subsection (g) as sub- 22 section (f). 23 VerDate Nov 24 2008 11:47 Jul 02, NCATS PHASE IIB RESTRICTION. 1 Section 479 of the Public Health Service Act (42 2 U.S.C. 287) is amended\u2014 3 (1) prior to making the amendments under 4 paragraph (2), by striking ''IIB'' each place it ap- 5 pears and inserting ''III''; and 6 (2) by striking ''IIA'' each place it appears and 7 inserting ''IIB''. 8 SEC. 1028. HIGH-RISK, HIGH-REWARD RESEARCH. 9 Part B of title IV of the Public Health Service Act 10 (42 U.S.C. 284 et seq.) is amended by adding at the end 11 the following: 12 ''SEC. 409K. HIGH-RISK, HIGH-REWARD RESEARCH PRO-13 GRAM. 14 ''The director of each national research institute 15 shall, as appropriate\u2014 16 ''(1) establish programs to conduct or support 17 research projects that pursue innovative approaches 18 to major contemporary challenges in biomedical re- 19 search that involve inherent high risk, but have the 20 potential to lead to breakthroughs; and 21 ''(2) set aside a specific percentage of funding, 22 to be determined by the Director of NIH for each 23 national research institute, for such projects.''. 24 VerDate Nov 24 2008 11:47 Jul SEC. 1029. SENSE OF CONGRESS ON INCREASED INCLUSION 1 OF UNDERREPRESENTED COMMUNITIES IN 2 CLINICAL TRIALS. 3 It is the sense of Congress that the National Institute 4 on Minority Health and Health Disparities (NIMHD) 5 should include within its strategic plan ways to increase 6 representation of underrepresented communities in clinical 7 trials. 8 Subtitle C\u2014Supporting Young 9 Emerging Scientists 10 SEC. 1041. IMPROVEMENT OF LOAN REPAYMENT PRO-11 GRAMS OF THE NATIONAL INSTITUTES OF 12 HEALTH. 13 (a) I NGENERAL .\u2014Part G of title IV of the Public 14 Health Service (42 U.S.C. 288 et seq.) is amended\u2014 15 (1) by redesignating the second section 487F 16 (42 U.S.C. 288-6; relating to pediatric research loan 17 repayment program) as section 487G; and 18 (2) by inserting after section 487G, as so redes- 19 ignated, the following: 20 LOAN REPAYMENT PROGRAM. 21 ''(a) I NGENERAL .\u2014The Secretary shall establish a 22 program, based on workforce and scientific needs, of en-23 tering into contracts with qualified health professionals 24 under which such health professionals agree to engage in 25 research in consideration of the Federal Government 26 VerDate Nov 24 2008 11:47 Jul 02, 28 agreeing to pay, for each year of engaging in such re-1 search, not more than $50,000 of the principal and inter-2 est of the educational loans of such health professionals. 3 ''(b) A DJUSTMENT FOR INFLATION .\u2014Beginning with 4 respect to fiscal year 2017, the Secretary may increase 5 the maximum amount specified in subsection (a) by an 6 amount that is determined by the Secretary, on an annual 7 basis, to reflect inflation. 8 ''(c) L IMITATION .\u2014The Secretary may not enter into 9 a contract with a health professional pursuant to sub-10 section (a) unless such professional has a substantial 11 amount of educational loans relative to income. 12 ''(d) A PPLICABILITY OF CERTAIN PROVISIONS RE- 13 GARDING OBLIGATED SERVICE .\u2014Except to the extent in- 14 consistent with this section, the provisions of sections 15 338B, 338C, and 338E shall apply to the program estab-16 lished under this section to the same extent and in the 17 same manner as such provisions apply to the National 18 Health Service Corps Loan Repayment Program estab-19 lished under section 338B. 20 ''(e) A VAILABILITY OF APPROPRIATIONS .\u2014Amounts 21 appropriated for a fiscal year for contracts under sub-22 section (a) are authorized to remain available until the ex-23 piration of the second fiscal year beginning after the fiscal 24 year for which the amounts were appropriated.''. 25 VerDate Nov 24 2008 11:47 Jul (b) U PDATE OF OTHER LOAN REPAYMENT PRO- 1 GRAMS .\u2014 2 (1) Section 464z-5(a) of the Public Health 3 Service Act (42 U.S.C.285t-2(a)) is amended\u2014 4 (A) by striking ''$35,000'' and inserting 5 ''$50,000''; and 6 (B) by adding at the end the following new 7 sentence: ''Subsection (b) of section 487H shall 8 apply with respect to the maximum amount 9 specified in this subsection in the same manner 10 as it applies to the maximum amount specified 11 in subsection (a) of such section.''. 12 (2) Section 487A(a) of such Act (42 U.S.C. 13 288-1(a)) is amended\u2014 14 (A) by striking ''$35,000'' and inserting 15 ''$50,000''; and 16 (B) by adding at the end the following new 17 sentence: ''Subsection (b) of section 487H shall 18 apply with respect to the maximum amount 19 specified in this subsection in the same manner 20 as it applies to the maximum amount specified 21 in subsection (a) of such section.''. 22 (3) Section 487B(a) of such Act (42 U.S.C. 23 288-2(a)) is amended\u2014 24 VerDate Nov 24 2008 by striking ''$35,000'' and inserting 1 ''$50,000''; and 2 (B) by adding at the end the following new 3 sentence: ''Subsection (b) of section 487H shall 4 apply with respect to the maximum amount 5 specified in this subsection in the same manner 6 as it applies to the maximum amount specified 7 in such subsection (a) of such section.''. 8 (4) Section 487C(a)(1) of such Act (42 U.S.C. 9 288-3(a)(1)) is amended\u2014 10 (A) by striking ''$35,000'' and inserting 11 ''$50,000''; and 12 (B) by adding at the end the following new 13 sentence: ''Subsection (b) of section 487H shall 14 apply with respect to the maximum amount 15 specified in this paragraph in the same manner 16 as it applies to the maximum amount specified 17 in such subsection (a) of such section.''. 18 (5) Section 487E(a)(1) of such Act (42 U.S.C. 19 288-5(a)(1)) is amended\u2014 20 (A) by striking ''$35,000'' and inserting 21 ''$50,000''; and 22 (B) by adding at the end the following new 23 sentence: ''Subsection (b) of section 487H shall 24 apply with respect to the maximum amount 25 VerDate Nov 24 2008 11:47 Jul 02, 31 specified in this paragraph in the same manner 1 as it applies to the maximum amount specified 2 in such subsection (a) of such section.''. 3 (6) Section 487F(a) of such Act (42 U.S.C. 4 288-5a(a)), as added by section 205 of Public Law 5 106-505, is amended\u2014 6 (A) by striking ''$35,000'' and inserting 7 ''$50,000''; and 8 (B) by adding at the end the following new 9 sentence: ''Subsection (b) of section 487H shall 10 apply with respect to the maximum amount 11 specified in this subsection in the same manner 12 as it applies to the maximum amount specified 13 in such subsection (a) of such section.''. 14 (7) Section 487G of such Act (42 U.S.C. 288- 15 6, as redesignated by subsection (a)(1)), is further 16 amended\u2014 17 (A) in subsection (a)(1), by striking 18 ''$35,000'' and inserting ''$50,000''; and 19 (B) in subsection (b), by adding at the end 20 the following new sentence: ''Subsection (b) of 21 section 487H shall apply with respect to the 22 maximum amount specified in subsection (a)(1) 23 in the same manner as it applies to the max- 24 VerDate Nov 24 2008 11:47 Jul specified in such subsection (a) 1 of such section.''. 2 SEC. 1042. REPORT. 3 Not later than 18 months after the date of the enact- 4 ment of this Act, the Director of the National Institutes 5 of Health shall submit to Congress a report on efforts of 6 the National Institutes of Health to attract, retain, and 7 develop emerging scientists. 8 Subtitle D\u2014Capstone Grant 9 Program 10 SEC. 1061. CAPSTONE AWARD. 11 Part G of title IV of the Public Health Service Act 12 (42 U.S.C. 288 et seq.) is amended by adding at the end 13 the following: 14 ''SEC. 490. CAPSTONE AWARD. 15 ''(a) I NGENERAL .\u2014The Secretary may make awards 16 (each of which, hereafter in this section, referred to as 17 a 'Capstone Award') to support outstanding scientists who 18 have been funded by the National Institutes of Health. 19 ''(b) P URPOSE .\u2014Capstone Awards shall be made to 20 facilitate the successful transition or conclusion of re-21 search programs, or for other purposes, as determined by 22 the Director of NIH, in consultation with the directors 23 of the national research institutes and national centers. 24 VerDate Nov 24 2008 11:47 Jul 02, URATION AND AMOUNT .\u2014The duration and 1 amount of each Capstone Award shall be determined by 2 the Director of NIH in consultation with the directors of 3 the national research institutes and national centers. 4 ''(d) L IMITATION .\u2014Individuals who have received a 5 Capstone Award shall not be eligible to have principle in-6 vestigator status on subsequent awards from the National 7 Institutes of Health.''. 8 Subtitle E\u2014Promoting Pediatric 9 Research Through the National 10 Institutes of Health 11 SEC. 1081. NATIONAL PEDIATRIC RESEARCH NETWORK. 12 Section 409D(d) of the Public Health Service Act (42 13 U.S.C. 284h(d)) is amended\u2014 14 (1) in paragraph (1)\u2014 15 (A) by striking ''in consultation with the 16 Director of the Eunice Kennedy Shriver Na- 17 tional Institute of Child Health and Human 18 Development and in collaboration with other 19 appropriate national research institutes and na- 20 tional centers that carry out activities involving 21 pediatric research'' and inserting ''in collabora- 22 tion with the national research institutes and 23 national centers that carry out activities involv- 24 ing pediatric research''; 25 VerDate Nov 24 2008 11:47 Jul striking subparagraph (B); 1 (C) by striking ''may be comprised of, as 2 appropriate'' and all that follows through ''the 3 pediatric research consortia'' and inserting 4 ''may be comprised of, as appropriate, the pedi- 5 atric research consortia''; and 6 (D) by striking ''; or'' at the end and in- 7 serting a period; and 8 (2) in paragraph (1), paragraph (2)(A), the 9 first sentence of paragraph (2)(E), and paragraph 10 (4), by striking ''may'' each place it appears and in- 11 serting ''shall''. 12 SEC. 1082. GLOBAL PEDIATRIC CLINICAL STUDY NETWORK 13 SENSE OF CONGRESS. 14 It is the sense of Congress that\u2014 15 (1) the National Institutes of Health should en- 16 courage a global pediatric clinical study network 17 through the allocation of grants, contracts, or coop- 18 erative agreements to supplement the salaries of new 19 and early investigators who participate in the global 20 pediatric clinical study network; 21 (2) National Institutes of Health grants, con- 22 tracts, or cooperative agreements should be awarded, 23 solely for the purpose of supplementing the salaries 24 of new and early investigators, to entities that par- 25 VerDate Nov 24 2008 11:47 Jul 02, the global pediatric clinical study net- 1 work; 2 (3) the Food and Drug Administration should 3 engage the European Medicines Agency and other 4 foreign regulatory entities during the formation of 5 the global pediatric clinical study network to encour- 6 age their participation; and 7 (4) once a global pediatric clinical study net- 8 work is established and becomes operational, the 9 Food and Drug Administration should continue to 10 engage the European Medicines Agency and other 11 foreign regulatory entities to encourage and facili- 12 tate their participation in the network with the goal 13 of enhancing the global reach of the network. 14 SEC. 1083. APPROPRIATE AGE GROUPINGS IN CLINICAL RE-15 SEARCH. 16 (a) I NPUT FROM EXPERTS .\u2014Not later than 180 17 days after the date of enactment of this Act, the Director 18 of the National Institutes of Health shall convene a work-19 shop of experts on pediatrics and experts on geriatrics to 20 provide input on\u2014 21 (1) appropriate age groupings to be included in 22 research studies involving human subjects; and 23 VerDate Nov 24 2008 11:47 Jul (2) acceptable scientific justifications for ex- 1 cluding participants from a range of age groups 2 from human subjects research studies. 3 (b) G UIDELINES .\u2014Not later than 180 days after the 4 conclusion of the workshop under subsection (a), the Di-5 rector of the National Institutes of Health shall publish 6 guidelines\u2014 7 (1) addressing the consideration of age as an 8 inclusion variable in research involving human sub- 9 jects; and 10 (2) identifying criteria for justifications for any 11 age-related exclusions in such research. 12 (c) P UBLIC AVAILABILITY OF FINDINGS AND CON- 13 CLUSIONS .\u2014The Director of the National Institutes of 14 Health shall\u2014 15 (1) make the findings and conclusions resulting 16 from the workshop under subsection (a) available to 17 the public on the website of the National Institutes 18 of Health; and 19 (2) not less than biennially, disclose to the pub- 20 lic on such website the number of children included 21 in research that is conducted or supported by the 22 National Institutes of Health, disaggregated by de- 23 velopmentally appropriate age group, race, and gen- 24 der. 25 VerDate Nov 24 2008 11:47 Jul Subtitle F\u2014Advancement of the 1 National Institutes of Health Re- 2 search and Data Access 3 SEC. 1101. STANDARDIZATION OF DATA IN CLINICAL TRIAL 4 REGISTRY DATA BANK ON ELIGIBILITY FOR 5 CLINICAL TRIALS. 6 (a) S TANDARDIZATION .\u2014 7 (1) I N GENERAL .\u2014Section 402(j) of the Public 8 Health Service Act (42 U.S.C. 282(j)) is amended\u2014 9 (A) by redesignating paragraph (7) as 10 paragraph (8); and 11 (B) by inserting after paragraph (6) the 12 following: 13 ''(7) S TANDARDIZATION .\u2014The Director of NIH 14 shall\u2014 15 ''(A) ensure that the registry and results 16 data bank is easily used by the public; 17 ''(B) ensure that entries in the registry 18 and results data bank are easily compared; 19 ''(C) ensure that information required to 20 be submitted to the registry and results data 21 bank, including recruitment information under 22 paragraph (2)(A)(ii)(II), is submitted by per- 23 sons and posted by the Director of NIH in a 24 standardized format and includes at least\u2014 25 VerDate Nov 24 2008 11:47 Jul disease or indication being 1 studied; 2 ''(ii) inclusion criteria such as age, 3 gender, diagnosis or diagnoses, laboratory 4 values, or imaging results; and 5 ''(iii) exclusion criteria such as spe- 6 cific diagnosis or diagnoses, laboratory val- 7 ues, or prohibited medications; and 8 ''(D) to the extent possible, in carrying out 9 this paragraph, make use of standard health 10 care terminologies, such as the International 11 Classification of Diseases or the Current Proce- 12 dural Terminology, that facilitate electronic 13 matching to data in electronic health records or 14 other relevant health information tech- 15 nologies.''. 16 (2) C ONFORMING AMENDMENT .\u2014Clause (iv) of 17 section 402(j)(2)(B) of the Public Health Service 18 Act (42 U.S.C. 282(j)(2)(B)) is hereby stricken. 19 (b) C ONSULTATION .\u2014Not later than 90 days after 20 the date of enactment of this Act, the Secretary of Health 21 and Human Services shall consult with stakeholders (in-22 cluding patients, researchers, physicians, industry rep-23 resentatives, health information technology providers, the 24 Food and Drug Administration, and standard setting or-25 VerDate Nov 24 2008 11:47 Jul such as CDISC that have experience working 1 with Federal agencies to standardize health data submis-2 sions) to receive advice on enhancements to the clinical 3 trial registry data bank under section 402(j) of the Public 4 Health Service Act (42 U.S.C. 282(j)) (including enhance-5 ments to usability, functionality, and search capability) 6 that are necessary to implement paragraph (7) of section 7 402(j) of such Act, as added by subsection (a). 8 (c) A PPLICABILITY .\u2014Not later than 18 months after 9 the date of enactment of this Act, the Secretary of Health 10 and Human Services shall begin implementation of para-11 graph (7) of section 402(j) of the Public Health Service 12 Act, as added by subsection (a). 13 Subtitle G\u2014Facilitating 14 Collaborative Research 15 SEC. 1121. CLINICAL TRIAL DATA SYSTEM. 16 (a) E STABLISHMENT .\u2014The Secretary, acting 17 through the Commissioner of Food and Drugs and the Di-18 rector of the National Institutes of Health, shall enter into 19 a cooperative agreement, contract, or grant for a period 20 of 7 years, to be known as the Clinical Trial Data System 21 Agreement, with one or more eligible entities to implement 22 a pilot program with respect to all clinical trial data ob-23 tained from qualified clinical trials for purposes of reg-24 istered users conducting further research on such data. 25 VerDate Nov 24 2008 11:47 Jul 02, A PPLICATION .\u2014Eligible entities seeking to enter 1 into a cooperative agreement, contract, or grant with the 2 Secretary under this section shall submit to the Secretary 3 an application in such time and manner, and containing 4 such information, as the Secretary may require in accord-5 ance with this section. The Secretary shall not enter into 6 a cooperative agreement, contract, or grant under this sec-7 tion with an eligible entity unless such entity submits an 8 application including the following: 9 (1) A certification that the eligible entity is not 10 currently and does not plan to be involved in spon- 11 soring, operating, or participating in a clinical trial 12 nor collaborating with another entity for the pur- 13 poses of sponsoring, operating, or participating in a 14 clinical trial. 15 (2) Information demonstrating that the eligible 16 entity can compile clinical trial data in standardized 17 formats using terminologies and standards that have 18 been developed by recognized standards developing 19 organizations with input from diverse stakeholder 20 groups, and information demonstrating that the eli- 21 gible entity can de-identify clinical trial data con- 22 sistent with the requirements of section 164.514 of 23 title 45, Code of Federal Regulations (or successor 24 regulations). 25 VerDate Nov 24 2008 11:47 Jul 02, (3) A description of the system the eligible enti- 1 ty will use to store and maintain such data, and in- 2 formation demonstrating that this system will com- 3 ply with applicable standards and requirements for 4 ensuring the security of the clinical trial data. 5 (4) A certification that the eligible entity will 6 allow only registered users to access and use de- 7 identified clinical trial data, gathered from qualified 8 clinical trials, and that the eligible entity will allow 9 each registered user to access and use such data 10 only after such registered user agrees in writing to 11 the terms described in (e)(4)(B), and such other 12 carefully controlled contractual terms as may be de- 13 fined by the Secretary. 14 (5) Evidence demonstrating the ability of the 15 eligible entity to ensure that registered users dis- 16 seminate the results of the research conducted in ac- 17 cordance with this section to interested parties to 18 serve as a guide to future medical product develop- 19 ment or scientific research. 20 (6) The plan of the eligible entity for securing 21 funding for the activities it would conduct under the 22 clinical trial data system agreement from govern- 23 mental sources and private foundations, entities, and 24 individuals. 25 VerDate Nov 24 2008 11:47 Jul 02, (7) Evidence demonstrating a proven track 1 record of\u2014 2 (A) being a neutral third party in working 3 with medical product manufacturers, academic 4 institutions, and the Food and Drug Adminis- 5 tration; and 6 (B) having the ability to protect confiden- 7 tial data. 8 (8) An agreement that the eligible entity will 9 work with the Comptroller General of the United 10 States for purposes of the study and report under 11 subsection (d). 12 (c) E XTENSION , E XPANSION , T ERMINATION .\u2014The 13 Secretary, acting through the Commissioner of Food and 14 Drugs and the Director of the National Institutes of 15 Health, upon the expiration of the 7-year period referred 16 to in subsection (a), may extend (including permanently), 17 expand, or terminate the pilot program established under 18 such subsection, in whole or in part. 19 (d) S TUDY AND REPORT .\u2014 20 (1) I N GENERAL .\u2014The Comptroller General of 21 the United States shall conduct a study and issue a 22 report to the Congress and the Secretary with re- 23 spect to the pilot program established under sub- 24 section (a), not later than 6 years after the date on 25 VerDate Nov 24 2008 11:47 Jul 02, which the pilot program is established under sub- 1 section (a). 2 (2) S TUDY .\u2014The study under paragraph (1) 3 shall\u2014 4 (A) review the effectiveness of the pilot 5 program established under subsection (a); and 6 (B) be designed to formulate recommenda- 7 tions on improvements to the program. 8 (3) R EPORT .\u2014The report under paragraph (1) 9 shall contain at least the following information: 10 (A) The new discoveries, research inquir- 11 ies, or clinical trials that have resulted from ac- 12 cessing clinical trial data under the pilot pro- 13 gram established under subsection (a). 14 (B) The number of times scientists have 15 accessed such data, disaggregated by research 16 area and clinical trial phase. 17 (C) An analysis of whether the program 18 has helped to reduce adverse events in clinical 19 trials. 20 (D) An analysis of whether scientists have 21 raised any concerns about the burden of having 22 to share data with the system established under 23 the program and, if so, a description of such 24 concerns. 25 VerDate Nov 24 2008 11:47 Jul 02, An analysis of privacy and data integ- 1 rity practices used in the program. 2 (e) D EFINITIONS .\u2014In this section: 3 (1) The term ''eligible entity'' means an entity 4 that has experienced personnel with clinical and 5 other technical expertise in the biomedical sciences 6 and biomedical ethics and that is\u2014 7 (A) an institution of higher education (as 8 such term is defined in section 1001 of the 9 Higher Education Act of 1965 (20 U.S.C. 10 1001)) or a consortium of such institutions; or 11 (B) an organization described in section 12 501(c)(3) of title 26 of the Internal Revenue 13 Code of 1986 and exempt from tax under sec- 14 tion 501(a) of such title. 15 (2) The term ''medical product'' means a drug 16 (as defined in section 201(g) of the Federal Food, 17 Drug, and Cosmetic Act (21 U.S.C. 331(g))), a de- 18 vice (as defined in section 201(h) of such Act (21 19 U.S.C. 331(h)), a biological product (as defined in 20 section 351 of the Public Health Service Act (42 21 U.S.C. 262)), or any combination thereof. 22 (3) The term ''qualified clinical trial'' means a 23 clinical trial sponsored solely by an agency of the 24 VerDate Nov 24 2008 11:47 Jul 02, 45 Department of Health and Human Services with re- 1 spect to a medical product\u2014 2 (A) that\u2014 3 (i) was approved or cleared under sec- 4 tion 505, 510(k), or 515, or has an exemp- 5 tion for investigational use in effect under 6 section 505 or 520(m), of the Federal 7 Food, Drug, and Cosmetic Act (42 U.S.C. 8 301 et seq.); or 9 (ii) was licensed under section 351 of 10 the Public Health Service Act (42 U.S.C. 11 262) or has an exemption for investiga- 12 tional use in effect under such section 351; 13 or 14 (B) that is an investigational product for 15 which the original development was discon- 16 tinued and with respect to which\u2014 17 (i) no additional work to support ap- 18 proval, licensure, or clearance of such med- 19 ical product is being or is planned to be 20 undertaken by the sponsor of the original 21 development program, its successors, as- 22 signs, or collaborators; and 23 (ii) the sponsor of the original inves- 24 tigational development program has pro- 25 VerDate Nov 24 2008 11:47 Jul 02, consent to the Secretary for inclu- 1 sion of data regarding such product in the 2 system established under this section. 3 (4) The term ''registered user'' means a sci- 4 entific or medical researcher who has\u2014 5 (A) a legitimate biomedical research pur- 6 pose for accessing information from the clinical 7 trials data system and has appropriate quali- 8 fications to conduct such research; and 9 (B) agreed in writing not to transfer to 10 any other person that is not a registered user 11 de-identified clinical trial data from qualified 12 clinical trials accessed through an eligible enti- 13 ty, use such data for reasons not specified in 14 the research proposal, or seek to re-identify 15 qualified clinical trial participants. 16 (5) The term ''Secretary'' means the Secretary 17 of Health and Human Services. 18 SEC. 1122. NATIONAL NEUROLOGICAL DISEASES SURVEIL-19 LANCE SYSTEM. 20 Part P of title III of the Public Health Service Act 21 (42 U.S.C. 280g et seq.) is amended by adding at the end 22 the following: 23 VerDate Nov 24 2008 11:47 Jul NEUROLOGICAL DISEASES. 1 ''(a) I NGENERAL .\u2014The Secretary, acting through 2 the Director of the Centers for Disease Control and Pre-3 vention and in coordination with other agencies as deter-4 mined appropriate by the Secretary, shall\u2014 5 ''(1) enhance and expand infrastructure and ac- 6 tivities to track the epidemiology of neurological dis- 7 eases, including multiple sclerosis and Parkinson's 8 disease; and 9 ''(2) incorporate information obtained through 10 such activities into a statistically sound, scientifically 11 credible, integrated surveillance system, to be known 12 as the National Neurological Diseases Surveillance 13 System. 14 ''(b) R ESEARCH .\u2014The Secretary shall ensure that 15 the National Neurological Diseases Surveillance System is 16 designed in a manner that facilitates further research on 17 neurological diseases. 18 ''(c) C ONTENT .\u2014In carrying out subsection (a), the 19 Secretary\u2014 20 ''(1) shall provide for the collection and storage 21 of information on the incidence and prevalence of 22 neurological diseases in the United States; 23 ''(2) to the extent practicable, shall provide for 24 the collection and storage of other available informa- 25 VerDate Nov 24 2008 11:47 Jul neurological diseases, such as information 1 concerning\u2014 2 ''(A) demographics and other information 3 associated or possibly associated with neuro- 4 logical diseases, such as age, race, ethnicity, 5 sex, geographic location, and family history; 6 ''(B) risk factors associated or possibly as- 7 sociated with neurological diseases, including 8 genetic and environmental risk factors; and 9 ''(C) diagnosis and progression markers; 10 ''(3) may provide for the collection and storage 11 of information relevant to analysis on neurological 12 diseases, such as information concerning\u2014 13 ''(A) the epidemiology of the diseases; 14 ''(B) the natural history of the diseases; 15 ''(C) the prevention of the diseases; 16 ''(D) the detection, management, and 17 treatment approaches for the diseases; and 18 ''(E) the development of outcomes meas- 19 ures; and 20 ''(4) may address issues identified during the 21 consultation process under subsection (d). 22 ''(d) C ONSULTATION .\u2014In carrying out this section, 23 the Secretary shall consult with individuals with appro-24 priate expertise, including\u2014 25 VerDate Nov 24 2008 experience in disease 1 surveillance or registries; 2 ''(2) representatives of national voluntary 3 health associations that\u2014 4 ''(A) focus on neurological diseases, includ- 5 ing multiple sclerosis and Parkinson's disease; 6 and 7 ''(B) have demonstrated experience in re- 8 search, care, or patient services; 9 ''(3) health information technology experts or 10 other information management specialists; 11 ''(4) clinicians with expertise in neurological 12 diseases; and 13 ''(5) research scientists with experience con- 14 ducting translational research or utilizing surveil- 15 lance systems for scientific research purposes. 16 ''(e) G RANTS .\u2014The Secretary may award grants to, 17 or enter into contracts or cooperative agreements with, 18 public or private nonprofit entities to carry out activities 19 under this section. 20 ''(f) C OORDINATION WITHOTHER FEDERAL , STATE , 21 AND LOCAL AGENCIES .\u2014Subject to subsection (h), the 22 Secretary shall make information and analysis in the Na-23 tional Neurological Diseases Surveillance System avail-24 able, as appropriate\u2014 25 VerDate Nov 24 2008 11:47 ''(1) to Federal departments and agencies, such 1 as the National Institutes of Health, the Food and 2 Drug Administration, the Centers for Medicare & 3 Medicaid Services, the Agency for Healthcare Re- 4 search and Quality, the Department of Veterans Af- 5 fairs, and the Department of Defense; and 6 ''(2) to State and local agencies. 7 ''(g) P UBLIC ACCESS .\u2014Subject to subsection (h), the 8 Secretary shall make information and analysis in the Na-9 tional Neurological Diseases Surveillance System avail-10 able, as appropriate, to the public, including researchers. 11 ''(h) P RIVACY .\u2014The Secretary shall ensure that pri- 12 vacy and security protections applicable to the National 13 Neurological Diseases Surveillance System are at least as 14 stringent as the privacy and security protections under 15 HIPAA privacy and security law (as defined in section 16 3009(a)(2)). 17 ''(i) R EPORT .\u2014Not later than 4 years after the date 18 of the enactment of this section, the Secretary shall sub-19 mit a report to the Congress concerning the implementa-20 tion of this section. Such report shall include information 21 on\u2014 22 ''(1) the development and maintenance of the 23 National Neurological Diseases Surveillance System; 24 VerDate Nov 24 2008 11:47 Jul ''(2) the type of information collected and 1 stored in the System; 2 ''(3) the use and availability of such informa- 3 tion, including guidelines for such use; and 4 ''(4) the use and coordination of databases that 5 collect or maintain information on neurological dis- 6 eases. 7 ''(j) D EFINITION .\u2014In this section, the term 'national 8 voluntary health association' means a national nonprofit 9 organization with chapters, other affiliated organizations, 10 or networks in States throughout the United States. 11 ''(k) A UTHORIZATION OF APPROPRIATIONS .\u2014To 12 carry out this section, there is authorized to be appro-13 priated $5,000,000 for each of fiscal years 2016 through 14 2020.''. 15 SEC. 1123. DATA ON NATURAL HISTORY OF DISEASES. 16 (a) S ENSE OF CONGRESS .\u2014It is the sense of the Con- 17 gress that studies on the natural history of diseases can 18 help to facilitate and expedite the development of medical 19 products for such diseases. 20 (b) A UTHORITY .\u2014Part A of title II of the Public 21 Health Service Act (42 U.S.C. 202 et seq.) is amended 22 by adding at the end the following: 23 VerDate Nov 24 2008 11:47 Jul NATURAL HISTORY OF DISEASES. 1 ''(a) I NGENERAL .\u2014The Secretary, acting through 2 the Commissioner of Food and Drugs, may, for the pur-3 poses described in subsection (b)\u2014 4 ''(1) participate in public-private partnerships 5 engaged in one or more activities specified in sub- 6 section (c); and 7 ''(2) award grants to patient advocacy groups 8 or other organizations determined appropriate by the 9 Secretary. 10 ''(b) P URPOSES DESCRIBED .\u2014The purposes de- 11 scribed in this subsection are to establish or facilitate the 12 collection, maintenance, analysis, and interpretation of 13 data regarding the natural history of diseases, with a par-14 ticular focus on rare diseases. 15 ''(c) A CTIVITIES OF PUBLIC -PRIVATE PARTNER - 16 SHIPS .\u2014The activities of public-private partnerships in 17 which the Secretary may participate for purposes of this 18 section include\u2014 19 ''(1) cooperating with other entities that spon- 20 sor or maintain disease registries, including disease 21 registries and disease registry platforms for rare dis- 22 eases; 23 ''(2) developing or enhancing a secure informa- 24 tion technology system that\u2014 25 VerDate Nov 24 2008 11:47 ''(A) has the capacity to support data 1 needs across a wide range of disease studies; 2 ''(B) is easily modified as knowledge is 3 gained during such studies; and 4 ''(C) is capable of handling increasing 5 amounts of data as more studies are carried 6 out; and 7 ''(3) providing advice to clinical researchers, pa- 8 tient advocacy groups, and other entities with re- 9 spect to\u2014 10 ''(A) the design and conduct of disease 11 studies; 12 ''(B) the modification of any such ongoing 13 studies; and 14 ''(C) addressing associated patient privacy 15 issues. 16 ''(d) A VAILABILITY OF DATA ON NATURAL HISTORY 17 OFDISEASES .\u2014Data relating to the natural history of 18 diseases obtained, aggregated, or otherwise maintained by 19 a public-private partnership in which the Secretary par-20 ticipates under subsection (a) shall be made available, con-21 sistent with otherwise applicable Federal and State pri-22 vacy laws, to the public (including patient advocacy 23 groups, researchers, and drug developers) to help to facili-24 tate and expedite medical product development programs. 25 VerDate Nov 24 2008 11:47 Jul 02, .\u2014Notwithstanding sub- 1 section (d), nothing in this section authorizes the disclo-2 sure of any information that is a trade secret or commer-3 cial or financial information that is privileged or confiden-4 tial and subject to section 552(b)(4) of title 5, United 5 States Code, or section 1905 of title 18, United States 6 Code. 7 ''(f) A UTHORIZATION OF APPROPRIATIONS .\u2014There 8 is authorized to be appropriated to carry out this section 9 $5,000,000 for each of fiscal years 2016 through 2020.''. 10 SEC. 1124. ACCESSING, SHARING, AND USING HEALTH DATA 11 FOR RESEARCH PURPOSES. 12 (a) I NGENERAL .\u2014(1) The HITECH Act (title XIII 13 of division A of Public Law 111-5) is amended by adding 14 at the end of subtitle D of such Act (42 U.S.C. 17921 15 et seq.) the following: 16 ''PART 4\u2014ACCESSING, SHARING, AND USING 17 HEALTH DATA FOR RESEARCH PURPOSES 18 ''SEC. 13441. REFERENCES. 19 ''In this part: 20 ''(1) T HE RULE .\u2014References to 'the Rule' refer 21 to part 160 or part 164, as appropriate, of title 45, 22 Code of Federal Regulations (or any successor regu- 23 lation). 24 VerDate Nov 24 2008 11:47 ART 164 .\u2014References to a specified sec- 1 tion of 'part 164', refer to such specified section of 2 part 164 of title 45, Code of Federal Regulations (or 3 any successor section). 4 ''SEC. 13442. DEFINING HEALTH DATA RESEARCH AS PART 5 OF HEALTH CARE OPERATIONS. 6 ''(a) I NGENERAL .\u2014Subject to subsection (b), the 7 Secretary shall revise or clarify the Rule to allow the use 8 and disclosure of protected health information by a cov-9 ered entity for research purposes, including studies whose 10 purpose is to obtain generalizable knowledge, to be treated 11 as the use and disclosure of such information for health 12 care operations described in subparagraph (1) of the defi-13 nition of health care operations in section 164.501 of part 14 164. 15 ''(b) M ODIFICATIONS TO RULES FOR DISCLOSURES 16 FOR HEALTH CARE OPERATIONS .\u2014In applying section 17 164.506 of part 164 to the disclosure of protected health 18 information described in subsection (a)\u2014 19 ''(1) the Secretary shall revise or clarify the 20 Rule so that the disclosure may be made by the cov- 21 ered entity to only\u2014 22 ''(A) another covered entity for health care 23 operations (as defined in section 164.501 of 24 part 164); 25 VerDate Nov 24 2008 11:47 Jul ''(B) a business associate that has entered 1 into a contract under section 164.504(e) of part 2 164 with a disclosing covered entity to perform 3 health care operations; or 4 ''(C) a business associate that has entered 5 into a contract under section 164.504(e) of part 6 164 for the purpose of data aggregation (as de- 7 fined in section 164.501 of part 164); and 8 ''(2) the Secretary shall further revise or clarify 9 the Rule so that the limitation specified by section 10 164.506(c)(4) of part 164 does not apply to disclo- 11 sures that are described by subsection (a). 12 ''(c) R ULE OF CONSTRUCTION .\u2014This section shall 13 not be construed as prohibiting or restricting a use or dis-14 closure of protected health information for research pur-15 poses that is otherwise permitted under part 164. 16 ''SEC. 13443. TREATING DISCLOSURES OF PROTECTED 17 HEALTH INFORMATION FOR RESEARCH SIMI- 18 LARLY TO DISCLOSURES OF SUCH INFORMA- 19 TION FOR PUBLIC HEALTH PURPOSES. 20 ''(a) R EMUNERATION .\u2014The Secretary shall revise or 21 clarify the Rule so that disclosures of protected health in-22 formation for research purposes are not subject to the lim-23 itation on remuneration described in section 24 164.502(a)(5)(ii)(B)(2)(ii) of part 164. 25 VerDate Nov 24 2008 11:47 Jul 02, ERMITTED USES AND DISCLOSURES .\u2014The 1 Secretary shall revise or clarify the Rule so that research 2 activities, including comparative research activities, re-3 lated to the quality, safety, or effectiveness of a product 4 or activity that is regulated by the Food and Drug Admin-5 istration are included as public health activities for pur-6 poses of which a covered entity may disclose protected 7 health information to a person described in section 8 164.512(b)(1)(iii) of part 164. 9 ''SEC. 13444. PERMITTING REMOTE ACCESS TO PROTECTED 10 HEALTH INFORMATION BY RESEARCHERS. 11 ''The Secretary shall revise or clarify the Rule so that 12 subparagraph (B) of section 164.512(i)(1)(ii) of part 164 13 (prohibiting the removal of protected health information 14 by a researcher) does not prohibit remote access to health 15 information by a researcher so long as\u2014 16 ''(1) appropriate security and privacy safe- 17 guards are maintained by the covered entity and the 18 researcher; and 19 ''(2) the protected health information is not 20 copied or otherwise retained by the researcher. 21 VerDate Nov 24 2008 11:47 Jul 02, ALLOWING ONE-TIME AUTHORIZATION OF USE 1 AND DISCLOSURE OF PROTECTED HEALTH 2 INFORMATION FOR RESEARCH PURPOSES. 3 ''(a) I NGENERAL .\u2014The Secretary shall revise or 4 clarify the Rule to specify that an authorization for the 5 use or disclosure of protected health information, with re-6 spect to an individual, for future research purposes shall 7 be deemed to contain a sufficient description of the pur-8 pose of the use or disclosure if the authorization\u2014 9 ''(1) sufficiently describes the purposes such 10 that it would be reasonable for the individual to ex- 11 pect that the protected health information could be 12 used or disclosed for such future research; 13 ''(2) either\u2014 14 ''(A) states that the authorization will ex- 15 pire on a particular date or on the occurrence 16 of a particular event; or 17 ''(B) states that the authorization will re- 18 main valid unless and until it is revoked by the 19 individual; and 20 ''(3) provides instruction to the individual on 21 how to revoke such authorization at any time. 22 ''(b) R EVOCATION OF AUTHORIZATION .\u2014The Sec- 23 retary shall revise or clarify the Rule to specify that, if 24 an individual revokes an authorization for future research 25 purposes such as is described by subsection (a), the cov-26 VerDate Nov 24 2008 11:47 ered entity may not make any further uses or disclosures 1 based on that authorization, except, as provided in para-2 graph (b)(5) of section 164.508 of part 164, to the extent 3 that the covered entity has taken action in reliance on the 4 authorization.''. 5 (2) The table of sections in section 13001(b) of such 6 Act is amended by adding at the end of the items relating 7 to subtitle D the following new items: 8 ''PART 4\u2014A CCESSING , SHARING , AND RESEARCH PURPOSES ''Sec. 13441. References. ''Sec. 13442. Defining health data research as part of health care operations. ''Sec. 13443. Treating disclosures of protected health information for research similarly to disclosures of such information for public health purposes. ''Sec. 13444. Permitting remote access to protected health information by re- searchers. ''Sec. 13445. Allowing one-time authorization of use and disclosure of protected health information for research purposes.''. (b) R EVISION OF REGULATIONS .\u2014Not later than 12 9 months after the date of the enactment of this Act, the 10 Secretary of Health and Human Services shall revise and 11 clarify the provisions of title 45, Code of Federal Regula-12 tions, for consistency with part 4 of subtitle D of the 13 HITECH Act, as added by subsection (a). 14 Subtitle H\u2014Council for 21st 15 Century Cures 16 SEC. 1141. COUNCIL FOR 21ST CENTURY CURES. 17 Title II of the Public Health Service Act (42 U.S.C. 18 202 et seq.) is amended by adding at the end the fol-19 lowing: 20 VerDate Nov 24 2008 11:47 21ST CENTURY CURES 1 ''SEC. 281. ESTABLISHMENT. 2 ''A nonprofit corporation to be known as the Council 3 for 21st Century Cures (referred to in this part as the 4 'Council') shall be established in accordance with this sec-5 tion. The Council shall be a public-private partnership 6 headed by an Executive Director (referred to in this part 7 as the 'Executive Director'), appointed by the members 8 of the Board of Directors. The Council shall not be an 9 agency or instrumentality of the United States Govern-10 ment. 11 ''SEC. 281A. PURPOSE. 12 ''The purpose of the Council is to accelerate the dis- 13 covery, development, and delivery in the United States of 14 innovative cures, treatments, and preventive measures for 15 patients. 16 ''SEC. 281B. DUTIES. 17 ''For the purpose described in section 281A, the 18 Council shall\u2014 19 ''(1) foster collaboration and coordination 20 among the entities that comprise the Council, includ- 21 ing academia, government agencies, industry, health 22 care payors and providers, patient advocates, and 23 others engaged in the cycle of discovery, develop- 24 ment, and delivery of life-saving and health-enhanc- 25 ing innovative interventions; 26 VerDate Nov 24 2008 11:47 Jul dissemina- 1 activities; 2 ''(3) publish information on the activities fund- 3 ed under section 281D; 4 ''(4) establish a strategic agenda for accel- 5 erating the discovery, development, and delivery in 6 the United States of innovative cures, treatments, 7 and preventive measures for patients; 8 ''(5) identify gaps and opportunities within and 9 across the discovery, development, and delivery cycle; 10 ''(6) develop and propose recommendations 11 based on the gaps and opportunities so identified; 12 ''(7) facilitate the interoperability of the compo- 13 nents of the discovery, development, and delivery 14 cycle; 15 ''(8) propose recommendations that will facili- 16 tate precompetitive collaboration; 17 ''(9) identify opportunities to work with, but 18 not duplicate the efforts of, nonprofit organizations 19 and other public-private partnerships; and 20 ''(10) identify opportunities for collaboration 21 with organizations operating outside of the United 22 States, such as the Innovative Medicines Initiative of 23 the European Union. 24 VerDate Nov 24 2008 11:47 Jul 02, DIRECTORS .\u2014 2 ''(1) E STABLISHMENT .\u2014 3 ''(A) I N GENERAL .\u2014The Council shall 4 have a Board of Directors (in this part referred 5 to as the 'Board of Directors'), which shall be 6 composed of the ex officio members under sub- 7 paragraph (B) and the appointed members 8 under subparagraph (C). All members of the 9 Board shall be voting members. 10 ''(B) E X OFFICIO MEMBERS .\u2014The ex offi- 11 cio members of the Board shall be the following 12 individuals or their designees: 13 ''(i) The Director of the National In- 14 stitutes of Health. 15 ''(ii) The Commissioner of Food and 16 Drugs. 17 ''(iii) The Administrator of the Cen- 18 ters for Medicare & Medicaid Services. 19 ''(iv) The heads of five other Federal 20 agencies deemed by the Secretary to be en- 21 gaged in biomedical research and develop- 22 ment. 23 ''(C) A PPOINTED MEMBERS .\u2014The ap- 24 pointed members of the Board shall consist of 25 17 individuals, of whom\u2014 26 VerDate Nov 24 2008 11:47 Jul ''(i) 8 shall be appointed by the 1 Comptroller General of the United States 2 from a list of nominations submitted by 3 leading trade associations\u2014 4 ''(I) 4 of whom shall be rep- 5 resentatives of the biopharmaceutical 6 industry; 7 ''(II) 2 of whom shall be rep- 8 resentatives of the medical device in- 9 dustry; and 10 ''(III) 2 of whom shall be rep- 11 resentatives of the information and 12 digital technology industry; and 13 ''(ii) 9 shall be appointed by the 14 Comptroller General of the United States, 15 after soliciting nominations\u2014 16 ''(I) 2 of whom shall be rep- 17 resentatives of academic researchers; 18 ''(II) 3 of whom shall be rep- 19 resentatives of patients; 20 ''(III) 2 of whom shall be rep- 21 resentatives of health care providers; 22 and 23 VerDate Nov 24 2008 11:47 Jul of whom shall be rep- 1 resentatives of health care plans and 2 insurers. 3 ''(D) C HAIR .\u2014The Chair of the Board 4 shall be selected by the members of the Board 5 by majority vote from among the members of 6 the Board. 7 ''(2) T ERMS AND VACANCIES .\u2014 8 ''(A) I N GENERAL .\u2014The term of office of 9 each member of the Board appointed under 10 paragraph (1)(C) shall be 5 years. 11 ''(B) V ACANCY .\u2014Any vacancy in the mem- 12 bership of the Board\u2014 13 ''(i) shall not affect the power of the 14 remaining members to execute the duties 15 of the Board; and 16 ''(ii) shall be filled by appointment by 17 the appointed members described in para- 18 graph (1)(C) by majority vote. 19 ''(C) P ARTIAL TERM .\u2014If a member of the 20 Board does not serve the full term applicable 21 under subparagraph (A), the individual ap- 22 pointed under subparagraph (B) to fill the re- 23 sulting vacancy shall be appointed for the re- 24 VerDate Nov 24 2008 11:47 Jul 02, mainder of the term of the predecessor of the 1 individual. 2 ''(3) R ESPONSIBILITIES .\u2014Not later than 90 3 days after the date on which the Council is incor- 4 porated and its Board of Directors is fully con- 5 stituted, the Board of Directors shall establish by- 6 laws and policies for the Council that\u2014 7 ''(A) are published in the Federal Register 8 and available for public comment; 9 ''(B) establish policies for the selection 10 and, as applicable, appointment of\u2014 11 ''(i) the officers, employees, agents, 12 and contractors of the Council; and 13 ''(ii) the members of any committees 14 of the Council; 15 ''(C) establish policies, including ethical 16 standards, for the conduct of programs and 17 other activities under section 281D; and 18 ''(D) establish specific duties of the Execu- 19 tive Director. 20 ''(4) M EETINGS .\u2014 21 ''(A) I N GENERAL .\u2014The Board of Direc- 22 tors shall\u2014 23 ''(i) meet on a quarterly basis; and 24 VerDate Nov 24 2008 11:47 Jul ''(ii) submit to Congress, and make 1 publicly available, the minutes of such 2 meetings. 3 ''(B) A GENDA .\u2014The Board of Directors 4 shall, not later than 3 months after the incorpo- 5 ration of the Council\u2014 6 ''(i) issue an agenda (in this part re- 7 ferred to as the 'agenda') outlining how 8 the Council will achieve the purpose de- 9 scribed in section 281A; and 10 ''(ii) annually thereafter, in consulta- 11 tion with the Executive Director, review 12 and update such agenda. 13 ''(b) A PPOINTMENT AND INCORPORATION .\u2014Not 14 later than 6 months after the date of enactment of the 15 21st Century Cures Act\u2014 16 ''(1) the Comptroller General of the United 17 States shall appoint the appointed members of the 18 Board of Directors under subsection (a)(1)(C); and 19 ''(2) the ex officio members of the Board of Di- 20 rectors under subsection (a)(1)(B) shall serve as 21 incorporators and shall take whatever actions are 22 necessary to incorporate the Council. 23 ''(c) N ONPROFIT STATUS .\u2014In carrying out this part, 24 the Board of Directors shall establish such policies and 25 VerDate Nov 24 2008 11:47 Jul 02, 67 bylaws, and the Executive Director shall carry out such 1 activities, as may be necessary to ensure that the Council 2 maintains status as an organization that\u2014 3 ''(1) is described in subsection (c)(3) of section 4 501 of the Internal Revenue Code of 1986; and 5 ''(2) is, under subsection (a) of such section, ex- 6 empt from taxation. 7 ''(d) E XECUTIVE DIRECTOR .\u2014The Executive Direc- 8 tor shall\u2014 9 ''(1) be the chief executive officer of the Coun- 10 cil; and 11 ''(2) subject to the oversight of the Board of 12 Directors, be responsible for the day-to-day manage- 13 ment of the Council. 14 ''SEC. 281D. OPERATIONAL ACTIVITIES AND ASSISTANCE. 15 ''(a) I NGENERAL .\u2014The Council shall establish a 16 sufficient operational infrastructure to fulfill the duties 17 specified in section 281B. 18 ''(b) P RIVATE SECTOR MATCHING FUNDS .\u2014The 19 Council may accept financial or in-kind support from par-20 ticipating entities or private foundations or organizations 21 when such support is deemed appropriate. 22 ''SEC. 281E. TERMINATION; REPORT. 23 ''(a) I NGENERAL .\u2014The Council shall terminate on 24 September 30, 2023. 25 VerDate Nov 24 2008 11:47 Jul 02, EPORT .\u2014Not later than one year after the 1 date on which the Council is established and each year 2 thereafter, the Executive Director shall submit to the ap-3 propriate congressional committees a report on the per-4 formance of the Council. In preparing such report, the 5 Council shall consult with a nongovernmental consultant 6 with appropriate expertise. 7 ''SEC. 281F. FUNDING. 8 ''For the each of fiscal years 2016 through 2023, 9 there is authorized to be appropriated $10,000,000 to the 10 Council for purposes of carrying out the duties of the 11 Council under this part.''. 12 TITLE II\u2014DEVELOPMENT 13 Subtitle A\u2014Patient-Focused Drug 14 Development 15 SEC. 2001. DEVELOPMENT AND USE OF PATIENT EXPERI-16 ENCE DATA TO ENHANCE STRUCTURED RISK- 17 BENEFIT ASSESSMENT FRAMEWORK. 18 (a) I NGENERAL .\u2014Section 505 of the Federal Food, 19 Drug, and Cosmetic Act (21 U.S.C. 355) is amended\u2014 20 (1) in subsection (d), by striking ''The Sec- 21 retary shall implement'' and all that follows through 22 ''premarket approval of a drug.''; and 23 (2) by adding at the end the following new sub- 24 sections: 25 VerDate Nov 24 2008 11:47 RISK-BENEFIT ASSESSMENT 1 FRAMEWORK .\u2014 2 ''(1) I N GENERAL .\u2014The Secretary shall imple- 3 ment a structured risk-benefit assessment frame- 4 work in the new drug approval process\u2014 5 ''(A) to facilitate the balanced consider- 6 ation of benefits and risks; and 7 ''(B) to develop and implement a con- 8 sistent and systematic approach to the discus- 9 sion of, regulatory decisionmaking with respect 10 to, and the communication of, the benefits and 11 risks of new drugs. 12 ''(2) R ULE OF CONSTRUCTION .\u2014Nothing in 13 paragraph (1) shall alter the criteria for evaluating 14 an application for premarket approval of a drug. 15 ''(y) D EVELOPMENT AND USE OF PATIENT EXPERI - 16 ENCE DATA TOENHANCE STRUCTURED RISK-BENEFIT 17 ASSESSMENT FRAMEWORK .\u2014 18 ''(1) I N GENERAL .\u2014Not later than two years 19 after the date of the enactment of this subsection, 20 the Secretary shall establish and implement proc- 21 esses under which\u2014 22 ''(A) an entity seeking to develop patient 23 experience data may submit to the Secretary\u2014 24 VerDate Nov 24 2008 11:47 Jul research concepts for feed- 1 back from the Secretary; and 2 ''(ii) with respect to patient experience 3 data collected by the entity, draft guidance 4 documents, completed data, and sum- 5 maries and analyses of such data; 6 ''(B) the Secretary may request such an 7 entity to submit such documents, data, and 8 summaries and analyses; and 9 ''(C) patient experience data may be devel- 10 oped and used to enhance the structured risk- 11 benefit assessment framework under subsection 12 (x). 13 ''(2) P ATIENT EXPERIENCE DATA .\u2014In this sub- 14 section, the term 'patient experience data' means 15 data collected by patients, parents, caregivers, pa- 16 tient advocacy organizations, disease research foun- 17 dations, medical researchers, research sponsors, or 18 other parties determined appropriate by the Sec- 19 retary that is intended to facilitate or enhance the 20 Secretary's risk-benefit assessments, including infor- 21 mation about the impact of a disease or a therapy 22 on patients' lives.''. 23 (b) G UIDANCE .\u2014 24 VerDate Nov 24 2008 11:47 Jul (1) I N GENERAL .\u2014The Secretary of Health and 1 Human Services shall publish guidance on the imple- 2 mentation of subsection (y) of section 505 of the 3 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 4 355), as added by subsection (a). Such guidance 5 shall include\u2014 6 (A) with respect to draft guidance docu- 7 ments, data, or summaries and analyses sub- 8 mitted to the Secretary under paragraph (1)(A) 9 of such subsection, guidance\u2014 10 (i) specifying the timelines for the re- 11 view of such documents, data, or sum- 12 maries and analyses by the Secretary; and 13 (ii) on how the Secretary will use such 14 documents, data, or summaries and anal- 15 yses to update any guidance documents 16 published under this subsection or publish 17 new guidance; 18 (B) with respect to the collection and anal- 19 ysis of patient experience data (as defined in 20 paragraph (2) of such subsection (y)), guidance 21 on\u2014 22 (i) methodological considerations for 23 the collection of patient experience data, 24 VerDate Nov 24 2008 11:47 Jul 02, 72 which may include structured approaches 1 to gathering information on\u2014 2 (I) the experience of a patient liv- 3 ing with a particular disease; 4 (II) the burden of living with or 5 managing the disease; 6 (III) the impact of the disease on 7 daily life and long-term functioning; 8 and 9 (IV) the effect of current thera- 10 peutic options on different aspects of 11 the disease; and 12 (ii) the establishment and mainte- 13 nance of registries designed to increase un- 14 derstanding of the natural history of a dis- 15 ease; 16 (C) methodological approaches that may be 17 used to assess patients' beliefs with respect to 18 the benefits and risks in the management of the 19 patient's disease; and 20 (D) methodologies, standards, and poten- 21 tial experimental designs for patient-reported 22 outcomes. 23 (2) T IMING .\u2014Not later than 3 years after the 24 date of the enactment of this Act, the Secretary of 25 VerDate Nov 24 2008 11:47 Jul 02, and Human Services shall issue draft guid- 1 ance on the implementation of subsection (y) of sec- 2 tion 505 of the Federal Food, Drug, and Cosmetic 3 Act (21 U.S.C. 355), as added by subsection (a). 4 The Secretary shall issue final guidance on the im- 5 plementation of such subsection not later than one 6 year after the date on which the comment period for 7 the draft guidance closes. 8 (3) W ORKSHOPS .\u2014 9 (A) I N GENERAL .\u2014Not later than 6 10 months after the date of the enactment of this 11 Act and once every 6 months during the fol- 12 lowing 12-month period, the Secretary of 13 Health and Human Services shall convene a 14 workshop to obtain input regarding methodolo- 15 gies for developing the guidance under para- 16 graph (1), including the collection of patient ex- 17 perience data. 18 (B) A TTENDEES .\u2014A workshop convened 19 under this paragraph shall include\u2014 20 (i) patients; 21 (ii) representatives from patient advo- 22 cacy organizations, biopharmaceutical com- 23 panies, and disease research foundations; 24 VerDate Nov 24 2008 11:47 Jul 74 (iii) representatives of the reviewing 1 divisions of the Food and Drug Adminis- 2 tration; and 3 (iv) methodological experts with sig- 4 nificant expertise in patient experience 5 data. 6 (4) P UBLIC MEETING .\u2014Not later than 90 days 7 after the date on which the draft guidance is pub- 8 lished under this subsection, the Secretary of Health 9 and Human Services shall convene a public meeting 10 to solicit input on the guidance. 11 Subtitle B\u2014Qualification and Use 12 of Drug Development Tools 13 SEC. 2021. QUALIFICATION OF DRUG DEVELOPMENT 14 TOOLS. 15 (a) F INDINGS .\u2014Congress finds the following: 16 (1) Development of new drugs has become in- 17 creasingly challenging and resource intensive. 18 (2) Development of drug development tools can 19 benefit the availability of new medical therapies by 20 helping to translate scientific discoveries into clinical 21 applications. 22 (3) Biomedical research consortia (as defined in 23 section 507(f) of the Federal Food, Drug, and Cos- 24 metic Act, as added by subsection (c)) can play a 25 VerDate Nov 24 2008 11:47 Jul 02, 75 valuable role in helping to develop and qualify drug 1 development tools. 2 (b) S ENSE OF CONGRESS .\u2014It is the sense of Con- 3 gress that\u2014 4 (1) Congress should promote and facilitate a 5 collaborative effort among the biomedical research 6 consortia described in subsection (a)(3)\u2014 7 (A) to develop, through a transparent pub- 8 lic process, data standards and scientific ap- 9 proaches to data collection accepted by the 10 medical and clinical research community for 11 purposes of qualifying drug development tools; 12 (B) to coordinate efforts toward developing 13 and qualifying drug development tools in key 14 therapeutic areas; and 15 (C) to encourage the development of acces- 16 sible databases for collecting relevant drug de- 17 velopment tool data for such purposes; and 18 (2) an entity seeking to qualify a drug develop- 19 ment tool should be encouraged, in addition to con- 20 sultation with the Secretary, to consult with bio- 21 medical research consortia and other individuals and 22 entities with expert knowledge and insights that may 23 assist the requestor and benefit the process for such 24 qualification. 25 VerDate Nov 24 2008 11:47 Jul 02, Q UALIFICATION OF DRUG DEVELOPMENT 1 TOOLS .\u2014Chapter V of the Federal Food, Drug, and Cos- 2 metic Act is amended by inserting after section 506F the 3 following new section: 4 ''SEC. 507. QUALIFICATION OF DRUG DEVELOPMENT 5 TOOLS. 6 ''(a) P ROCESS FOR QUALIFICATION .\u2014 7 ''(1) I N GENERAL .\u2014The Secretary shall estab- 8 lish a process for the qualification of drug develop- 9 ment tools for a proposed context of use under 10 which\u2014 11 ''(A)(i) a requestor initiates such process 12 by submitting a letter of intent to the Sec- 13 retary; and 14 ''(ii) the Secretary accepts or declines to 15 accept such letter of intent; 16 ''(B)(i) if the Secretary accepts the letter 17 of intent, a requestor submits a qualification 18 plan to the Secretary; and 19 ''(ii) the Secretary accepts or declines to 20 accept the qualification plan; and 21 ''(C)(i) if the Secretary accepts the quali- 22 fication plan, the requestor submits to the Sec- 23 retary a full qualification package; 24 VerDate Nov 24 2008 11:47 Jul ''(ii) the Secretary determines whether to 1 accept such qualification package for review; 2 and 3 ''(iii) if the Secretary accepts such quali- 4 fication package for review, the Secretary con- 5 ducts such review in accordance with this sec- 6 tion. 7 ''(2) A CCEPTANCE AND REVIEW OF SUBMIS - 8 SIONS .\u2014 9 ''(A) I N GENERAL .\u2014The succeeding provi- 10 sions of this paragraph shall apply with respect 11 to the treatment of a letter of intent, a quali- 12 fication plan, or a full qualification package 13 submitted under paragraph (1) (referred to in 14 this paragraph as 'qualification submissions'). 15 ''(B) A CCEPTANCE FACTORS ; NONACCEPT - 16 ANCE .\u2014The Secretary shall determine whether 17 to accept a qualification submission based on 18 factors which may include the scientific merit of 19 the submission and the available resources of 20 the Food and Drug Administration to review 21 the qualification submission. A determination 22 not to accept a submission under paragraph (1) 23 shall not be construed as a final determination 24 by the Secretary under this section regarding 25 VerDate Nov 24 2008 11:47 Jul 02, 78 the qualification of a drug development tool for 1 its proposed context of use. 2 ''(C) P RIORITIZATION OF QUALIFICATION 3 REVIEW .\u2014The Secretary may prioritize the re- 4 view of a full qualification package submitted 5 under paragraph (1) with respect to a drug de- 6 velopment tool, based on factors determined ap- 7 propriate by the Secretary, including\u2014 8 ''(i) as applicable, the severity, rarity, 9 or prevalence of the disease or condition 10 targeted by the drug development tool and 11 the availability or lack of alternative treat- 12 ments for such disease or condition; and 13 ''(ii) the identification, by the Sec- 14 retary or by biomedical research consortia 15 and other expert stakeholders, of such a 16 drug development tool and its proposed 17 context of use as a public health priority. 18 ''(D) E NGAGEMENT OF EXTERNAL EX - 19 PERTS .\u2014The Secretary may, for purposes of 20 the review of qualification submissions, through 21 the use of cooperative agreements, grants, or 22 other appropriate mechanisms, consult with bio- 23 medical research consortia and may consider 24 the recommendations of such consortia with re- 25 VerDate Nov 24 2008 11:47 Jul 02, spect to the review of any qualification plan 1 submitted under paragraph (1) or the review of 2 any full qualification package under paragraph 3 (3). 4 ''(3) R EVIEW OF FULL QUALIFICATION PACK - 5 AGE.\u2014The Secretary shall\u2014 6 ''(A) conduct a comprehensive review of a 7 full qualification package accepted under para- 8 graph (1)(C); and 9 ''(B) determine whether the drug develop- 10 ment tool at issue is qualified for its proposed 11 context of use. 12 ''(4) Q UALIFICATION .\u2014The Secretary shall de- 13 termine whether a drug development tool is qualified 14 for a proposed context of use based on the scientific 15 merit of a full qualification package reviewed under 16 paragraph (3). 17 ''(b) E FFECT OF QUALIFICATION .\u2014 18 ''(1) I N GENERAL .\u2014A drug development tool 19 determined to be qualified under subsection (a)(4) 20 for a proposed context of use specified by the re- 21 questor may be used by any person in such context 22 of use for the purposes described in paragraph (2). 23 VerDate Nov 24 2008 11:47 Jul 02, ''(2) U SE OF A DRUG DEVELOPMENT TOOL .\u2014 1 Subject to paragraph (3), a drug development tool 2 qualified under this section may be used for\u2014 3 ''(A) supporting or obtaining approval or 4 licensure (as applicable) of a drug or biological 5 product (including in accordance with section 6 506(c)) under section 505 of this Act or section 7 351 of the Public Health Service Act; or 8 ''(B) supporting the investigational use of 9 a drug or biological product under section 10 505(i) of this Act or section 351(a)(3) of the 11 Public Health Service Act. 12 ''(3) R ESCISSION OR MODIFICATION .\u2014 13 ''(A) I N GENERAL .\u2014The Secretary may re- 14 scind or modify a determination under this sec- 15 tion to qualify a drug development tool if the 16 Secretary determines that the drug development 17 tool is not appropriate for the proposed context 18 of use specified by the requestor. Such a deter- 19 mination may be based on new information that 20 calls into question the basis for such qualifica- 21 tion. 22 ''(B) M EETING FOR REVIEW .\u2014If the Sec- 23 retary rescinds or modifies under subparagraph 24 (A) a determination to qualify a drug develop- 25 VerDate Nov 24 2008 11:47 Jul ment tool, the requestor involved shall, on re- 1 quest, be granted a meeting with the Secretary 2 to discuss the basis of the Secretary's decision 3 to rescind or modify the determination before 4 the effective date of the rescission or modifica- 5 tion. 6 ''(c) T RANSPARENCY .\u2014 7 ''(1) I N GENERAL .\u2014Subject to paragraph (3), 8 the Secretary shall make publicly available, and up- 9 date on at least a biannual basis, on the Internet 10 website of the Food and Drug Administration the 11 following: 12 ''(A) Information with respect to each 13 qualification submission under the qualification 14 process under subsection (a), including\u2014 15 ''(i) the stage of the review process 16 applicable to the submission; 17 ''(ii) the date of the most recent 18 change in stage status; 19 ''(iii) whether the external scientific 20 experts were utilized in the development of 21 a qualification plan or the review of a full 22 qualification package; and 23 ''(iv) submissions from requestors 24 under the qualification process under sub- 25 VerDate Nov 24 2008 11:47 Jul (a), including any data and evi- 1 dence contained in such submissions, and 2 any updates to such submissions. 3 ''(B) The Secretary's formal written deter- 4 minations in response to such qualification sub- 5 missions. 6 ''(C) Any rescissions or modifications 7 under subsection (b)(3) of a determination to 8 qualify a drug development tool. 9 ''(D) Summary reviews that document con- 10 clusions and recommendations for determina- 11 tions to qualify drug development tools under 12 subsection (a). 13 ''(E) A comprehensive list of\u2014 14 ''(i) all drug development tools quali- 15 fied under subsection (a); and 16 ''(ii) all surrogate endpoints which 17 were the basis of approval or licensure (as 18 applicable) of a drug or biological product 19 (including in accordance with section 20 506(c)) under section 505 of this Act or 21 section 351 of the Public Health Service 22 Act. 23 ''(2) R ELATION TO TRADE SECRETS ACT .\u2014In- 24 formation made publicly available by the Secretary 25 VerDate Nov 24 2008 11:47 Jul 02, 83 under paragraph (1) shall be considered a disclosure 1 authorized by law for purposes of section 1905 of 2 title 18, United States Code. 3 ''(3) A PPLICABILITY .\u2014Nothing in this section 4 shall be construed as authorizing the Secretary to 5 disclose any information contained in an application 6 submitted under section 505 of this Act or section 7 351 of the Public Health Service Act that is con- 8 fidential commercial or trade secret information sub- 9 ject to section 552(b)(4) of title 5, United States 10 Code, or section 1905 of title 18, United States 11 Code. 12 ''(d) R ULE OF CONSTRUCTION .\u2014Nothing in this sec- 13 tion shall be construed\u2014 14 ''(1) to alter the standards of evidence under 15 subsection (c) or (d) of section 505, including the 16 substantial evidence standard in such subsection (d), 17 or under section 351 of the Public Health Service 18 Act (as applicable); or 19 ''(2) to limit the authority of the Secretary to 20 approve or license products under this Act or the 21 Public Health Service Act, as applicable (as in effect 22 before the date of the enactment of the 21st Century 23 Cures Act). 24 ''(e) D EFINITIONS .\u2014In this section: 25 VerDate Nov 24 .\u2014(A) The term 'biomarker' 1 means a characteristic (such as a physiologic, 2 pathologic, or anatomic characteristic or measure- 3 ment) that is objectively measured and evaluated as 4 an indicator of normal biologic processes, pathologic 5 processes, or biological responses to a therapeutic 6 intervention; and 7 ''(B) such term includes a surrogate endpoint. 8 ''(2) B IOMEDICAL RESEARCH CONSORTIA .\u2014The 9 term 'biomedical research consortia' means collabo- 10 rative groups that may take the form of public-pri- 11 vate partnerships and may include government agen- 12 cies, institutions of higher education (as defined in 13 section 101(a) of the Higher Education Act of 1965, 14 patient advocacy groups, industry representatives, 15 clinical and scientific experts, and other relevant en- 16 tities and individuals. 17 ''(3) C LINICAL OUTCOME ASSESSMENT .\u2014(A) 18 The term 'clinical outcome assessment' means a 19 measurement of a patient's symptoms, overall men- 20 tal state, or the effects of a disease or condition on 21 how the patient functions; and 22 ''(B) such term includes a patient-reported out- 23 come. 24 VerDate Nov 24 2008 11:47 Jul 02, USE .\u2014The term 'context of 1 use' means, with respect to a drug development tool, 2 the circumstances under which the drug development 3 tool is to be used in drug development and regu- 4 latory review. 5 ''(5) D RUG DEVELOPMENT TOOL .\u2014The term 6 'drug development tool' includes\u2014 7 ''(A) a 8 ''(B) a clinical outcome assessment; and 9 ''(C) any other method, material, or meas- 10 ure that the Secretary determines aids drug de- 11 velopment and regulatory review for purposes of 12 this section. 13 ''(6) P ATIENT -REPORTED OUTCOME .\u2014The term 14 'patient-reported outcome' means a measurement 15 based on a report from a patient regarding the sta- 16 tus of the patient's health condition without amend- 17 ment or interpretation of the patient's report by a 18 clinician or any other person. 19 ''(7) Q UALIFICATION .\u2014The terms 'qualifica- 20 tion' and 'qualified' mean a determination by the 21 Secretary that a drug development tool and its pro- 22 posed context of use can be relied upon to have a 23 specific interpretation and application in drug devel- 24 opment and regulatory review under this Act. 25 VerDate Nov 24 2008 11:47 Jul 02, .\u2014The term 'requestor' means 1 an entity or entities, including a drug sponsor or a 2 biomedical research consortia, seeking to qualify a 3 drug development tool for a proposed context of use 4 under this section. 5 ''(9) S URROGATE ENDPOINT .\u2014The term 'surro- 6 gate endpoint' means a marker, such as a laboratory 7 measurement, radiographic image, physical sign, or 8 other measure, that is not itself a direct measure- 9 ment of clinical benefit, and\u2014 10 ''(A) is known to predict clinical benefit 11 and could be used to support traditional ap- 12 proval of a drug or biological product; or 13 ''(B) is reasonably likely to predict clinical 14 benefit and could be used to support the accel- 15 erated approval of a drug or biological product 16 in accordance with section 506(c). 17 ''(f) A UTHORIZATION OF APPROPRIATIONS .\u2014There 18 are authorized to be appropriated to carry out this section, 19 $10,000,000 for each of fiscal years 2016 through 2020.''. 20 (d) G UIDANCE .\u2014 21 (1) I N GENERAL .\u2014The Secretary of Health and 22 Human Services shall, in consultation with bio- 23 medical research consortia (as defined in subsection 24 (f) of section 507 the Federal Food, Drug, and Cos- 25 VerDate Nov 24 2008 11:47 Jul Act (as added by subsection (c))) and other 1 interested parties through a collaborative public 2 process, issue guidance to implement such section 3 507 that\u2014 4 (A) provides a conceptual framework de- 5 scribing appropriate standards and scientific 6 approaches to support the development of bio- 7 markers delineated under the taxonomy estab- 8 lished under paragraph (3); 9 (B) makes recommendations for dem- 10 onstrating that a surrogate endpoint is reason- 11 ably likely to predict clinical benefit for the pur- 12 pose of supporting the accelerated approval of 13 a drug under section 506(c) of the Federal 14 Food, Drug, and Cosmetic Act (21 U.S.C. 15 356(c)); 16 (C) with respect to the qualification proc- 17 ess under such section 507\u2014 18 (i) describes the requirements that en- 19 tities seeking to qualify a drug develop- 20 ment tool under such section shall observe 21 when engaging in such process; 22 (ii) outlines reasonable timeframes for 23 the Secretary's review of letters, qualifica- 24 VerDate Nov 24 2008 11:47 Jul tion plans, or full qualification packages 1 submitted under such process; and 2 (iii) establishes a process by which 3 such entities or the Secretary may consult 4 with biomedical research consortia and 5 other individuals and entities with expert 6 knowledge and insights that may assist the 7 Secretary in the review of qualification 8 plans and full qualification submissions 9 under such section; and 10 (D) includes such other information as the 11 Secretary determines appropriate. 12 (2) T IMING .\u2014Not later than 24 months after 13 the date of the enactment of this Act, the Secretary 14 of Health and Human Services shall issue draft 15 guidance under paragraph (1) on the implementa- 16 tion of section 507 of the Federal Food, Drug, and 17 Cosmetic Act (as added by subsection (c)). The Sec- 18 retary shall issue final guidance on the implementa- 19 tion of such section not later than 6 months after 20 the date on which the comment period for the draft 21 guidance closes. 22 (3) T AXONOMY .\u2014 23 (A) I N GENERAL .\u2014For purposes of in- 24 forming guidance under this subsection, the 25 VerDate Nov 24 2008 11:47 Jul 89 Secretary of Health and Human Services shall, 1 in consultation with biomedical research con- 2 sortia and other interested parties through a 3 collaborative public process, establish a tax- 4 onomy for the classification of biomarkers (and 5 related scientific concepts) for use in drug de- 6 velopment. 7 (B) P UBLIC AVAILABILITY .\u2014Not later 8 than 12 months after the date of the enactment 9 of this Act, the Secretary of Health and Human 10 Services shall make such taxonomy publicly 11 available in draft form for public comment. The 12 Secretary shall finalize the taxonomy not later 13 than 12 months after the close of the public 14 comment period. 15 (e) M EETING AND REPORT .\u2014 16 (1) M EETING .\u2014Not later than 12 months after 17 the date of the enactment of this Act, the Secretary 18 of Health and Human Services shall convene a pub- 19 lic meeting to describe and solicit public input re- 20 garding the qualification process under section 507 21 of the Federal Food, Drug, and Cosmetic Act, as 22 added by subsection (c). 23 (2) R EPORT .\u2014Not later than 5 years after the 24 date of the enactment of this Act, the Secretary 25 VerDate Nov 24 2008 11:47 Jul 02, 90 shall make publicly available on the Internet website 1 of the Food and Drug Administration a report. Such 2 report shall include, with respect to the qualification 3 process under section 507 of the Federal Food, 4 Drug, and Cosmetic Act, as added by subsection (c), 5 information on\u2014 6 (A) the number of requests submitted, as 7 a letter of intent, for qualification of a drug de- 8 velopment tool (as defined in subsection (f) of 9 such section); 10 (B) the number of such requests accepted 11 and determined to be eligible for submission of 12 a qualification plan or full qualification package 13 (as such terms are defined in such subsection), 14 respectively; 15 (C) the number of such requests for which 16 external scientific experts were utilized in the 17 development of a qualification plan or review of 18 a full qualification package; and 19 (D) the number of qualification plans and 20 full qualification packages, respectively, sub- 21 mitted to the Secretary; and 22 (3) the drug development tools qualified 23 through such qualification process, specified by type 24 of tool, such as a biomarker or clinical outcome as- 25 VerDate Nov 24 2008 11:47 Jul (as such terms are defined in subsection 1 (f) of such section 507). 2 SEC. 2022. ACCELERATED APPROVAL DEVELOPMENT PLAN. 3 (a) I NGENERAL .\u2014Section 506 of the Federal Food, 4 Drug, and Cosmetic Act (21 U.S.C. 356) is amended by 5 adding the following subsection: 6 ''(g) A CCELERATED APPROVAL DEVELOPMENT 7 PLAN.\u2014 8 ''(1) I N GENERAL .\u2014In the case of a drug that 9 the Secretary determines may be eligible for acceler- 10 ated approval in accordance with subsection (c), the 11 sponsor of such drug may request, at any time after 12 the submission of an application for the investigation 13 of the drug under section 505(i) of this Act or sec- 14 tion 351(a)(3) of the Public Health Service Act, that 15 the Secretary agree to an accelerated approval devel- 16 opment plan described in paragraph (2). 17 ''(2) P LAN DESCRIBED .\u2014A plan described in 18 this paragraph, with respect to a drug described in 19 paragraph (1), is an accelerated approval develop- 20 ment plan, which shall include agreement on\u2014 21 ''(A) the surrogate endpoint to be assessed 22 under such plan; 23 ''(B) the design of the study that will uti- 24 lize the surrogate endpoint; and 25 VerDate Nov 24 2008 11:47 Jul ''(C) the magnitude of the effect of the 1 drug on the surrogate endpoint that is the sub- 2 ject of the agreement that would be sufficient 3 to form the primary basis of a claim that the 4 drug is effective. 5 ''(3) M ODIFICATION ; TERMINATION .\u2014The Sec- 6 retary may require the sponsor of a drug that is the 7 subject of an accelerated approval development plan 8 to modify or terminate the plan if additional data or 9 information indicates that\u2014 10 ''(A) the plan as originally agreed upon is 11 no longer sufficient to demonstrate the safety 12 and effectiveness of the drug involved; or 13 ''(B) the drug is no longer eligible for ac- 14 celerated approval under subsection (c). 15 ''(4) S PONSOR CONSULTATION .\u2014If the Sec- 16 retary requires the modification or termination of an 17 accelerated approval development plan under para- 18 graph (3), the sponsor shall be granted a request for 19 a meeting to discuss the basis of the Secretary's de- 20 cision before the effective date of the modification or 21 termination. 22 ''(5) D EFINITION .\u2014In this section, the term 23 'accelerated approval development plan' means a de- 24 velopment plan agreed upon by the Secretary and 25 VerDate Nov 24 2008 11:47 Jul 02, 93 the sponsor submitting the plan that contains study 1 parameters for the use of a surrogate endpoint 2 that\u2014 3 ''(A) is reasonably likely to predict clinical 4 benefit; and 5 ''(B) is intended to be the basis of the ac- 6 celerated approval of a drug in accordance with 7 subsection (c).''. 8 (b) T ECHNICAL AMENDMENTS .\u2014Section 506 of the 9 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356) 10 is amended\u2014 11 (1) by striking ''(f) A WARENESS EFFORTS '' and 12 inserting ''(e) A WARENESS EFFORTS ''; and 13 (2) by striking ''(e) C ONSTRUCTION '' and in- 14 serting ''(f) C ONSTRUCTION ''. 15 Subtitle C\u2014FDA Advancement of 16 Precision Medicine 17 SEC. 2041. PRECISION MEDICINE GUIDANCE AND OTHER 18 PROGRAMS OF FOOD AND DRUG ADMINIS- 19 TRATION. 20 Chapter V of the Federal Food, Drug, and Cosmetic 21 Act (21 U.S.C. 351 et seq.) is amended by adding at the 22 end the following: 23 VerDate Nov 24 2008 11:47 Jul 1 ''SEC. 591. GENERAL AGENCY GUIDANCE ON PRECISION 2 MEDICINE. 3 ''(a) I NGENERAL .\u2014The Secretary shall issue and 4 periodically update guidance to assist sponsors in the de-5 velopment of a precision drug or biological product. Such 6 guidance shall\u2014 7 ''(1) define the term 'precision drug or biologi- 8 cal product'; and 9 ''(2) address the topics described in subsection 10 (b). 11 ''(b) C ERTAIN ISSUES .\u2014The topics to be addressed 12 by guidance under subsection (a) are\u2014 13 ''(1) the evidence needed to support the use of 14 biomarkers (as defined in section 507(e)) that iden- 15 tify subsets of patients as likely responders to thera- 16 pies in order to streamline the conduct of clinical 17 trials; 18 ''(2) recommendations for the design of studies 19 to demonstrate the validity of a biomarker as a pre- 20 dictor of drug or biological product response; 21 ''(3) the manner and extent to which a benefit- 22 risk assessment may be affected when clinical trials 23 are limited to patient population subsets that are 24 identified using biomarkers; 25 VerDate Nov 24 2008 11:47 Jul ''(4) the development of companion diagnostics 1 in the context of a drug development program; and 2 ''(5) considerations for developing biomarkers 3 that inform prescribing decisions for a drug or bio- 4 logical product, and when information regarding a 5 biomarker may be included in the approved prescrip- 6 tion labeling for a precision drug or biological prod- 7 uct. 8 ''(c) D ATE CERTAIN FOR INITIAL GUIDANCE .\u2014The 9 Secretary shall issue guidance under subsection (a) not 10 later than 18 months after the date of the enactment of 11 the 21st Century Cures Act. 12 ''SEC. 592. PRECISION MEDICINE REGARDING ORPHAN- 13 DRUG AND EXPEDITED-APPROVAL PRO- 14 GRAMS. 15 ''(a) I NGENERAL .\u2014In the case of a precision drug 16 or biological product that is the subject of an application 17 submitted under section 505(b)(1), or section 351(a) of 18 the Public Health Service Act, for the treatment of a seri-19 ous or life-threatening disease or condition and has been 20 designated under section 526 as a drug for a rare disease 21 or condition, the Secretary may\u2014 22 ''(1) consistent with applicable standards for 23 approval, rely upon data or information previously 24 submitted by the sponsor of the precision drug or bi- 25 VerDate Nov 24 2008 11:47 Jul 02, ological product, or another sponsor, provided that 1 the sponsor of the precision drug or biological prod- 2 uct has obtained a contractual right of reference to 3 such other sponsor's data and information, in an ap- 4 plication approved under section 505(c) or licensed 5 under section 351(a) of the Public Health Service 6 Act, as applicable\u2014 7 ''(A) for a different drug or biological 8 product; or 9 ''(B) for a different indication for such 10 precision drug or biological product, 11 in order to expedite clinical development for a preci- 12 sion drug or biological product that is using the 13 same or similar approach as that used to support 14 approval of the prior approved application or license, 15 as appropriate; and 16 ''(2) as appropriate, consider the application for 17 approval of such precision drug or biological product 18 to be eligible for expedited review and approval pro- 19 grams described in section 506, including acceler- 20 ated approval in accordance with subsection (c) of 21 such section. 22 ''(b) R ULE OF CONSTRUCTION .\u2014Nothing in this sec- 23 tion shall be construed to\u2014 24 VerDate Nov 24 2008 11:47 Jul ''(1) limit the authority of the Secretary to ap- 1 prove products pursuant to this Act and the Public 2 Health Service Act as authorized prior to the date 3 of enactment of this section; or 4 ''(2) confer any new rights, beyond those au- 5 thorized under this Act prior to enactment of this 6 section, with respect to a sponsor's ability to ref- 7 erence information contained in another application 8 submitted under section 505(b)(1) of this Act or sec- 9 tion 351(a) of the Public Health Service Act.''. 10 Subtitle D\u2014Modern Trial Design 11 and Evidence Development 12 SEC. 2061. BROADER APPLICATION OF BAYESIAN STATIS-13 TICS AND ADAPTIVE TRIAL DESIGNS. 14 (a) P ROPOSALS FOR USE OF INNOVATIVE STATIS - 15 TICAL METHODS IN CLINICAL PROTOCOLS FOR DRUGS 16 AND BIOLOGICAL PRODUCTS .\u2014For purposes of assisting 17 sponsors in incorporating adaptive trial design and 18 Bayesian methods into proposed clinical protocols and ap-19 plications for new drugs under section 505 of the Federal 20 Food, Drug, and Cosmetic Act (21 U.S.C. 355) and bio-21 logical products under section 351 of the Public Health 22 Service Act (42 U.S.C. 262), the Secretary shall conduct 23 a public meeting and issue guidance in accordance with 24 subsection (b). 25 VerDate Nov 24 2008 11:47 Jul (b) G UIDANCE ADDRESSING USE OF ADAPTIVE 1 TRIAL DESIGNS AND BAYESIAN METHODS .\u2014 2 (1) I N GENERAL .\u2014The Secretary of Health and 3 Human Services, acting through the Commissioner 4 of Food and Drugs (in this subsection referred to as 5 the ''Secretary''), shall\u2014 6 (A) update and finalize the draft guidance 7 addressing the use of adaptive trial design for 8 drugs and biological products; and 9 (B) issue draft guidance on the use of 10 Bayesian methods in the development and regu- 11 latory review and approval or licensure of drugs 12 and biological products. 13 (2) C ONTENTS .\u2014The guidances under para- 14 graph (1) shall address\u2014 15 (A) the use of adaptive trial designs and 16 Bayesian methods in clinical trials, including 17 clinical trials proposed or submitted to help to 18 satisfy the substantial evidence standard under 19 section 505(d) of the Federal Food, Drug, and 20 Cosmetic Act (21 U.S.C. 355(d)); 21 (B) how sponsors may obtain feedback 22 from the Secretary on technical issues related 23 to modeling and simulations prior to\u2014 24 VerDate Nov 24 2008 11:47 Jul (i) completion of such modeling or 1 simulations; or 2 (ii) the submission of resulting infor- 3 mation to the Secretary; 4 (C) the types of quantitative and quali- 5 tative information that should be submitted for 6 review; and 7 (D) recommended analysis methodologies. 8 (3) P UBLIC MEETING .\u2014Prior to updating or 9 developing the guidances required by paragraph (1), 10 the Secretary shall consult with stakeholders, includ- 11 ing representatives of regulated industry, academia, 12 patient advocacy organizations, and disease research 13 foundations, through a public meeting to be held not 14 later than 1 year after the date of enactment of this 15 Act. 16 (4) S CHEDULE .\u2014The Secretary shall publish\u2014 17 (A) the final guidance required by para- 18 graph (1)(A) not later than 18 months after the 19 date of the public meeting required by para- 20 graph (3); and 21 (B) the guidance required by paragraph 22 (1)(B) not later than 48 months after the date 23 of the public meeting required by paragraph 24 (3). 25 VerDate Nov 24 2008 11:47 Jul 02, UTILIZING EVIDENCE FROM CLINICAL EXPERI-1 ENCE. 2 Chapter V of the Federal Food, Drug, and Cosmetic 3 Act is amended by inserting after section 505E of such 4 Act (21 U.S.C. 355f) the following: 5 ''SEC. 505F. ENCE. 7 ''(a) I NGENERAL .\u2014The Secretary shall establish a 8 program to evaluate the potential use of evidence from 9 clinical experience\u2014 10 ''(1) to help to support the approval of a new 11 indication for a drug approved under section 505(b); 12 and 13 ''(2) to help to support or satisfy postapproval 14 study requirements. 15 ''(b) E VIDENCE FROM CLINICAL EXPERIENCE DE- 16 FINED .\u2014In this section, the term 'evidence from clinical 17 experience' means data regarding the usage, or the poten-18 tial benefits or risks, of a drug derived from sources other 19 than randomized clinical trials, including from observa-20 tional studies, registries, and therapeutic use. 21 ''(c) P ROGRAM FRAMEWORK .\u2014 22 ''(1) I N GENERAL .\u2014Not later than 18 months 23 after the date of enactment of this section, the Sec- 24 retary shall establish a draft framework for imple- 25 mentation of the program under this section. 26 VerDate Nov 24 2008 11:47 Jul 02, FRAMEWORK 1 work shall include information describing\u2014 2 ''(A) the current sources of data developed 3 through clinical experience, including ongoing 4 safety surveillance, registry, claims, and pa- 5 tient-centered outcomes research activities; 6 ''(B) the gaps in current data collection ac- 7 tivities; 8 ''(C) the current standards and methodolo- 9 gies for collection and analysis of data gen- 10 erated through clinical experience; and 11 ''(D) the priority areas, remaining chal- 12 lenges, and potential pilot opportunities that 13 the program established under this section will 14 address. 15 ''(3) C ONSULTATION .\u2014 16 ''(A) I N GENERAL .\u2014In developing the pro- 17 gram framework under this subsection, the Sec- 18 retary shall consult with regulated industry, 19 academia, medical professional organizations, 20 representatives of patient advocacy organiza- 21 tions, disease research foundations, and other 22 interested parties. 23 VerDate Nov 24 2008 11:47 Jul 02, .\u2014The consultation under 1 subparagraph (A) may be carried out through 2 approaches such as\u2014 3 ''(i) a public-private partnership with 4 the entities described in such subparagraph 5 in which the Secretary may participate; or 6 ''(ii) a contract, grant, or other ar- 7 rangement, as determined appropriate by 8 the Secretary with such a partnership or 9 an independent research organization. 10 ''(d) P ROGRAM IMPLEMENTATION .\u2014The Secretary 11 shall, not later than 24 months after the date of enact-12 ment of this section and in accordance with the framework 13 established under subsection (c), implement the program 14 to evaluate the potential use of evidence from clinical expe-15 rience. 16 ''(e) G UIDANCE FOR INDUSTRY .\u2014The Secretary 17 shall\u2014 18 ''(1) utilize the program established under sub- 19 section (a), its activities, and any subsequent pilots 20 or written reports, to inform a guidance for industry 21 on\u2014 22 ''(A) the circumstances under which spon- 23 sors of drugs and the Secretary may rely on 24 evidence from clinical experience for the pur- 25 VerDate Nov 24 2008 11:47 Jul subsection (a)(1) or (a)(2); 1 and 2 ''(B) the appropriate standards and meth- 3 odologies for collection and analysis of evidence 4 from clinical experience submitted for such pur- 5 poses; 6 ''(2) not later than 36 months after the date of 7 enactment of this section, issue draft guidance for 8 industry as described in paragraph (1); and 9 ''(3) not later than 48 months after the date of 10 enactment of this section, after providing an oppor- 11 tunity for public comment on the draft guidance, 12 issue final guidance. 13 ''(f) R ULE OF CONSTRUCTION .\u2014 14 ''(1) Subject to paragraph (2), nothing in this 15 section prohibits the Secretary from using evidence 16 from clinical experience for purposes not specified in 17 this section, provided the Secretary determines that 18 sufficient basis exists for any such nonspecified use. 19 ''(2) This section shall not be construed to 20 alter\u2014 21 ''(A) the standards of evidence under\u2014 22 ''(i) subsection (c) or (d) of section 23 505, including the substantial evidence 24 standard in such subsection (d); or 25 VerDate Nov 24 2008 11:47 351(a) of the Public 1 Health Service Act; or 2 ''(B) the Secretary's authority to require 3 postapproval studies or clinical trials, or the 4 standards of evidence under which studies or 5 trials are evaluated. 6 ''SEC. 505G. COLLECTING EVIDENCE FROM CLINICAL EXPE-7 RIENCE THROUGH TARGETED EXTENSIONS 8 OF THE SENTINEL SYSTEM. 9 ''(a) I NGENERAL .\u2014The Secretary shall, in parallel 10 to implementing the program established under section 11 505F and in order to build capacity for utilizing the evi-12 dence from clinical experience described in that section, 13 identify and execute pilot demonstrations to extend exist-14 ing use of the Sentinel System surveillance infrastructure 15 authorized under section 505(k). 16 ''(b) P ILOT DEMONSTRATIONS .\u2014 17 ''(1) I N GENERAL .\u2014The Secretary\u2014 18 ''(A) shall design and implement pilot dem- 19 onstrations to utilize data captured through the 20 Sentinel System surveillance infrastructure au- 21 thorized under section 505(k) for purposes of, 22 as appropriate\u2014 23 ''(i) generating evidence from clinical 24 experience to improve characterization or 25 VerDate Nov 24 2008 11:47 Jul 02, 105 assessment of risks or benefits of a drug 1 approved under section 505(c); 2 ''(ii) protecting the public health; or 3 ''(iii) advancing patient-centered care; 4 and 5 ''(B) may make strategic linkages with 6 sources of complementary public health data 7 and infrastructure the Secretary determines ap- 8 propriate and necessary. 9 ''(2) C ONSULTATION .\u2014In developing the pilot 10 demonstrations under this subsection, the Secretary 11 shall\u2014 12 ''(A) consult with regulated industry, aca- 13 demia, medical professional organizations, rep- 14 resentatives of patient advocacy organizations, 15 disease research foundations, and other inter- 16 ested parties through a public process; and 17 ''(B) develop a framework to promote ap- 18 propriate transparency and dialogue about re- 19 search conducted under these pilot demonstra- 20 tions, including by\u2014 21 ''(i) providing adequate notice to a 22 sponsor of a drug approved under section 23 505 or section 351 of the Public Health 24 Service Act of the Secretary's intent to 25 VerDate Nov 24 2008 11:47 Jul conduct analyses of such sponsor's drug or 1 drugs under these pilot demonstrations; 2 ''(ii) providing adequate notice of the 3 findings related to analyses described in 4 clause (i) and an opportunity for the spon- 5 sor of such drug or drugs to comment on 6 such findings; and 7 ''(iii) ensuring the protection from 8 public disclosure of any information that is 9 a trade secret or confidential information 10 subject to section 552(b)(4) of title 5, 11 United States Code, or section 1905 of 12 title 18, United States Code. 13 ''(3) HIPAA PRIVACY RULE ; HUMAN SUBJECT 14 RESEARCH REGULATION .\u2014The Secretary may deem 15 such pilot demonstrations\u2014 16 ''(A) public health activities, for purposes 17 of which a use or disclosure of protected health 18 information would be permitted as described in 19 section 164.512(b)(1) of title 45, Code of Fed- 20 eral Regulations (or any successor regulation); 21 and 22 ''(B) outside the scope of 'research' as de- 23 fined in section 46.102(d) of title 45, Code of 24 VerDate Nov 24 2008 11:47 Jul 02, any successor regula- 1 tion). 2 ''(c) A UTHORIZATION OF APPROPRIATIONS .\u2014There 3 are authorized to be appropriated to carry out this section 4 $3,000,000 for each of fiscal years 2016 through 2020.''. 5 SEC. 2063. STREAMLINED DATA REVIEW PROGRAM. 6 (a) I NGENERAL .\u2014Chapter V of the Federal Food, 7 Drug, and Cosmetic Act, as amended by section 2062, is 8 further amended by inserting after section 505G of such 9 Act the following: 10 ''SEC. 505H. STREAMLINED DATA REVIEW PROGRAM. 11 ''(a) I NGENERAL .\u2014The Secretary shall establish a 12 streamlined data review program under which a holder of 13 an approved application submitted under section 14 505(b)(1) or under section 351(a) of the Public Health 15 Service Act may, to support the approval or licensure (as 16 applicable) of the use of the drug that is the subject of 17 such approved application for a new qualified indication, 18 submit qualified data summaries. 19 ''(b) E LIGIBILITY .\u2014In carrying out the streamlined 20 data review program under subsection (a), the Secretary 21 may authorize the holder of the approved application to 22 include one or more qualified data summaries described 23 in subsection (a) in a supplemental application if\u2014 24 VerDate Nov 24 2008 11:47 Jul the drug has been approved under section 1 505(c) of this Act or licensed under section 351(a) 2 of the Public Health Service Act for one or more in- 3 dications, and such approval or licensure remains in 4 effect; 5 ''(2) the supplemental application is for ap- 6 proval or licensure (as applicable) under such section 7 505(c) or 351(a) of the use of the drug for a new 8 qualified indication under such section 505(c) or 9 351(a); 10 ''(3) there is an existing database acceptable to 11 the Secretary regarding the safety of the drug devel- 12 oped for one or more indications of the drug ap- 13 proved under such section 505(c) or licensed under 14 such section 351(a); 15 ''(4) the supplemental application incorporates 16 or supplements the data submitted in the application 17 for approval or licensure referred to in paragraph 18 (1); and 19 ''(5) the full data sets used to develop the quali- 20 fied data summaries are submitted, unless the Sec- 21 retary determines that the full data sets are not re- 22 quired. 23 ''(c) P UBLIC AVAILABILITY OF INFORMATION ON 24 PROGRAM .\u2014The Secretary shall post on the public website 25 VerDate Nov 24 2008 11:47 Jul 02, the Food and Drug Administration and update annu-1 ally\u2014 2 ''(1) the number of applications reviewed under 3 the streamlined data review program; 4 ''(2) the average time for completion of review 5 under the streamlined data review program versus 6 other review of applications for new indications; and 7 ''(3) the number of applications reviewed under 8 the streamlined data review program for which the 9 Food and Drug Administration made use of full 10 data sets in addition to the qualified data summary. 11 ''(d) D EFINITIONS .\u2014In this indication' means\u2014 13 ''(A) an indication for the treatment of 14 cancer, as determined appropriate by the Sec- 15 retary; or 16 ''(B) such other types of indications as the 17 Secretary determines to be subject to the 18 streamlined data review program under this 19 section. 20 ''(2) The term 'qualified data summary' means 21 a summary of clinical data intended to demonstrate 22 safety and effectiveness with respect to a qualified 23 indication for use of a drug.''. 24 VerDate Nov 24 2008 11:47 Jul S ENSE OF CONGRESS .\u2014It is the sense of Con- 1 gress that the streamlined data review program under sec-2 tion 505H of the Federal Food, Drug, and Cosmetic Act, 3 as added by subsection (a), should enable the Food and 4 Drug Administration to make approval decisions for cer-5 tain supplemental applications based on qualified data 6 summaries (as defined in such section 505H). 7 (c) G UIDANCE ; R EGULATIONS .\u2014The Commissioner 8 of Food and Drugs\u2014 9 (1) shall\u2014 10 (A) issue final guidance for implementation 11 of the streamlined data review program estab- 12 lished under section 505H of the Federal Food, 13 Drug, and Cosmetic Act, as added by sub- 14 section (a), not later than 24 months after the 15 date of enactment of this Act; and 16 (B) include in such guidance the process 17 for expanding the types of indications to be 18 subject to the streamlined data review program, 19 as authorized by section 505H(c)(1)(B) of such 20 Act; and 21 (2) in addition to issuing guidance under para- 22 graph (1), may issue such regulations as may be 23 necessary for implementation of the program. 24 VerDate Nov 24 2008 11:47 Jul 02, E\u2014Expediting Patient 1 Access 2 SEC. 2081. SENSE OF CONGRESS. 3 It is the sense of Congress that the Food and Drug 4 Administration should continue to expedite the approval 5 of drugs designated as breakthrough therapies pursuant 6 to section 506(a) of the Federal Food, Drug, and Cos-7 metic Act (21 U.S.C. 356(a)) by approving drugs so des-8 ignated as early as possible in the clinical development 9 process, regardless of the phase of development, provided 10 that the Secretary of Health and Human Services deter-11 mines that an application for such a drug meets the stand-12 ards of evidence of safety and effectiveness under section 13 505 of such Act (21 U.S.C. 355), including the substantial 14 evidence standard under subsection (d) of such section or 15 under section 351(a) of the Public Health Service Act (42 16 U.S.C. 262(a)). 17 SEC. 2082. EXPANDED ACCESS POLICY. 18 Chapter V of the Federal Food, Drug, and Cosmetic 19 Act is amended by inserting after section 561 (21 U.S.C. 20 360bbb) the following: 21 ''SEC. 561A. ACCESS IN-22 VESTIGATIONAL DRUGS. 23 ''(a) I NGENERAL .\u2014The manufacturer or distributor 24 of one or more investigational drugs for the diagnosis, 25 VerDate Nov 24 2008 11:47 Jul 02, 112 monitoring, or treatment of one or more serious diseases 1 or conditions shall make publicly available the policy of 2 the manufacturer or distributor on evaluating and re-3 sponding to requests submitted under section 561(b) for 4 provision of such a drug. A manufacturer or distributor 5 may satisfy the requirement of the preceding sentence by 6 posting such policy as generally applicable to all of such 7 manufacturer's or distributor's investigational drugs. 8 ''(b) C ONTENT OF POLICY .\u2014A policy described in 9 subsection (a) shall include making publicly available\u2014 10 ''(1) contact information for the manufacturer 11 or distributor to facilitate communication about re- 12 quests described in subsection (a); 13 ''(2) procedures for making such requests; 14 ''(3) the general criteria the manufacturer or 15 distributor will consider or use to approve such re- 16 quests; and 17 ''(4) the length of time the manufacturer or dis- 18 tributor anticipates will be necessary to acknowledge 19 receipt of such requests. 20 ''(c) N OGUARANTEE OF ACCESS .\u2014The posting of 21 policies by manufacturers and distributors under sub-22 section (a) shall not serve as a guarantee of access to any 23 specific investigational drug by any individual patient. 24 VerDate Nov 24 2008 11:47 Jul 02, .\u2014A manufacturer or dis- 1 tributor that has made a policy publicly available as re-2 quired by this section may revise the policy at any time. 3 ''(e) A PPLICATION .\u2014This section shall apply to a 4 manufacturer or distributor with respect to an investiga-5 tional drug beginning on the later of\u2014 6 ''(1) the date that is 60 days after the date of 7 enactment of the 21st Century Cures Act; or 8 ''(2) the first initiation of a phase 2 or phase 9 3 study (as such terms are defined in section 10 312.21(b) and (c) of title 21, Code of Federal Regu- 11 lations (or any successor regulations)) with respect 12 to such investigational new drug.''. 13 SEC. 2083. FINALIZING DRAFT GUIDANCE ON EXPANDED 14 ACCESS. 15 (a) I NGENERAL .\u2014Not later than 12 months after 16 the date of enactment of this Act, the Secretary of Health 17 and Human Services shall finalize the draft guidance enti-18 tled ''Expanded Access to Investigational Drugs for Treat-19 ment Use\u2014Qs & As'' and dated May 2013. 20 (b) C ONTENTS .\u2014The final guidance referred to in 21 subsection (a) shall clearly define how the Secretary of 22 Health and Human Services interprets and uses adverse 23 drug event data reported by investigators in the case of 24 data reported from use under a request submitted under 25 VerDate Nov 24 2008 11:47 Jul 02, section 561(b) of the Federal Food, Drug, and Cosmetic 1 Act (21 U.S.C. 360bbb(b)). 2 Subtitle F\u2014Facilitating Respon-3 sible Manufacturer Communica- 4 tions 5 SEC. 2101. FACILITATING DISSEMINATION OF HEALTH 6 CARE ECONOMIC INFORMATION. 7 Section 502(a) of the Federal Food, Drug, and Cos- 8 metic Act (21 U.S.C. 352(a)) is amended\u2014 9 (1) by striking ''(a) If its'' and inserting 10 ''(a)(1) If its''; 11 (2) by striking ''a formulary committee, or 12 other similar entity, in the course of the committee 13 or the entity carrying out its responsibilities for the 14 selection of drugs for managed care or other similar 15 organizations'' and inserting ''a payor, formulary 16 committee, or other similar entity with knowledge 17 and expertise in the area of health care economic 18 analysis, carrying out its responsibilities for the se- 19 lection of drugs for coverage or reimbursement''; 20 (3) by striking ''directly relates'' and inserting 21 ''relates''; 22 (4) by striking ''and is based on competent and 23 reliable scientific evidence. The requirements set 24 forth in section 505(a) or in section 351(a) of the 25 VerDate Nov 24 2008 11:47 Jul 115 Public Health Service Act shall not apply to health 1 care economic information provided to such a com- 2 mittee or entity in accordance with this paragraph'' 3 and inserting '', is based on competent and reliable 4 scientific evidence, and includes, where applicable, a 5 conspicuous and prominent statement describing any 6 material differences between the health care eco- 7 nomic information and the labeling approved for the 8 drug under section 505 or under section 351 of the 9 Public Health Service Act. The requirements set 10 forth in section 505(a) or in subsections (a) and (k) 11 of section 351 of the Public Health Service Act shall 12 not apply to health care economic information pro- 13 vided to such a payor, committee, or entity in ac- 14 cordance with this paragraph''; and 15 (5) by striking ''In this paragraph, the term'' 16 and all that follows and inserting the following: 17 ''(2)(A) For purposes of this paragraph, the term 18 'health care economic information' means any analysis (in-19 cluding the clinical data, inputs, clinical or other assump-20 tions, methods, results, and other components underlying 21 or comprising the analysis) that identifies, measures, or 22 describes the economic consequences, which may be based 23 on the separate or aggregated clinical consequences of the 24 represented health outcomes, of the use of a drug. Such 25 VerDate Nov 24 2008 11:47 Jul 02, 116 analysis may be comparative to the use of another drug, 1 to another health care intervention, or to no intervention. 2 ''(B) Such term does not include any analysis that 3 relates only to an indication that is not approved under 4 section 505 or under section 351 of the Public Health 5 Service Act for such drug.''. 6 SEC. 2102. FACILITATING RESPONSIBLE COMMUNICATION 7 OF SCIENTIFIC AND MEDICAL DEVELOP- 8 MENTS. 9 (a) G UIDANCE .\u2014Not later than 18 months after the 10 date of enactment of this Act, the Secretary of Health and 11 Human Services shall issue draft guidance on facilitating 12 the responsible dissemination of truthful and nonmis-13 leading scientific and medical information not included in 14 the approved labeling of drugs and devices. 15 (b) D EFINITION .\u2014In this section, the terms ''drug'' 16 and ''device'' have the meaning given to such terms in sec-17 tion 201 of the Federal Food, Drug, and Cosmetic Act 18 (21 U.S.C. 321). 19 Subtitle G\u2014Antibiotic Drug 20 Development 21 SEC. 2121. APPROVAL OF CERTAIN DRUGS FOR USE IN A 22 LIMITED POPULATION OF PATIENTS. 23 (a) P URPOSE .\u2014The purpose of this section is to help 24 to expedite the development and availability of treatments 25 VerDate Nov 24 2008 11:47 Jul 02, serious or life-threatening bacterial or fungal infections 1 in patients with unmet needs, while maintaining safety 2 and effectiveness standards for such treatments, taking 3 into account the severity of the infection and the avail-4 ability or lack of alternative treatments. 5 (b) A PPROVAL OF CERTAIN ANTIBACTERIAL AND 6 ANTIFUNGAL DRUGS .\u2014Section 505 of the Federal Food, 7 Drug, and Cosmetic Act (21 U.S.C. 355), as amended by 8 section 2001, is further amended by adding at the end 9 the following new subsection: 10 ''(z) A PPROVAL OF CERTAIN ANTIBACTERIAL AND 11 ANTIFUNGAL DRUGS FOR USE IN A LIMITED POPU- 12 LATION OF PATIENTS .\u2014 13 ''(1) P ROCESS .\u2014At the request of the sponsor 14 of an antibacterial or antifungal drug that is in- 15 tended to treat a serious or life-threatening infec- 16 tion, the Secretary\u2014 17 ''(A) may execute a written agreement 18 with the sponsor on the process for developing 19 data to support an application for approval of 20 such drug, for use in a limited population of pa- 21 tients in accordance with this subsection; 22 ''(B) shall proceed in accordance with this 23 subsection only if a written agreement is 24 reached under subparagraph (A); 25 VerDate Nov 24 2008 11:47 shall provide the sponsor with an op- 1 portunity to request meetings under paragraph 2 (2); 3 ''(D) if a written agreement is reached 4 under subparagraph (A), may approve the drug 5 under this subsection for such use\u2014 6 ''(i) in a limited population of patients 7 for which there is an unmet medical need; 8 ''(ii) based on a streamlined develop- 9 ment program; and 10 ''(iii) only if the standards for ap- 11 proval under subsections (c) and (d) of this 12 section or licensure under section 351 of 13 the Public Health Service Act, as applica- 14 ble, are met; and 15 ''(E) in approving a drug in accordance 16 with this subsection, subject to subparagraph 17 (D)(iii), may rely upon\u2014 18 ''(i) traditional endpoints, alternate 19 endpoints, or a combination of traditional 20 and alternate endpoints, and, as appro- 21 priate, data sets of a limited size; and 22 ''(ii)(I) additional data, including pre- 23 clinical, pharmacologic, or pathophysiologic 24 evidence; 25 VerDate Nov 24 2008 1 pharmacokinetic 2 ''(III) data from phase 2 clinical 3 trials; and 4 ''(IV) such other confirmatory evi- 5 dence as the Secretary determines appro- 6 priate to approve the drug. 7 ''(2) F ORMAL MEETINGS .\u2014 8 ''(A) I N GENERAL .\u2014To help to expedite 9 and facilitate the development and review of a 10 drug for which a sponsor intends to request ap- 11 proval in accordance with this subsection, the 12 Secretary may, at the request of the sponsor, 13 conduct meetings that provide early consulta- 14 tion, timely advice, and sufficient opportunities 15 to develop an agreement described in paragraph 16 (1)(A) and help the sponsor design and conduct 17 a drug development program as efficiently as 18 possible, including the following types of meet- 19 ings: 20 ''(i) An early consultation meeting. 21 ''(ii) An assessment meeting. 22 ''(iii) A postapproval meeting. 23 ''(B) N O ALTERING OF GOALS .\u2014Nothing 24 in this paragraph shall be construed to alter 25 VerDate Nov 24 2008 11:47 Jul 02, 120 agreed upon goals and procedures identified in 1 the letters described in section 101(b) of the 2 Prescription Drug User Fee Amendments of 3 2012. 4 ''(C) B REAKTHROUGH THERAPIES .\u2014In the 5 case of a drug designated as a breakthrough 6 therapy under section 506(a), the sponsor of 7 such drug may elect to utilize meetings pro- 8 vided under such section with respect to such 9 drug in lieu of meetings described in subpara- 10 graph (A). 11 ''(3) L ABELING REQUIREMENT .\u2014The labeling 12 of an antibacterial or antifungal drug approved in 13 accordance with this subsection shall contain the 14 statement 'Limited Population' in a prominent man- 15 ner and adjacent to, and not more prominent than, 16 the brand name of the product. The prescribing in- 17 formation for such antibacterial or antifungal drug 18 required by section 201.57 of title 21, Code of Fed- 19 eral Regulations (or any successor regulation) shall 20 also include the following statement: 'This drug is 21 indicated for use in a limited and specific population 22 of patients.'. 23 ''(4) P ROMOTIONAL MATERIALS .\u2014The provi- 24 sions of section 506(c)(2)(B) shall apply with re- 25 VerDate Nov 24 2008 11:47 Jul 02, to approval in accordance with this subsection 1 to the same extent and in the same manner as such 2 provisions apply with respect to accelerated approval 3 in accordance with section 506(c)(1). 4 ''(5) T ERMINATION OF REQUIREMENTS OR CON - 5 DITIONS .\u2014If a drug is approved in accordance with 6 this subsection for an indication in a limited popu- 7 lation of patients and is subsequently approved or li- 8 censed under this section or section 351 of the Pub- 9 lic Health Service Act, other than in accordance with 10 this subsection, for\u2014 11 ''(A) the same indication and the same 12 conditions of use, the Secretary shall remove 13 any labeling requirements or postmarketing 14 conditions that were made applicable to the 15 drug under this subsection; or 16 ''(B) a different indication or condition of 17 use, the Secretary shall not apply the labeling 18 requirements and postmarketing conditions that 19 were made applicable to the drug under this 20 subsection to the subsequent approval of the 21 drug for such different indication or condition 22 of use. 23 ''(6) R ELATION TO OTHER PROVISIONS .\u2014Noth- 24 ing in this subsection shall be construed to prohibit 25 VerDate Nov 24 2008 11:47 Jul 02, 122 the approval of a drug for use in a limited popu- 1 lation of patients in accordance with this subsection, 2 in combination with\u2014 3 ''(A) an agreement on the design and size 4 of a clinical trial pursuant to subparagraphs 5 (B) and (C) of subsection (b)(5); 6 ''(B) designation and treatment of the 7 drug as a breakthrough therapy under section 8 506(a); 9 ''(C) designation and treatment of the 10 drug as a fast track product under section 11 506(b); or 12 ''(D) accelerated approval of the drug in 13 accordance with section 506(c). 14 ''(7) R ULE OF CONSTRUCTION .\u2014Nothing in 15 this subsection shall be construed\u2014 16 ''(A) to alter the standards of evidence 17 under subsection (c) or (d) (including the sub- 18 stantial evidence standard in subsection (d)); 19 ''(B) to waive or otherwise preclude the ap- 20 plication of requirements under subsection (o); 21 ''(C) to otherwise, in any way, limit the au- 22 thority of the Secretary to approve products 23 pursuant to this Act and the Public Health 24 VerDate Nov 24 2008 11:47 Jul 02, 123 Service Act as authorized prior to the date of 1 enactment of this subsection; or 2 ''(D) to restrict in any manner, the pre- 3 scribing of antibiotics or other products by 4 health care providers, or to otherwise limit or 5 restrict the practice of health care. 6 ''(8) E FFECTIVE IMMEDIATELY .\u2014The Sec- 7 retary shall have the authorities vested in the Sec- 8 retary by this subsection beginning on the date of 9 enactment of this subsection, irrespective of when 10 and whether the Secretary promulgates final regula- 11 tions or guidance. 12 .\u2014In this subsection: 13 ''(A) E ARLY CONSULTATION MEETING .\u2014 14 The term 'early consultation meeting' means a 15 pre-investigational new drug meeting or an end- 16 of-phase-1 meeting that\u2014 17 ''(i) is conducted to review and reach 18 a written agreement\u2014 19 ''(I) on the scope of the stream- 20 lined development plan for a drug for 21 which a sponsor intends to request ap- 22 proval in accordance with this sub- 23 section; and 24 VerDate Nov 24 2008 11:47 ''(II) which, as appropriate, may 1 include agreement on the design and 2 size of necessary preclinical and clin- 3 ical studies early in the development 4 process, including clinical trials whose 5 data are intended to form the primary 6 basis for an effectiveness claim; and 7 ''(ii) provides an opportunity to dis- 8 cuss expectations of the Secretary regard- 9 ing studies or other information that the 10 Secretary deems appropriate for purposes 11 of applying paragraph (5), relating to the 12 termination of labeling requirements or 13 postmarketing conditions. 14 ''(B) A SSESSMENT MEETING .\u2014The term 15 'assessment meeting' means an end-of-phase 2 16 meeting, pre-new drug application meeting, or 17 pre-biologics license application meeting con- 18 ducted to resolve questions and issues raised 19 during the course of clinical investigations, and 20 details addressed in the written agreement re- 21 garding postapproval commitments or expan- 22 sion of approved uses. ''(C) P OSTAPPROVAL MEETING .\u2014The term 24 'postapproval meeting' means a meeting fol- 25 VerDate Nov 24 2008 11:47 Jul initial approval or licensure of the drug 1 for use in a limited population, to discuss any 2 issues identified by the Secretary or the sponsor 3 regarding postapproval commitments or expan- 4 sion of approved uses.''. 5 (c) G UIDANCE .\u2014Not later than 18 months after the 6 date of enactment of this Act, the Secretary of Health and 7 Human Services, acting through the Commissioner of 8 Food and Drugs, shall issue draft guidance describing cri-9 teria, process, and other general considerations for dem-10 onstrating the safety and effectiveness of antibacterial and 11 antifungal drugs to be approved for use in a limited popu-12 lation in accordance with section 505(z) of the Federal 13 Food, Drug, and Cosmetic Act, as added by subsection 14 (b). 15 (d) C ONFORMING AMENDMENTS .\u2014 16 (1) L ICENSURE OF CERTAIN BIOLOGICAL PROD - 17 UCTS .\u2014Section 351(j) of the Public Health Service 18 Act (42 U.S.C. 262(j)) is amended\u2014 19 (A) by striking ''(j)'' and inserting 20 ''(j)(1)''; 21 (B) by inserting ''505(z),'' after ''505(p),''; 22 and 23 (C) by adding at the end the following new 24 paragraph: 25 VerDate Nov 24 2008 11:47 Jul In applying section 505(z) of the Federal Food, 1 Drug, and Cosmetic Act to the licensure of biological prod-2 ucts under this section\u2014 3 ''(A) references to an antibacterial or antifungal 4 drug that is intended to treat a serious or life- 5 threatening infection shall be construed to refer to 6 a biological product intended to treat a serious or 7 life-threatening bacterial or fungal infection; and 8 ''(B) references to approval of a drug under 9 section 505(c) of such Act shall be construed to 10 refer to a licensure of a biological product under 11 subsection (a) of this section.''. 12 (2) M ISBRANDING .\u2014Section 502 of the Federal 13 Food, Drug, and Cosmetic Act (21 U.S.C. 352) is 14 amended by adding at the end the following new 15 subsection: 16 ''(dd) If it is a drug approved in accordance with sec- 17 tion 505(z) and its labeling does not meet the require-18 ments under paragraph (3) of such subsection, subject to 19 paragraph (5) of such subsection.''. 20 (e) E VALUATION .\u2014 21 (1) A SSESSMENT .\u2014Not later than 48 months 22 after the date of enactment of this Act, the Sec- 23 retary of Health and Human Services shall publish 24 for public comment an assessment of the program 25 VerDate Nov 24 2008 11:47 Jul 02, established under section 505(z) of the Federal 1 Food, Drug, and Cosmetic Act, as added by sub- 2 section (b). Such assessment shall determine if the 3 limited-use pathway established under such section 4 505(z) has improved or is likely to improve patient 5 access to novel antibacterial or antifungal treat- 6 ments and assess how the pathway could be ex- 7 panded to cover products for serious or life-threat- 8 ening diseases or conditions beyond bacterial and 9 fungal infections. 10 (2) M EETING .\u2014Not later than 90 days after 11 the date of the publication of such assessment, the 12 Secretary, acting through the Commissioner of Food 13 and Drugs, shall hold a public meeting to discuss 14 the findings of the assessment, during which public 15 stakeholders may present their views on the success 16 of the program established under section 505(z) of 17 the Federal Food, Drug, and Cosmetic Act, as 18 added by subsection (b), and the appropriateness of 19 expanding such program. 20 (f) E XPANSION OF PROGRAM .\u2014If the Secretary of 21 Health and Human Services determines, based on the as-22 sessment under subsection (e)(1), evaluation of the assess-23 ment, and any other relevant information, that the public 24 health would benefit from expansion of the limited-use 25 VerDate Nov 24 2008 11:47 Jul pathway established under section 505(z) of the Federal 1 Food, Drug, and Cosmetic Act (as added by subsection 2 (b)) beyond the drugs approved in accordance with such 3 section, the Secretary may expand such limited-use path-4 way in accordance with such a determination. The ap-5 proval of any drugs under any such expansion shall be 6 subject to the considerations and requirements described 7 in such section 505(z) for purposes of expansion to other 8 serious or life-threatening diseases or conditions. 9 (g) M ONITORING .\u2014The Public Health Service Act is 10 amended by inserting after section 317T (42 U.S.C. 11 247b-22) the following: 12 ''SEC. 317U. MONITORING ANTIBACTERIAL AND 13 DRUG USE AND RESISTANCE. 14 ''(a) M ONITORING .\u2014The Secretary shall use an ap- 15 propriate monitoring system to monitor\u2014 16 ''(1) the use of antibacterial and antifungal 17 drugs, including those receiving approval or licensure 18 for a limited population pursuant to section 505(z) 19 of the Federal Food, Drug, and Cosmetic Act; and 20 ''(2) changes in bacterial and fungal resistance 21 to drugs. 22 ''(b) P UBLIC AVAILABILITY OF DATA.\u2014The Sec- 23 retary shall make summaries of the data derived from 24 VerDate Nov 24 2008 11:47 Jul 02, 129 monitoring under this section publicly available for the 1 purposes of\u2014 2 ''(1) improving the monitoring of important 3 trends in antibacterial and antifungal resistance; 4 and 5 ''(2) ensuring appropriate stewardship of anti- 6 bacterial and antifungal drugs, including those re- 7 ceiving approval or licensure for a limited population 8 pursuant to section 505(z) of the Federal Food, 9 Drug, and Cosmetic Act.''. 10 SEC. 2122. SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA 11 FOR MICROORGANISMS. 12 (a) I NGENERAL .\u2014Section 511 of the Federal Food, 13 Drug, and Cosmetic Act (21 U.S.C. 360a) is amended to 14 read as follows: 15 ''SEC. 511. IDENTIFYING AND UPDATING SUSCEPTIBILITY 16 TEST INTERPRETIVE CRITERIA FOR MICRO- 17 ORGANISMS. 18 ''(a) P URPOSE ; IDENTIFICATION OF CRITERIA .\u2014 19 ''(1) P URPOSE .\u2014The purpose of this section is 20 to provide the Secretary with an expedited, flexible 21 method for\u2014 22 ''(A) clearance or premarket approval of 23 antimicrobial susceptibility testing devices uti- 24 lizing updated, recognized susceptibility test in- 25 VerDate Nov 24 2008 11:47 Jul 02, terpretive criteria to characterize the in vitro 1 susceptibility of particular bacteria, fungi, or 2 other microorganisms to antimicrobial drugs; 3 and 4 ''(B) providing public notice of the avail- 5 ability of recognized interpretive criteria to 6 meet premarket submission requirements or 7 other requirements under this Act for anti- 8 microbial susceptibility testing devices. 9 ''(2) I N GENERAL .\u2014The Secretary shall iden- 10 tify appropriate susceptibility test interpretive 11 teria with respect to antimicrobial drugs\u2014 12 ''(A) if such criteria are available on the 13 date of approval of the drug under section 505 14 of this Act or licensure of the drug under sec- 15 tion 351 of the Public Health Service Act (as 16 applicable), upon such approval or licensure; or 17 ''(B) if such criteria are unavailable on 18 such date, on the date on which such criteria 19 are available for such drug. 20 ''(3) B ASES FOR INITIAL IDENTIFICATION .\u2014 21 The Secretary shall identify appropriate suscepti- 22 bility test interpretive criteria under paragraph (2), 23 based on the Secretary's review of, to the extent 24 available and relevant\u2014 25 VerDate Nov 24 2008 11:47 Jul and 5 ''(C) such other evidence and information 6 as the Secretary considers appropriate. 7 ''(b) S USCEPTIBILITY TESTINTERPRETIVE CRITERIA 8 WEBSITE .\u2014 9 ''(1) I N GENERAL .\u2014Not later than 1 year after 10 the date of the enactment of the 21st Century Cures 11 Act, the Secretary shall establish, and maintain 12 thereafter, on the website of the Food and Drug Ad- 13 ministration, a dedicated website that contains a list 14 of any appropriate new or updated susceptibility test 15 interpretive criteria standards in accordance with 16 paragraph (2) (referred to in this section as the 'In- 17 terpretive Criteria Website'). 18 ''(2) L ISTING OF SUSCEPTIBILITY TEST INTER - 19 PRETIVE CRITERIA STANDARDS .\u2014 20 ''(A) I N GENERAL .\u2014The list described in 21 paragraph (1) shall consist of any new or up- 22 dated susceptibility test interpretive criteria 23 standards that are\u2014 24 VerDate Nov 24 2008 11:47 Jul ''(i) established by a nationally or 1 internationally recognized standard devel- 2 opment organization that\u2014 3 ''(I) establishes and maintains 4 procedures to address potential con- 5 flicts of interest and ensure trans- 6 parent decisionmaking; 7 ''(II) holds open meetings to en- 8 sure that there is an opportunity for 9 public input by interested parties, and 10 establishes and maintains processes to 11 ensure that such input is considered 12 in decisionmaking; and 13 ''(III) permits its standards to be 14 made publicly available, through the 15 National Library of Medicine or an- 16 other similar source acceptable to the 17 Secretary; and 18 ''(ii) recognized in whole, or in part, 19 by the Secretary under subsection (c). 20 ''(B) O THER LIST .\u2014The Interpretive Cri- 21 teria Website shall, in addition to the list de- 22 scribed in subparagraph (A), include a list of 23 interpretive criteria, if any, that the Secretary 24 has determined to be appropriate with respect 25 VerDate Nov 24 2008 11:47 Jul 02, marketed antimicrobial drugs, 1 where\u2014 2 ''(i) the Secretary does not recognize, 3 in whole or in part, an interpretive criteria 4 standard described under subparagraph 5 (A) otherwise applicable to such a drug; 6 ''(ii) the Secretary withdraws under 7 subsection (c)(1)(B) recognition of a 8 standard, in whole or in part, otherwise 9 applicable to such a drug; 10 ''(iii) the Secretary approves an appli- 11 cation under section 505 of this Act or sec- 12 tion 351 of the Public Health Service Act, 13 as applicable, with respect to marketing of 14 such a drug for which there are no rel- 15 evant interpretive criteria included in a 16 standard recognized by the Secretary 17 under subsection (c); or 18 ''(iv) because the characteristics of 19 such a drug differ from other drugs with 20 the same active ingredient, the interpretive 21 criteria with respect to such drug\u2014 22 ''(I) differ from otherwise appli- 23 cable interpretive criteria included in 24 a standard listed under subparagraph 25 VerDate Nov 24 2008 11:47 Jul or interpretive criteria otherwise 1 listed under this subparagraph; and 2 ''(II) are determined by the Sec- 3 retary to be appropriate for the drug. 4 ''(C) R EQUIRED STATEMENTS OF LIMITA - 5 TIONS OF INFORMATION .\u2014The Interpretive Cri- 6 teria Website shall the following: 7 ''(i) A statement that\u2014 8 ''(I) the website provides infor- 9 mation about the susceptibility of bac- 10 teria, fungi, or other microorganisms 11 to a certain drug (or drugs); and 12 ''(II) the safety and efficacy of 13 the drug in treating clinical infections 14 due to such bacteria, fungi, or other 15 microorganisms may not have been es- 16 tablished in adequate and well-con- 17 trolled clinical trials and the clinical 18 significance of such susceptibility in- 19 formation in such trials is unknown. 20 ''(ii) A statement that directs health 21 care practitioners to consult the approved 22 product labeling for specific drugs to deter- 23 mine the uses for which the Food and 24 VerDate Nov 24 2008 11:47 Jul 02, Drug Administration has approved the 1 product. 2 ''(iii) Any other statement that the 3 Secretary determines appropriate to ade- 4 quately convey the limitations of the data 5 supporting susceptibility test interpretive 6 criteria standard listed on the website. 7 ''(3) N OTICE .\u2014Not later than the date on 8 which the Interpretive Criteria Website is estab- 9 lished, the Secretary shall publish a notice of that 10 establishment in the Federal Register. 11 ''(4) I NAPPLICABILITY OF MISBRANDING PROVI - 12 SION.\u2014The inclusion in the approved labeling of an 13 antimicrobial drug of a reference or hyperlink to the 14 Interpretive Criteria Website, in and of itself, shall 15 not cause the drug to be misbranded in violation of 16 section 502, or the regulations promulgated there- 17 under. 18 ''(5) T RADE SECRETS AND CONFIDENTIAL IN - 19 FORMATION .\u2014Nothing in this section shall be con- 20 strued as authorizing the Secretary to disclose any 21 information that is a trade secret or confidential in- 22 formation subject to section 552(b)(4) of title 5, 23 United States Code. 24 VerDate Nov 24 2008 11:47 Jul 02, OF SUSCEPTIBILITY TESTINTER - 1 PRETIVE CRITERIA FROM STANDARD DEVELOPMENT OR- 2 GANIZATIONS .\u2014 3 ''(1) I N GENERAL .\u2014Beginning on the date of 4 the establishment of the Interpretive Criteria 5 Website, and at least every 6 months thereafter, the 6 Secretary shall\u2014 7 ''(A) evaluate any appropriate new or up- 8 dated susceptibility test interpretive criteria 9 standards established by a nationally or inter- 10 nationally recognized standard development or- 11 ganization described in subsection (b)(2)(A)(i); 12 and 13 ''(B) publish on the public website of the 14 Food and Drug Administration a notice\u2014 15 ''(i) withdrawing recognition of any 16 different susceptibility test interpretive cri- 17 teria standard, in whole or in part; 18 ''(ii) recognizing the new or updated 19 standards; 20 ''(iii) recognizing one or more parts of 21 the new or updated interpretive criteria 22 specified in such a standard and declining 23 to recognize the remainder of such stand- 24 ard; and 25 VerDate Nov 24 2008 11:47 ''(iv) making any necessary updates to 1 the lists under subsection (b)(2). 2 ''(2) B ASES FOR UPDATING INTERPRETIVE CRI - 3 TERIA STANDARDS .\u2014In evaluating new or updated 4 susceptibility test interpretive criteria standards 5 under paragraph (1)(A), the Secretary may con- 6 sider\u2014 7 ''(A) the Secretary's determination that 8 such a standard is not applicable to a particular 9 drug because the characteristics of the drug dif- 10 fer from other drugs with the same active in- 11 gredient; 12 ''(B) information provided by interested 13 third parties, including public comment on the 14 annual compilation of notices published under 15 paragraph (3); 16 ''(C) any bases used to identify suscepti- 17 bility test interpretive criteria under subsection 18 (a)(2); and 19 ''(D) such other information or factors as 20 the Secretary determines appropriate. 21 ''(3) A NNUAL COMPILATION OF NOTICES .\u2014 22 Each year, the Secretary shall compile the notices 23 published under paragraph (1)(B) and publish such 24 compilation in the Federal Register and provide for 25 VerDate Nov 24 2008 11:47 Jul 02, 138 public comment. If the Secretary receives comments, 1 the Secretary shall review such comments and, if the 2 Secretary determines appropriate, update pursuant 3 to this subsection susceptibility test interpretive cri- 4 teria standards\u2014 5 ''(A) recognized by the Secretary under 6 this subsection; or 7 ''(B) otherwise listed on the Interpretive 8 Criteria Website under subsection (b)(2). 9 ''(4) R TO SECTION 514( c).\u2014Any sus- 10 ceptibility test interpretive standard recognized 11 under this subsection or any criteria otherwise listed 12 under subsection (b)(2)(B) shall be deemed to be 13 recognized as a standard by the Secretary under sec- 14 tion 514(c)(1). 15 ''(5) V OLUNTARY USE OF INTERPRETIVE CRI - 16 TERIA .\u2014Nothing in this section prohibits a person 17 from seeking approval or clearance of a drug or de- 18 vice, or changes to the drug or the device, on the 19 basis of susceptibility test interpretive criteria stand- 20 ards which differ from those recognized pursuant to 21 paragraph (1). 22 ''(d) A NTIMICROBIAL DRUG LABELING .\u2014 23 ''(1) D RUGS MARKETED PRIOR TO ESTABLISH - 24 MENT OF INTERPRETIVE CRITERIA WEBSITE .\u2014With 25 VerDate Nov 24 2008 11:47 respect to an antimicrobial drug lawfully introduced 1 or delivered for introduction into interstate com- 2 merce for commercial distribution before the estab- 3 lishment of the Interpretive Criteria Website, a hold- 4 er of an approved application under section 505 of 5 this Act or section 351 of the Public Health Service 6 Act, as applicable, for each such drug\u2014 7 ''(A) not later than 1 year after establish- 8 ment of the Interpretive Criteria Website, shall 9 submit to the Secretary a supplemental applica- 10 tion for purposes of changing the drug's label- 11 ing to substitute a reference or hyperlink to 12 such Website for any susceptibility test inter- 13 pretive criteria and related information; and 14 ''(B) may begin distribution of the drug in- 15 volved upon receipt by the Secretary of the sup- 16 plemental application for such change. 17 ''(2) D RUGS MARKETED SUBSEQUENT TO ES - 18 TABLISHMENT OF INTERPRETIVE CRITERIA 19 WEBSITE .\u2014With respect to antimicrobial drugs law- 20 fully introduced or delivered for introduction into 21 interstate commerce for commercial distribution on 22 or after the date of the establishment of the Inter- 23 pretive Criteria Website, the labeling for such a drug 24 shall include, in lieu of susceptibility test interpretive 25 VerDate Nov 24 2008 11:47 Jul 140 criteria and related information, a reference to such 1 Website. 2 ''(e) S PECIAL CONDITION FOR MARKETING OF ANTI- 3 MICROBIAL SUSCEPTIBILITY TESTING DEVICES .\u2014 4 ''(1) I N GENERAL .\u2014Notwithstanding sections 5 501, 502, 510, 513, and 515, if the conditions speci- 6 fied in paragraph (2) are met (in addition to other 7 applicable provisions under this chapter) with re- 8 spect to an antimicrobial susceptibility testing device 9 described in subsection (f)(1), the Secretary may au- 10 thorize the marketing of such device for a use de- 11 scribed in such subsection. 12 ''(2) C ONDITIONS APPLICABLE TO ANTI - 13 MICROBIAL SUSCEPTIBILITY TESTING DEVICES .\u2014 14 The conditions specified in this paragraph are the 15 following: 16 ''(A) The device is used to make a deter- 17 mination of susceptibility using susceptibility 18 test interpretive criteria that are\u2014 19 ''(i) included in a standard recognized 20 by the Secretary under subsection (c); or 21 ''(ii) otherwise listed on the Interpre- 22 tive Criteria Website under subsection 23 (b)(2). 24 VerDate Nov 24 2008 11:47 such device promi- 1 nently and conspicuously\u2014 2 ''(i) includes a statement that\u2014 3 ''(I) the device provides informa- 4 tion about the susceptibility of bac- 5 teria and fungi to certain drugs; and 6 ''(II) the safety and efficacy of 7 such drugs in treating clinical infec- 8 tions due to such bacteria or fungi 9 may not have been established in ade- 10 quate and well-controlled clinical trials 11 and the clinical significance of such 12 susceptibility information in those in- 13 stances is unknown; 14 ''(ii) includes a statement directing 15 health care practitioners to consult the ap- 16 proved labeling for drugs tested using such 17 a device, to determine the uses for which 18 the Food and Drug Administration has ap- 19 proved such drugs; and 20 ''(iii) includes any other statement the 21 Secretary determines appropriate to ade- 22 quately convey the limitations of the data 23 supporting the interpretive criteria de- 24 scribed in subparagraph (A). 25 VerDate Nov 24 2008 11:47 The term 'antimicrobial susceptibility test- 2 ing device' means a device that utilizes susceptibility 3 test interpretive criteria to determine and report the 4 in vitro susceptibility of certain microorganisms to a 5 drug (or drugs). 6 ''(2) The term 'qualified infectious disease 7 product' means a qualified infectious disease product 8 designated under section 505E(d). 9 ''(3) The term 'susceptibility test interpretive 10 criteria' means\u2014 11 ''(A) one or more specific numerical values 12 which characterize the susceptibility of bacteria 13 or other microorganisms to the drug tested; and 14 ''(B) related categorizations of such sus- 15 ceptibility, including categorization of the drug 16 as susceptible, intermediate, resistant, or such 17 other term as the Secretary determines appro- 18 priate. 19 ''(4)(A) The term 'antimicrobial drug' means, 20 subject to subparagraph (B), a systemic anti- 21 bacterial or antifungal drug that\u2014 22 ''(i) is intended for human use in the treat- 23 ment of a disease or condition caused by a bac- 24 terium or fungus; 25 VerDate Nov 24 2008 may include a qualified infectious dis- 1 ease product designated under section 505E(d); 2 and 3 ''(iii) is subject to section 503(b)(1). 4 ''(B) If provided by the Secretary through regu- 5 lations, such term may include\u2014 6 ''(i) drugs other than systemic anti- 7 bacterial and antifungal drugs; and 8 ''(ii) biological products (as such term is 9 defined in section 351 of the Public Health 10 Service Act) to the extent such products exhibit 11 antimicrobial activity. 12 ''(g) R ULE OF CONSTRUCTION .\u2014Nothing in this sec- 13 tion shall be construed\u2014 14 ''(1) to alter the standards of evidence\u2014 15 ''(A) under subsection (c) or (d) of section 16 505, including the substantial evidence stand- 17 ard in section 505(d), or under section 351 of 18 the Public Health Service Act (as applicable); 19 or 20 ''(B) with respect to marketing authoriza- 21 tion for devices, under section 510, 513, or 515; 22 ''(2) to apply with respect to any drug, device, 23 or biological product, in any context other than\u2014 24 ''(A) an antimicrobial drug; or 25 VerDate Nov 24 2008 an antimicrobial susceptibility testing 1 device that uses susceptibility test interpretive 2 criteria to characterize and report the in vitro 3 susceptibility of certain bacteria, fungi, or other 4 microorganisms to antimicrobial drugs in ac- 5 cordance with this section; or 6 ''(3) unless specifically stated, to have any ef- 7 fect on authorities provided under other sections of 8 this Act, including any regulations issued under such 9 sections.''. 10 (b) C ONFORMING AMENDMENTS .\u2014 11 (1) R EPEAL OF RELATED AUTHORITY .\u2014Section 12 1111 of the Food and Drug Administration Amend- 13 ments Act of 2007 (42 U.S.C. 247d-5a; relating to 14 identification of clinically susceptible concentrations 15 of antimicrobials) is repealed. 16 (2) C LERICAL AMENDMENT .\u2014The table of con- 17 tents in section 2 of the Food and Drug Administra- 18 tion Amendments Act of 2007 is amended by strik- 19 ing the item relating to section 1111. 20 (3) M ISBRANDING .\u2014Section 502 of the Federal 21 Food, Drug, and Cosmetic Act (21 U.S.C. 352), as 22 amended by section 2121, is further amended by 23 adding at the end the following: 24 VerDate Nov 24 2008 11:47 Jul If it is an antimicrobial drug and its labeling 1 fails to conform with the requirements under section 2 511(d).''. 3 (4) R ECOGNITION OF INTERPRETIVE CRITERIA 4 AS DEVICE STANDARD .\u2014Section 514(c)(1)(A) of the 5 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 6 360d(c)(1)(A)) is amended by inserting after ''the 7 Secretary shall, by publication in the Federal Reg- 8 ister'' the following: ''(or, with respect to suscepti- bility test interpretive criteria or standards recog- 10 nized or otherwise listed under section 511, by post- 11 ing on the Interpretive Criteria Website in accord- 12 ance with such section)''. 13 (c) R EPORT TO CONGRESS .\u2014Not later than two 14 years after the date of enactment of this Act, the Sec-15 retary of Health and Human Services shall submit to the 16 Committee on Energy and Commerce of the House of 17 Representatives and the Committee on Health, Education, 18 Labor and Pensions of the Senate a report on the progress 19 made in implementing section 511 of the Federal Food, 20 Drug, and Cosmetic Act (21 U.S.C. 360a), as amended 21 by this section. 22 (d) R EQUESTS FOR UPDATES TO INTERPRETIVE CRI- 23 TERIA WEBSITE .\u2014Chapter 35 of title 44, United States 24 Code, shall not apply to the collection of information from 25 VerDate Nov 24 2008 11:47 Jul 02, 146 interested parties regarding the updating of lists under 1 paragraph (2) of subsection (b) section 511 of the Federal 2 Food, Drug, and Cosmetic Act (as amended by subsection 3 (a)) and posted on the Interpretive Criteria Website estab-4 lished under paragraph (1) of such subsection (b). 5 (e) N OEFFECT ON HEALTH CARE PRACTICE .\u2014 6 Nothing in this subtitle (including the amendments made 7 by this subtitle) shall be construed to restrict, in any man-8 ner, the prescribing or administering of antibiotics or 9 other products by health care practitioners, or to limit the 10 practice of health care. 11 SEC. 2123. ENCOURAGING THE DEVELOPMENT AND USE OF 12 DISARM DRUGS. 13 (a) A DDITIONAL PAYMENT FOR DISARM D RUGS 14 UNDER MEDICARE .\u2014 15 (1) I N GENERAL .\u2014Section 1886(d)(5) of the 16 Social Security Act (42 U.S.C. 1395ww(d)(5)) is 17 amended by adding at the end the following new 18 subparagraph: 19 ''(M)(i) As part of the annual rulemaking conducted 20 with respect to payment for subsection (d) hospitals for 21 each fiscal year beginning with fiscal year 2018, the Sec-22 retary shall\u2014 23 ''(I) include a list of the DISARM drugs for 24 such fiscal year; and 25 VerDate Nov 24 2008 11:47 Jul respect to discharges by eligible hos- 1 pitals that involve a drug so listed, provide for an 2 additional payment to be made under this subsection 3 in accordance with the provisions of this subpara- 4 graph. 5 ''(ii) Additional payments may not be made for a 6 drug under this subparagraph\u2014 7 ''(I) other than during the 5-fiscal-year period 8 beginning with the fiscal year for which the drug is 9 first included in the list described in clause (i)(I); 10 and 11 ''(II) with respect to which payment has ever 12 been made pursuant to subparagraph (K). 13 ''(iii) For purposes of this subparagraph, the term 14 'DISARM drug' means a product that is approved for use, 15 or a product for which an indication is first approved for 16 use, by the Food and Drug Administration on or after 17 December 1, 2014, and that the Food and Drug Adminis-18 tration determines is an antimicrobial product (as defined 19 in clause (iv)) and is intended to treat an infection\u2014 20 ''(I) for which there is an unmet medical need; 21 and 22 ''(II) which is associated with high rates of 23 mortality or significant patient morbidity, as deter- 24 mined in consultation with the Director of the Cen- 25 VerDate Nov 24 2008 11:47 Jul ters for Disease Control and Prevention and the in- 1 fectious disease professional community. 2 ''(iv) For purposes of clause (iii), the term 'anti- 3 microbial product' means a product that either\u2014 4 ''(I) is intended to treat an infection caused by, 5 or likely to be caused by, a qualifying pathogen (as 6 defined under section 505E(f) of the Federal Food, 7 Drug, and Cosmetic Act); or 8 ''(II) meets the definition of a qualified infec- 9 tious disease product under section 505E(g) of the 10 Federal Food, Drug, and Cosmetic Act. 11 Such determination may be revoked only upon a finding 12 that the request for such determination contained an un-13 true statement of material fact. 14 ''(v) For purposes of this subparagraph, the term 'eli- 15 gible hospital' means a subsection (d) hospital that partici-16 pates in the National Healthcare Safety Network of the 17 Centers for Disease Control and Prevention (or, to the ex-18 tent a similar surveillance system that includes reporting 19 about antimicrobial drugs is determined by the Secretary 20 to be available to such hospitals, such similar surveillance 21 system as the Secretary may specify). 22 ''(vi) Subject to the succeeding provisions of this sub- 23 paragraph, the additional payment under this subpara-24 VerDate Nov 24 2008 11:47 Jul 149 graph, with respect to a drug, shall be in the amount pro-1 vided for such drug under section 1847A. 2 ''(vii) As part of the rulemaking referred to in clause 3 (i) for each fiscal year, the Secretary shall estimate\u2014 4 ''(I) total add-on payments (as defined in sub- 5 clause (I) of clause (ix)); and 6 ''(II) total hospital payments (as defined in 7 subclause (II) of such clause). 8 ''(viii) If the total add-on payments estimated pursu- 9 ant to clause (vii)(I) for a fiscal year exceed 0.02 percent 10 of the total hospital payments estimated pursuant to 11 clause (vii)(II) for such fiscal year, the Secretary shall re-12 duce in a pro rata manner the amount of each additional 13 payment under this subsection pursuant to this subpara-14 graph for such fiscal year in order to ensure that the total 15 add-on payments estimated for such fiscal year do not ex-16 ceed 0.02 percent of the total hospital payments estimated 17 for such fiscal year. 18 ''(ix) In this subparagraph: 19 ''(I) The term 'total add-on payments' means, 20 with respect to a fiscal year, the total amount of the 21 additional payments under this subsection pursuant 22 to this subparagraph for discharges in such fiscal 23 year without regard to the application of clause 24 (viii). 25 VerDate Nov 24 2008 11:47 Jul term 'total hospital payments' means, 1 with respect to a fiscal year, the total amount of 2 payments made under this subsection for all dis- 3 charges in such fiscal year.''. 4 (2) C ONFORMING AMENDMENTS .\u2014 5 (A) N O DUPLICATIVE NTAP PAYMENTS .\u2014 6 Section 1886(d)(5)(K)(vi) of the Social Security 7 Act (42 U.S.C. 1395ww(d)(5)(K)(vi)) is amend- 8 ed by inserting ''and if additional payment has 9 never been made under this subsection pursu- 10 ant to subparagraph (M) with respect to the 11 service or technology'' before the period at the 12 end. 13 (B) A CCESS TO PRICE INFORMATION .\u2014 14 Section 1927(b)(3)(A) of the Social Security 15 Act (42 U.S.C. 1396r-8(b)(3)(A)) is amend- 16 ed\u2014 17 (i) in clause (ii)\u2014 18 (I) by striking ''for each'' and in- 19 serting '', for each''; and 20 (II) by striking ''and'' at the end; 21 (ii) in clause (iii)\u2014 22 (I) in subclause (II), by inserting 23 ''or under section 1886(d) pursuant to 24 VerDate Nov 24 2008 11:47 Jul of such section,'' 1 after ''1847A,''; 2 (II) in the matter following sub- 3 clause (III), by striking ''or 4 1881(b)(13)(A)(ii)'' and inserting '', 5 section 1881(b)(13)(A)(ii), or section 6 1886(d)(5)(M)''; and 7 (III) by striking the period at the 8 end and inserting ''; and''; and 9 (iii) in clause (iv), by striking the 10 semicolon at the end and inserting a pe- 11 riod. 12 (b) S TUDY AND REPORT ON REMOVING BARRIERS TO 13 DEVELOPMENT OF DISARM D RUGS .\u2014 14 (1) S TUDY .\u2014The Comptroller General of the 15 United States shall, in consultation with the Direc- 16 tor of the National Institutes of Health, the Com- 17 missioner of Food and Drugs, and the Director of 18 the Centers for Disease Control and Prevention, con- 19 duct a study to\u2014 20 (A) identify and examine the barriers that 21 prevent the development of DISARM drugs, as 22 defined in section 1886(d)(5)(M)(iii) of the So- 23 cial Security Act (42 U.S.C. 24 VerDate Nov 24 2008 11:47 Jul added by subsection 1 (a)(1); and 2 (B) develop recommendations for actions 3 to be taken in order to overcome any barriers 4 identified under subparagraph (A). 5 (2) R EPORT .\u2014Not later than 1 year after the 6 date of the enactment of this Act, the Comptroller 7 General shall submit to Congress a report on the 8 study conducted under paragraph (1). 9 Subtitle H\u2014Vaccine Access, 10 Certainty, and Innovation 11 SEC. 2141. TIMELY REVIEW OF VACCINES BY THE ADVISORY 12 COMMITTEE ON IMMUNIZATION PRACTICES. 13 Section 2102(a) of the Public Health Service Act (42 14 U.S.C. 300aa-2(a)) is amended by adding at the end the 15 following: 16 ''(10) A DVISORY COMMITTEE ON IMMUNIZATION 17 PRACTICES .\u2014 18 ''(A) S TANDARD PERIODS OF TIME FOR 19 MAKING RECOMMENDATIONS .\u2014Upon the licen- 20 sure of any vaccine or any new indication for a 21 vaccine, the Director of the Program shall di- 22 rect the Advisory Committee on Immunization 23 Practices, at its next regularly scheduled meet- 24 ing, to consider the use of the vaccine. 25 VerDate Nov 24 2008 11:47 Jul 02, E XPEDITED REVIEW PURSUANT TO 1 REQUEST BY SPONSOR OR MANUFACTURER .\u2014If 2 the Advisory Committee does not make rec- 3 ommendations with respect to the use of a vac- 4 cine at the Advisory Committee's first regularly 5 scheduled meeting after the licensure of the 6 vaccine or any new indication for the vaccine, 7 the Advisory Committee, at the request of the 8 sponsor of the vaccine, shall make such rec- 9 ommendations on an expedited basis. 10 ''(C) E XPEDITED REVIEW FOR BREAK - 11 THROUGH THERAPIES AND FOR USE DURING 12 PUBLIC HEALTH EMERGENCIES .\u2014If a vaccine 13 is designated as a breakthrough therapy under 14 section 506 of the Federal Food, Drug, and 15 Cosmetic Act and is licensed under section 351 16 of this Act, the Advisory Committee shall make 17 recommendations with respect to the use of the 18 vaccine on an expedited basis. 19 ''(D) D EFINITION .\u2014In this paragraph, the 20 terms 'Advisory Committee on Immunization 21 Practices' and 'Advisory Committee' mean the 22 advisory committee on immunization practices 23 established by the Secretary pursuant to section 24 VerDate Nov 24 2008 11:47 Jul 02, 154 222, acting through the Director of the Centers 1 for Disease Control and Prevention.''. 2 SEC. 2142. REVIEW OF PROCESSES AND CONSISTENCY OF 3 ACIP RECOMMENDATIONS. 4 (a) R EVIEW .\u2014The Director of the Centers for Dis- 5 ease Control and Prevention shall conduct a review of the 6 process used by the Advisory Committee on Immunization 7 Practices to evaluate consistency in formulating and 8 issuing recommendations pertaining to vaccines. 9 (b) C ONSIDERATIONS .\u2014The review under subsection 10 (a) shall include assessment of\u2014 11 (1) the criteria used to evaluate new and exist- 12 ing vaccines; 13 (2) the Grading of Recommendations, Assess- 14 ment, Development, and Evaluation (GRADE) ap- 15 proach to the review and analysis of scientific and 16 economic data, including the scientific basis for such 17 approach; and 18 (3) the extent to which the processes used by 19 the working groups of the Advisory Committee on 20 Immunization Practices are consistent among 21 groups. 22 (c) S TAKEHOLDERS .\u2014In carrying out the review 23 under subsection (a), the Director of the Centers for Dis-24 VerDate Nov 24 2008 11:47 Jul Control and Prevention shall solicit input from vac-1 cine stakeholders. 2 (d) R EPORT .\u2014Not later than 18 months after the 3 date of enactment of this Act, the Director of the Centers 4 for Disease Control and Prevention shall submit to the 5 appropriate committees of the Congress and make publicly 6 available a report on the results of the review under sub-7 section (a), including recommendations on improving the 8 consistency of the process described in such subsection. 9 (e) D EFINITION .\u2014In this section, the term ''Advisory 10 Committee on Immunization Practices'' means the advi-11 sory committee on immunization practices established by 12 the Secretary of Health and Human Services pursuant to 13 section 222 of the Public Health Service Act (42 U.S.C. 14 217a), acting through the Director of the Centers for Dis-15 ease Control and Prevention. 16 SEC. 2143. MEETINGS BETWEEN CDC AND VACCINE DEVEL-17 OPERS. 18 Section 310 of the Public Health Service Act (42 19 U.S.C. 242o) is amended by adding at the end the fol-20 lowing: 21 ''(c)(1) In this subsection, the term 'vaccine devel- 22 oper' means a nongovernmental entity engaged in\u2014 23 VerDate Nov 24 2008 11:47 Jul ''(A)(i) the development of a vaccine with the 1 intent to pursue licensing of the vaccine by the Food 2 and Drug Administration; or 3 ''(ii) the production of a vaccine licensed by the 4 Food and Drug Administration; and 5 ''(B) vaccine research. 6 ''(2)(A) Upon the submission of a written request for 7 a meeting by a vaccine developer, that includes a valid jus-8 tification for the meeting, the Secretary, acting through 9 the Director of the Centers for Disease Control and Pre-10 vention, shall convene a meeting of representatives of the 11 vaccine developer and experts from the Centers for Dis-12 ease Control and Prevention in immunization programs, 13 epidemiology, and other relevant areas at which the Direc-14 tor (or the Director's designee), for the purpose of inform-15 ing the vaccine developer's understanding of public health 16 needs and priorities, shall provide the perspectives of the 17 Centers for Disease Control and Prevention and other rel-18 evant Federal agencies regarding\u2014 19 ''(i) public health needs, epidemiology, and im- 20 plementation considerations with regard to a vaccine 21 developer's potential vaccine profile; and 22 ''(ii) potential implications of such perspectives 23 for the vaccine developer's vaccine research and de- 24 velopment planning. 25 VerDate Nov 24 2008 11:47 In addition to the representatives specified in 1 subparagraph (A), the Secretary may, with the agreement 2 of the vaccine developer requesting a meeting under such 3 subparagraph, include in such meeting representatives 4 of\u2014 5 ''(i) the Food and Drug Administration; and 6 ''(ii) the National Vaccine Program. 7 ''(C) The Secretary shall convene a meeting re- 8 quested with a valid justification under subparagraph (A) 9 not later than 120 days after receipt of the request for 10 the meeting. 11 ''(3)(A) Upon the submission of a written request by 12 a vaccine developer, the Secretary, acting through the Di-13 rector of the Centers for Disease Control and Prevention, 14 shall provide to the vaccine developer any age-based or 15 other demographically assessed disease epidemiological 16 analyses or data that\u2014 17 ''(i) are specified in the request; 18 ''(ii) have been published; 19 ''(iii) have been performed by or are in the pos- 20 session of the Centers; 21 ''(iv) are not a trade secret or commercial or fi- 22 nancial information that is privileged or confidential 23 and subject to section 552(b)(4) of title 5, United 24 VerDate Nov 24 2008 11:47 Jul 02, 158 States Code, or section 1905 of title 18, United 1 States Code; and 2 ''(v) do not contain individually identifiable in- 3 formation. 4 ''(B) The Secretary shall provide analyses requested 5 by a vaccine manufacturer under subparagraph (A) not 6 later than 120 calendar days after receipt of the request 7 for the analyses. 8 ''(4) The Secretary shall promptly notify a vaccine 9 developer if\u2014 10 ''(A) the Secretary becomes aware of any sig- 11 nificant change to information that was\u2014 12 ''(i) shared by the Secretary with the vac- 13 cine developer during a meeting under para- 14 graph (2); or 15 ''(ii) provided by the Secretary to the vac- 16 cine developer in one or more analyses under 17 paragraph (3); and 18 ''(B) the change to such information may have 19 implications for the vaccine developer's vaccine re- 20 search and development.''. 21 VerDate Nov 24 2008 11:47 Jul 2 for Limited Popu- 3 lations 4 SEC. 2151. EXTENSION OF EXCLUSIVITY PERIODS FOR A 5 DRUG APPROVED FOR A NEW INDICATION 6 FOR A RARE DISEASE OR CONDITION. 7 (a) I NGENERAL .\u2014Chapter V of the Federal Food, 8 Drug, and Cosmetic Act, as amended by sections 2062 9 and 2063, is further amended by inserting after section 10 505H of such Act the following: 11 ''SEC. 505I. EXTENSION OF EXCLUSIVITY PERIODS FOR A 12 DRUG APPROVED FOR A NEW INDICATION 13 FOR A RARE DISEASE OR CONDITION. 14 ''(a) D ESIGNATION .\u2014 15 ''(1) I N GENERAL .\u2014The Secretary shall des- 16 ignate a drug as a drug approved for a new indica- 17 tion to prevent, diagnose, or treat a rare disease or 18 condition for purposes of granting the extensions 19 under subsection (b) if\u2014 20 ''(A) prior to approval of an application or 21 supplemental application for the new indication, 22 the drug was approved or licensed for mar- 23 keting under section 505(c) of this Act or sec- 24 tion 351(a) of the Public Health Service Act 25 VerDate Nov 24 2008 11:47 Jul 02, 160 but was not so approved or licensed for the new 1 indication; 2 ''(B)(i) the sponsor of the approved or li- 3 censed drug files an application or a supple- 4 mental application for approval of the new indi- 5 cation for use of the drug to prevent, diagnose, 6 or treat the rare disease or condition; and 7 ''(ii) the Secretary approves the application 8 or supplemental application; and 9 ''(C) the application or supplemental appli- 10 cation for the new indication contains the con- 11 sent of the applicant to notice being given by 12 the Secretary under paragraph (4) respecting 13 the designation of the drug. 14 ''(2) R EVOCATION OF DESIGNATION .\u2014 15 ''(A) I N GENERAL .\u2014Except as provided in 16 subparagraph (B), a designation under para- 17 graph (1) shall not be revoked for any reason. 18 ''(B) E XCEPTION .\u2014The Secretary may re- 19 voke a designation of a drug under paragraph 20 (1) if the Secretary finds that the application or 21 supplemental application resulting in such des- 22 ignation contained an untrue statement of ma- 23 terial fact. 24 VerDate Nov 24 2008 11:47 Jul N OTIFICATION PRIOR TO DISCONTINUANCE 1 OF PRODUCTION FOR SOLELY COMMERCIAL REA - 2 SONS .\u2014A designation of a drug under paragraph (1) 3 shall be subject to the condition that the sponsor of 4 the drug will notify the Secretary of any discontinu- 5 ance of the production of the drug for solely com- 6 mercial reasons at least one year before such dis- 7 continuance. 8 ''(4) N OTICE TO PUBLIC .\u2014Notice respecting 9 the designation of a drug under paragraph (1) shall 10 be made available to the public. 11 ''(b) E XTENSION .\u2014If the Secretary designates a 12 drug as a drug approved for a new indication for a rare 13 disease or condition, as described in subsection (a)(1)\u2014 14 ''(1)(A) the 4-, 5-, and 15 scribed in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) 16 of section 505, the 3-year periods described in 17 clauses (iii) and (iv) of subsection (c)(3)(E) and 18 clauses (iii) and (iv) of subsection (j)(5)(F) of sec- 19 tion 505, and the 7-year period described in section 20 527, as applicable, shall be extended by 6 months; 21 or 22 ''(B) the 4- and 12-year periods described in 23 subparagraphs (A) and (B) of section 351(k)(7) of 24 the Public Health Service Act and the 7-year period 25 VerDate Nov 24 2008 11:47 Jul 162 described in section 527, as applicable, shall be ex- 1 tended by 6 months; and 2 ''(2)(A) if the drug is the subject of a listed 3 patent for which a certification has been submitted 4 under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of 5 section 505 or a listed patent for which a certifi- 6 cation has been submitted under subsections 7 (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505, 8 the period during which an application may not be 9 approved under section 505(c)(3) or section 10 505(j)(5)(B) shall be extended by a period of 6 11 months after the date the patent expires (including 12 any patent extensions); or 13 ''(B) if the drug is the subject of a listed patent 14 for which a certification has been submitted under 15 subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of sec- 16 tion 505, and in the patent infringement litigation 17 resulting from the certification the court determines 18 that the patent is valid and would be infringed, the 19 period during which an application may not be ap- 20 proved under section 505(c)(3) or section 21 505(j)(5)(B) shall be extended by a period of 6 22 months after the date the patent expires (including 23 any patent extensions). 24 VerDate Nov 24 2008 11:47 Jul 02, R ELATION TO PEDIATRIC AND QUALIFIED IN- 1 FECTIOUS DISEASE PRODUCT EXCLUSIVITY .\u2014Any exten- 2 sion under subsection (b) of a period shall be in addition 3 to any extension of the periods under sections 505A and 4 505E of this Act and section 351(m) of the Public Health 5 Service Act, as applicable, with respect to the drug. 6 ''(d) L IMITATIONS .\u2014The extension described in sub- 7 section (b) shall not apply if the drug designated under 8 subsection (a)(1) has previously received an extension by 9 operation of subsection (b). 10 ''(e) D EFINITION .\u2014In this section, the term 'rare 11 disease or condition' has the meaning given to such term 12 in section 526(a)(2).''. 13 (b) A PPLICATION .\u2014Section 505G of the Federal 14 Food, Drug, and Cosmetic Act, as added by subsection 15 (a), applies only with respect to a drug for which an appli-16 cation or supplemental application described in subsection 17 (a)(1)(B)(i) of such section 505G is first approved under 18 section 505(c) of such Act (21 U.S.C. 355(c)) or section 19 351(a) of the Public Health Service Act (42 U.S.C. 20 262(a)) on or after the date of the enactment of this Act. 21 (c) C ONFORMING AMENDMENTS .\u2014 22 (1) R ELATION TO PEDIATRIC EXCLUSIVITY FOR 23 DRUGS .\u2014Section 505A of the Federal Food, Drug, 24 and Cosmetic Act (21 U.S.C. 355a) is amended\u2014 25 VerDate Nov 24 2008 (A) in subsection (b), by adding at the end 1 the following: 2 ''(3) R ELATION TO EXCLUSIVITY FOR A DRUG 3 APPROVED FOR A NEW INDICATION FOR A RARE DIS - 4 EASE OR CONDITION .\u2014Notwithstanding the ref- 5 erences in paragraph (1) to the lengths of the exclu- 6 sivity periods after application of pediatric exclu- 7 sivity, the 6-month extensions described in para- 8 graph (1) shall be in addition to any extensions 9 under section 505G.''; and 10 (B) in subsection (c), by adding at the end 11 the following: 12 ''(3) R ELATION TO EXCLUSIVITY FOR A DRUG 13 APPROVED FOR A NEW INDICATION FOR A RARE DIS - 14 EASE OR CONDITION .\u2014Notwithstanding the ref- 15 erences in paragraph (1) to the lengths of the exclu- 16 sivity periods after application of pediatric exclu- 17 sivity, the 6-month extensions described in para- 18 graph (1) shall be in addition to any extensions 19 under section 505G.''. 20 (2) R ELATION TO EXCLUSIVITY FOR NEW 21 QUALIFIED INFECTIOUS DISEASE PRODUCTS THAT 22 ARE DRUGS .\u2014Subsection (b) of section 505E of the 23 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 24 355f) is amended\u2014 25 VerDate Nov 24 2008 (A) by amending the subsection heading to 1 read as follows: ''R ELATION TO PEDIATRIC EX- 2 CLUSIVITY AND EXCLUSIVITY FOR A DRUG AP- 3 PROVED FOR A NEWINDICATION FOR A RARE 4 DISEASE OR CONDITION .\u2014''; and 5 (B) by striking ''any extension of the pe- 6 riod under section 505A'' and inserting ''any 7 extension of the periods under sections 505A 8 and 505G, as applicable,''. 9 (3) R ELATION TO PEDIATRIC EXCLUSIVITY FOR 10 BIOLOGICAL PRODUCTS .\u2014Section 351(m) of the 11 Public Health Service Act (42 U.S.C. 262(m)) is 12 amended by adding at the end the following: 13 ''(5) R ELATION TO EXCLUSIVITY FOR A BIO - 14 LOGICAL PRODUCT APPROVED FOR A NEW INDICA - 15 TION FOR A RARE DISEASE OR CONDITION .\u2014Not- 16 withstanding the references in paragraphs (2)(A), 17 (2)(B), (3)(A), and (3)(B) to the lengths of the ex- 18 clusivity periods after application of pediatric exclu- 19 sivity, the 6-month extensions described in such 20 paragraphs shall be in addition to any extensions 21 under section 505G.''. 22 VerDate Nov 24 2008 11:47 Jul 2152. REAUTHORIZATION OF RARE PEDIATRIC DIS-1 EASE PRIORITY REVIEW VOUCHER INCEN- 2 TIVE PROGRAM. 3 (a) I NGENERAL .\u2014Section 529 of the Federal Food, 4 Drug, and Cosmetic Act (21 U.S.C. 360ff) is amended\u2014 5 (1) in subsection (a)\u2014 6 (A) in paragraph (3), by amending sub- 7 paragraph (A) to read as follows: 8 ''(A) The disease is a serious or life-threat- 9 ening disease in which the serious or life-threat- 10 ening manifestations primarily affect individ- 11 uals aged from birth to 18 years, including age 12 groups often called neonates, infants, children, 13 and adolescents.''; and 14 (B) in paragraph (4)\u2014 15 (i) in subparagraph (E), by striking 16 ''and'' at the end; 17 (ii) in subparagraph (F), by striking 18 the period at the end and inserting ''; 19 and''; and 20 (iii) by adding at the end the fol- 21 lowing: 22 ''(G) is for a drug or biological product for 23 which a priority review voucher has not been 24 issued under section 524 (relating to tropical 25 disease products).''; and 26 VerDate Nov 24 2008 11:47 Jul (2) in subsection (b), by striking paragraph (5) 1 and inserting the following: 2 ''(5) T ERMINATION OF AUTHORITY .\u2014 3 ''(A) I N GENERAL .\u2014The Secretary may 4 not award any priority review vouchers under 5 paragraph (1) after December 31, 2018. 6 ''(B) E XCEPTION .\u2014Notwithstanding sub- 7 paragraph (A), the sponsor of a drug that is 8 designated under subsection (d) as a drug for 9 a rare pediatric disease and that is the subject 10 of a rare pediatric disease product application 11 that is submitted during the period beginning 12 on the date of enactment of the 21st Century 13 Cures Act and ending the date specified in sub- 14 paragraph (A) shall remain eligible to receive a 15 priority review voucher under paragraph (1) ir- 16 respective of whether the rare pediatric disease 17 product application with respect to such drug is 18 approved after the end of such period.''. 19 (b) GAO S TUDY AND REPORT .\u2014 20 (1) S TUDY .\u2014The Comptroller General of the 21 United States shall conduct a study on the effective- 22 ness of awarding priority review vouchers under sec- 23 tion 529 of the Federal Food, Drug, and Cosmetic 24 Act (21 U.S.C. 360ff) in providing incentives for the 25 VerDate Nov 24 2008 11:47 Jul 02, 168 development of drugs that treat or prevent rare pe- 1 diatric diseases (as defined in subsection (a)(3) of 2 such section) that would not otherwise have been de- 3 veloped. In conducting such study, the Comptroller 4 General shall examine the following: 5 (A) The indications for which each drug 6 for which a priority review voucher was award- 7 ed under such section 529 was approved under 8 section 505 of such Act (21 U.S.C. 355) or sec- 9 tion 351 of the Public Health Service Act (42 10 U.S.C. 262). 11 (B) Whether the priority review voucher 12 impacted a sponsor's decision to invest in devel- 13 oping a drug to treat or prevent a rare pedi- 14 atric disease. 15 (C) An analysis of the drugs that utilized 16 such priority review vouchers, which shall in- 17 clude\u2014 18 (i) the indications for which such 19 drugs were approved under section 505 of 20 the Federal Food, Drug, and Cosmetic Act 21 (21 U.S.C. 355) or section 351 of the Pub- 22 lic Health Service Act (42 U.S.C. 262); 23 VerDate Nov 24 2008 11:47 169 (ii) whether unmet medical needs were 1 addressed through the approval of such 2 drugs, including, for each such drug\u2014 3 (I) if an alternative therapy was 4 previously available to treat the indi- 5 cation; and 6 (II) the benefit or advantage the 7 drug provided over another available 8 therapy; 9 (iii) the number of patients potentially 10 treated by such drugs; 11 (iv) the value of the priority review 12 voucher if transferred; and 13 (v) the length of time between the 14 date on which a priority review voucher 15 was awarded and the date on which it was 16 used. 17 (D) With respect to the priority review 18 voucher program under section 529 of the Fed- 19 eral Food, Drug, and Cosmetic Act (21 U.S.C. 20 360ff)\u2014 21 (i) the resources used by, and burden 22 placed on, the Food and Drug Administra- 23 tion in implementing such program, includ- 24 ing the effect of such program on the Food 25 VerDate Nov 24 2008 11:47 Jul 02, and Drug Administration's review of drugs 1 for which a priority review voucher was not 2 awarded or used; 3 (ii) the impact of the program on the 4 public health as a result of the expedited 5 review of applications for drugs that treat 6 or prevent non-serious indications that are 7 generally used by the broader public; and 8 (iii) alternative approaches to improv- 9 ing such program so that the program is 10 appropriately targeted toward providing in- 11 centives for the development of clinically 12 important drugs that\u2014 13 (I) prevent or treat rare pediatric 14 diseases; and 15 (II) would likely not otherwise 16 have been developed to prevent or 17 treat such diseases. 18 (2) R EPORT .\u2014Not later than December 31, 19 2017, the Comptroller General of the United States 20 shall submit to the Committee on Energy and Com- 21 merce of the House of Representatives and the Com- 22 mittee on Health, Education, Labor and Pensions of 23 the Senate a report containing the results of the 24 study of conducted under paragraph (1). 25 VerDate Nov 24 2008 11:47 Jul 02, turing and Export Efficiencies 2 SEC. 2161. GRANTS FOR STUDYING THE PROCESS OF CON-3 TINUOUS DRUG MANUFACTURING. 4 (a) I NGENERAL .\u2014The Commissioner of Food and 5 Drugs may award grants to institutions of higher edu-6 cation and nonprofit organizations for the purpose of 7 studying and recommending improvements to the process 8 of continuous manufacturing of drugs and biological prod-9 ucts and similar innovative monitoring and control tech-10 niques. 11 (b) D EFINITIONS .\u2014In this section: 12 (1) The term ''drug'' has the meaning given to 13 such term in section 201 of the Federal Food, Drug, 14 and Cosmetic Act (21 U.S.C. 321). 15 (2) The term ''biological product'' has the 16 meaning given to such term in section 351(i) of the 17 Public Health Service Act (42 U.S.C. 262(i)). 18 (3) The term ''institution of higher education'' 19 has the meaning given to such term in section 101 20 of the Higher Education Act of 1965 (20 U.S.C. 21 1001). 22 (c) A UTHORIZATION OF APPROPRIATIONS .\u2014There is 23 authorized to be appropriated to carry out this section 24 $5,000,000 for each of fiscal years 2016 through 2020. 25 VerDate Nov 24 2008 11:47 Jul 02, AMONG MEMBERS OF THE EU-1 ROPEAN ECONOMIC AREA. 2 Section 1003 of the Controlled Substances Import 3 and Export Act (21 U.S.C. 953) is amended\u2014 4 (1) in subsection (f)\u2014 5 (A) in paragraph (5)\u2014 6 (i) by striking ''(5)'' and inserting 7 ''(5)(A)''; 8 (ii) by inserting '', except that the 9 controlled substance may be exported from 10 the second country to another country that 11 is a member of the European Economic 12 Area'' before the period at the end; and 13 (iii) by adding at the end the fol- 14 lowing: 15 ''(B) Subsequent to any re-exportation de- 16 scribed in subparagraph (A), a controlled substance 17 may continue to be exported from any country that 18 is a member of the European Economic Area to any 19 other such country, provided that\u2014 20 ''(i) the conditions applicable with respect 21 to the first country under paragraphs (1), (2), 22 (3), (4), (6), and (7) are met by each subse- 23 quent country from which the controlled sub- 24 stance is exported pursuant to this paragraph; 25 and 26 VerDate Nov 24 2008 11:47 Jul ''(ii) the conditions applicable with respect 1 to the second country under such paragraphs 2 are met by each subsequent country to which 3 the controlled substance is exported pursuant to 4 this paragraph.''; and 5 (B) in paragraph (6)\u2014 6 (i) by striking ''(6)'' and inserting 7 ''(6)(A)''; and 8 (ii) by adding at the end the fol- 9 lowing: 10 ''(B) In the case of re-exportation among mem- 11 bers of the European Economic Area, within 30 12 days after each re-exportation, the person who ex- 13 ported the controlled substance from the United 14 States delivers to the Attorney General\u2014 15 ''(i) documentation certifying that such re- 16 exportation has occurred; and 17 ''(ii) information concerning the consignee, 18 country, and product.''; and 19 (2) by adding at the end the following: 20 ''(g) L IMITATION .\u2014Subject to paragraphs (5) and 21 (6) of subsection (f) in the case of any controlled sub-22 stance in schedule I or II or any narcotic drug in schedule 23 III or IV, the Attorney General shall not promulgate nor 24 enforce any regulation, subregulatory guidance, or en-25 VerDate Nov 24 2008 11:47 impedes re-exportation of any con-1 trolled substance among European Economic Area coun-2 tries, including by promulgating or enforcing any require-3 ment that\u2014 4 ''(1) re-exportation from the first country to the 5 second country or re-exportation from the second 6 country to another country occur within a specified 7 period of time; or 8 ''(2) information concerning the consignee, 9 country, and product be provided prior to expor- 10 tation of the controlled substance from the United 11 States or prior to each re-exportation among mem- 12 bers of the European Economic Area.''. 13 Subtitle K\u2014Enhancing 14 Combination Products Review 15 SEC. 2181. ENHANCING COMBINATION PRODUCTS REVIEW. 16 Section 503(g)(4)(C) of the Federal Food, Drug, and 17 Cosmetic Act (21 U.S.C. 353(g)(4)(C)) is amended by 18 adding at the end the following new clause: 19 ''(iii) Not later than 18 months after the date of the 20 enactment of the 21st Century Cures Act, the Secretary 21 shall issue final guidance that describes the responsibilities 22 of each agency center regarding its review of combination 23 products. The Secretary shall, after soliciting public com-24 ment, review and update the guidance periodically.''. 25 VerDate Nov 24 2008 11:47 Jul L\u2014Priority Review for 1 Breakthrough Devices 2 SEC. 2201. PRIORITY REVIEW FOR BREAKTHROUGH DE-3 VICES. 4 (a) I NGENERAL .\u2014Chapter V of the Federal Food, 5 Drug, and Cosmetic Act is amended\u2014 6 (1) in section 515(d)\u2014 7 (A) by striking paragraph (5); and 8 (B) by redesignating paragraph (6) as 9 paragraph (5); and 10 (2) by inserting after section 515A (21 U.S.C. 11 360e-1) the following: 12 ''SEC. 515B. BREAKTHROUGH DE-13 VICES. 14 ''(a) I NGENERAL .\u2014In order to provide for more ef- 15 fective treatment or diagnosis of life-threatening or irre-16 versibly debilitating human diseases or conditions, the 17 Secretary shall establish a program to provide priority re-18 view for devices\u2014 19 ''(1) representing breakthrough technologies; 20 ''(2) for which no approved alternatives exist; 21 ''(3) offering significant advantages over exist- 22 ing approved or cleared alternatives, including the 23 potential to, compared to existing approved or 24 cleared alternatives, reduce or eliminate the need for 25 VerDate Nov 24 2008 11:47 Jul 02, improve patient quality of life, facili- 1 tate patients' ability to manage their own care (such 2 as through self-directed personal assistance), or es- 3 tablish long-term clinical efficiencies; or 4 ''(4) the availability of which is in the best in- 5 terest of patients. 6 ''(b) R EQUEST FOR DESIGNATION .\u2014A sponsor of a 7 device may request that the Secretary designate the device 8 for priority review under this section. Any such request 9 for designation may be made at any time prior to the sub-10 mission of an application under section 515(c), a petition 11 for classification under section 513(f)(2), or a notification 12 under section 510(k). 13 ''(c) D ESIGNATION PROCESS .\u2014 14 ''(1) I N GENERAL .\u2014Not later than 60 calendar 15 days after the receipt of a request under subsection 16 (b), the Secretary shall determine whether the device 17 that is the subject of the request meets the criteria 18 described in subsection (a). If the Secretary deter- 19 mines that the device meets the criteria, the Sec- 20 retary shall designate the device for priority review. 21 ''(2) R EVIEW .\u2014Review of a request under sub- 22 section (b) shall be undertaken by a team that is 23 composed of experienced staff and managers of the 24 VerDate Nov 24 2008 11:47 Jul 02, 177 Food and Drug Administration and is chaired by a 1 senior manager. 2 ''(3) D ESIGNATION DETERMINATION .\u2014A deter- 3 mination approving or denying a request under sub- 4 section (b) shall be considered a significant decision 5 under section 517A and the Secretary shall provide 6 a written, substantive summary of the basis for the 7 determination in accordance with section 517A(a). 8 ''(4) R ECONSIDERATION .\u2014 9 ''(A) R EQUEST FOR RECONSIDERATION .\u2014 10 Any person whose request under subsection (b) 11 is denied may, within 30 days of the denial, re- 12 quest reconsideration of the denial in accord- 13 ance with section 517A(b)\u2014 14 ''(i) based upon the submission of 15 documents by such person; or 16 ''(ii) based upon such documents and 17 a meeting or teleconference. 18 ''(B) R ESPONSE .\u2014Reconsideration of a 19 designation determination under this paragraph 20 shall be conducted in accordance with section 21 517A(b). 22 ''(5) W ITHDRAWAL .\u2014If the Secretary approves 23 a priority review designation for a device under this 24 section, the Secretary may not withdraw the des- 25 VerDate Nov 24 2008 11:47 Jul ignation based on the fact that the criteria specified 1 in subsection (a) are no longer met because of the 2 subsequent clearance or approval of another device 3 that was designated under\u2014 4 ''(A) this section; or 5 ''(B) section 515(d)(5) (as in effect imme- 6 diately prior to the enactment of the 21st Cen- 7 tury Cures Act). 8 ''(d) P RIORITY REVIEW .\u2014 9 ''(1) A CTIONS .\u2014For purposes of expediting the 10 development and review of devices designated under 11 subsection (c), the Secretary shall\u2014 12 ''(A) assign a team of staff, including a 13 team leader with appropriate subject matter ex- 14 pertise and experience, for each device for 15 which a request is submitted under subsection 16 (b); 17 ''(B) provide for oversight of the team by 18 senior agency personnel to facilitate the effi- 19 cient development of the device and the efficient 20 review of any submission described in sub- 21 section (b) for the device; 22 ''(C) adopt an efficient process for timely 23 dispute resolution; 24 VerDate Nov 24 2008 11:47 Jul ''(D) provide for interactive communication 1 with the sponsor of the device during the review 2 process; 3 ''(E) expedite the Secretary's review of 4 manufacturing and quality systems compliance, 5 as applicable; 6 ''(F) disclose to the sponsor in advance the 7 topics of any consultation concerning the spon- 8 sor's device that the Secretary intends to under- 9 take with external experts or an advisory com- 10 mittee and provide the sponsor an opportunity 11 to recommend such external experts; 12 ''(G) for applications submitted under sec- 13 tion 515(c), provide for advisory committee 14 input, as the Secretary determines appropriate 15 (including in response to the request of the 16 sponsor); and 17 ''(H) assign staff to be available within a 18 reasonable time to address questions posed by 19 institutional review committees concerning the 20 conditions and clinical testing requirements ap- 21 plicable to the investigational use of the device 22 pursuant to an exemption under section 520(g). 23 ''(2) A DDITIONAL ACTIONS .\u2014In addition to the 24 actions described in paragraph (1), for purposes of 25 VerDate Nov 24 2008 11:47 Jul 02, 180 expediting the development and review of devices 1 designated under subsection (c), the Secretary, in 2 collaboration with the device sponsor, may, as appro- 3 priate\u2014 4 ''(A) coordinate with the sponsor regarding 5 early agreement on a data development plan; 6 ''(B) take steps to ensure that the design 7 of clinical trials is as efficient as practicable, 8 such as through adoption of shorter or smaller 9 clinical trials, application of surrogate 10 endpoints, and use of adaptive trial designs and 11 Bayesian statistics, to the extent scientifically 12 appropriate; 13 ''(C) facilitate, to the extent scientifically 14 appropriate, expedited and efficient develop- 15 ment and review of the device through utiliza- 16 tion of timely postmarket data collection, with 17 regard to applications for approval under sec- 18 tion 515(c); and 19 ''(D) agree to clinical protocols that the 20 Secretary will consider binding on the Secretary 21 and the sponsor, subject to\u2014 22 ''(i) changes agreed to by the sponsor 23 and the Secretary; 24 VerDate Nov 24 2008 11:47 Jul changes that the Secretary deter- 1 mines are required to prevent an unreason- 2 able risk to the public health; or 3 ''(iii) the identification of a substan- 4 tial scientific issue determined by the Sec- 5 retary to be essential to the safety or effec- 6 tiveness of the device involved. 7 ''(e) P RIORITY REVIEW GUIDANCE .\u2014 8 ''(1) C ONTENT .\u2014The Secretary shall issue 9 guidance on the implementation of this section. Such 10 guidance shall include the following: 11 ''(A) The process for a person to seek a 12 priority review designation. 13 ''(B) A template for requests under sub- 14 section (b). 15 ''(C) The criteria the Secretary will use in 16 evaluating a request for priority review. 17 ''(D) The standards the Secretary will use 18 in assigning a team of staff, including team 19 leaders, to review devices designated for priority 20 review, including any training required for such 21 personnel on effective and efficient review. 22 ''(2) P ROCESS .\u2014Prior to finalizing the guid- 23 ance under paragraph (1), the Secretary shall pro- 24 pose such guidance for public comment. 25 VerDate Nov 24 2008 11:47 Jul 02, 1 ''(1) P URPOSE .\u2014This section is intended to en- 2 courage the Secretary and provide the Secretary suf- 3 ficient authorities to apply efficient and flexible ap- 4 proaches to expedite the development of, and 5 prioritize the agency's review of, devices that rep- 6 resent breakthrough technologies. 7 ''(2) C ONSTRUCTION .\u2014Nothing in this section 8 shall be construed to alter the criteria and standards 9 for evaluating an application pursuant to section 10 515(c), a report and request for classification under 11 section 513(f)(2), or a report under section 510(k), 12 including the recognition of valid scientific evidence 13 as described in section 513(a)(3)(B), and consider- 14 ation of the least burdensome means of evaluating 15 device effectiveness or demonstrating substantial 16 equivalence between devices with differing techno- 17 logical characteristics, as applicable. Nothing in this 18 section alters the authority of the Secretary to act 19 on an application pursuant to section 515(d) before 20 completion of an establishment inspection, as the 21 Secretary deems appropriate.''. 22 (b) C ONFORMING AMENDMENT RELATED TO DES- 23 IGNATION DETERMINATIONS .\u2014Section 517A(a)(1) of the 24 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360g- 25 VerDate Nov 24 2008 11:47 inserting for designa-1 tion section 515B,'' under sec-2 tion 515,''. 3 Subtitle M\u2014Medical Device 4 Regulatory Process Improvements 5 SEC. 2221. THIRD-PARTY QUALITY SYSTEM ASSESSMENT. 6 (a) E STABLISHMENT OF THIRD -PARTY QUALITY 7 SYSTEM ASSESSMENT PROGRAM .\u2014Chapter V of the Fed- 8 eral Food, Drug, and Cosmetic Act is amended by insert-9 ing after section 524A (21 U.S.C. 360n-1) the following 10 new section: 11 524B. THIRD-PARTY QUALITY SYSTEM ASSESSMENT. 12 ''(a) A CCREDITATION AND ASSESSMENT .\u2014 13 ''(1) I N GENERAL ; CERTIFICATION OF DEVICE 14 QUALITY SYSTEM .\u2014The Secretary shall, in accord- 15 ance with this section, establish a third-party quality 16 system assessment program\u2014 17 ''(A) to accredit persons to assess whether 18 a requestor's quality system, including its de- 19 sign controls, can reasonably assure the safety 20 and effectiveness of in-scope devices subject to 21 device-related changes; 22 ''(B) under which accredited persons shall 23 (as applicable) certify that a requestor's quality 24 system meets the criteria included in the guid- 25 VerDate Nov 24 2008 11:47 Jul ance issued under paragraph (5) with respect to 1 the in-scope devices at issue; and 2 ''(C) under which the Secretary shall rely 3 on such certifications for purposes of deter- 4 mining the safety and effectiveness (or as appli- 5 cable, substantial equivalence) of in-scope de- 6 vices subject to the device-related changes in- 7 volved, in lieu of compliance with the following 8 submission requirements: 9 ''(i) A premarket notification. 10 ''(ii) A thirty-day notice. 11 A Special PMA supplement. 12 ''(2) D EFINITIONS .\u2014For purposes of this sec- 13 tion 14 ''(A) the term 'device-related changes' 15 means changes made by a requestor with re- 16 spect to in-scope devices, which are\u2014 17 ''(i) changes to a device found to be 18 substantially equivalent under sections 19 513(i) and 510(k) to a predicate device, 20 that\u2014 21 ''(I) would otherwise be subject 22 to a premarket notification; and 23 ''(II) do not alter\u2014 24 VerDate Nov 24 2008 11:47 the intended use of 1 the changed device; or 2 ''(bb) the fundamental sci- 3 entific technology of such device; 4 ''(ii) manufacturing changes subject 5 to a 30-day notice; 6 ''(iii) changes that qualify for a Spe- 7 cial PMA Supplement; and 8 ''(iv) such other changes relating to 9 the devices or the device manufacturing 10 process as the Secretary determines appro- 11 priate; 12 ''(B) the term 'in-scope device' means a 13 device within the scope of devices agreed to by 14 the requestor and the accredited person for pur- 15 poses of a request for certification under this 16 section; 17 ''(C) the term 'premarket notification' 18 means a premarket notification under section 19 510(k); 20 ''(D) the term 'quality system' means the 21 methods used in, and the facilities and controls 22 used for, the design, manufacture, packaging, 23 labeling, storage, installation, and servicing of 24 devices, as described in section 520(f); 25 VerDate Nov 24 2008 11:47 Jul the term 'requestor' means a device 1 manufacturer that is seeking certification under 2 this section of a quality system used by such 3 manufacturer; 4 ''(F) the term 'Special PMA' means a Spe- 5 cial PMA supplement under section 814.39(d) 6 of title 21, Code of Federal Regulations (or any 7 successor regulations); and 8 ''(G) the term 'thirty-day notice' means a 9 notice described in section 515(d)(6). 10 ''(3) A CCREDITATION PROCESS ; ACCREDITATION 11 RENEWAL .\u2014Except as inconsistent with this section, 12 the process and qualifications for accreditation of 13 persons and renewal of such accreditation under sec- 14 tion 704(g) shall apply with respect to accreditation 15 of persons and renewal of such accreditation under 16 this section. 17 ''(4) U SE OF ACCREDITED PARTIES TO CON - 18 DUCT ASSESSMENTS .\u2014 19 ''(A) I NITIATION OF ASSESSMENT SERV - 20 ICES.\u2014 21 ''(i) D ATE ASSESSMENTS AUTHOR - 22 IZED .\u2014Beginning after the date on which 23 the final guidance is issued under para- 24 VerDate Nov 24 2008 11:47 Jul graph (5), an accredited person may con- 1 duct an assessment under this section. 2 ''(ii) I NITIATION OF ASSESSMENTS .\u2014 3 Use of one or more accredited persons to 4 assess a requestor's quality system under 5 this section with respect to in-scope devices 6 shall be at the initiation of the person who 7 registers and lists the devices at issue 8 under section 510. 9 ''(B) C OMPENSATION .\u2014Compensation for 10 such accredited persons shall\u2014 11 ''(i) be determined by agreement be- 12 tween the accredited person and the person 13 who engages the services of the accredited 14 person; and 15 ''(ii) be paid by the person who en- 16 gages such services. 17 ''(C) A CCREDITED PERSON SELECTION .\u2014 18 Each person who chooses to use an accredited 19 person to assess a requestor's quality system, 20 as described in this section, shall select the ac- 21 credited person from a list of such persons pub- 22 lished by the Secretary in accordance with sec- 23 tion 704(g)(4). 24 VerDate Nov 24 2008 11:47 CRITERIA FOR CERTIFI - 1 CATION .\u2014 2 ''(A) I N GENERAL .\u2014The criteria for cer- 3 tification of a quality system under this section 4 shall be as specified by the Secretary in guid- 5 ance issued under this paragraph. 6 ''(B) C ONTENTS ; CRITERIA .\u2014The guidance 7 under this paragraph shall include specification 8 of\u2014 9 ''(i) evaluative criteria to be used by 10 an accredited person to assess and, as ap- 11 plicable, certify a requestor's quality sys- 12 tem under this section with respect to in- 13 scope devices; and 14 ''(ii) criteria for accredited persons to 15 apply for a waiver of, and exemptions 16 from, the criteria under clause (i). 17 ''(C) T IMEFRAME FOR ISSUING GUID - 18 ANCE .\u2014The Secretary shall issue under this 19 paragraph\u2014 20 ''(i) draft guidance not later than 12 21 months after the enactment of the 21st 22 Century Cures Act; and 23 VerDate Nov 24 2008 11:47 Jul ''(ii) final guidance not later than 12 1 months after issuance of the draft guid- 2 ance under clause (i). 3 ''(b) U SE OF THIRD -PARTY ASSESSMENT .\u2014 4 ''(1) A SSESSMENT SUMMARY ; CERTIFI - 5 CATION .\u2014 6 ''(A) S UBMISSION OF ASSESSMENT TO SEC - 7 RETARY .\u2014An accredited person who assesses a 8 requestor's quality system under subsection (a) 9 shall submit to the Secretary a summary of the 10 assessment\u2014 11 ''(i) within 30 days of the assessment; 12 and 13 ''(ii) which shall include (as applica- 14 ble)\u2014 15 ''(I) the accredited person's that the requestor has satis- 17 fied the criteria specified in the guid- 18 ance issued under subsection (a)(5) 19 for quality system certification with 20 respect to the in-scope devices at 21 issue; and 22 ''(II) any waivers or exemptions 23 from such criteria applied by the ac- 24 credited person. 25 VerDate Nov 24 2008 11:47 Jul 02, T REATMENT OF ASSESSMENTS .\u2014 1 Subject to action by the Secretary under sub- 2 paragraph (C), with respect to assessments 3 which include a certification under this sec- 4 tion\u2014 5 ''(i) the Secretary's review of the as- 6 sessment summary shall be deemed com- 7 plete on the day that is 30 days after the 8 date on which the Secretary receives the 9 summary under subparagraph (A); and 10 ''(ii) the assessment summary and 11 certification of the quality system of a re- 12 questor shall be deemed accepted by the 13 Secretary on such 30th day. 14 ''(C) A CTIONS BY SECRETARY .\u2014 15 ''(i) I N GENERAL .\u2014Within 30 days of 16 receiving an assessment summary and cer- 17 tification under subparagraph (A), the Sec- 18 retary may, by written notice to the ac- 19 credited person submitting such assess- 20 ment certification, deem any such certifi- 21 cation to be provisional beyond such 30- 22 day period, suspended pending further re- 23 view by the Secretary, or otherwise quali- 24 VerDate Nov 24 2008 11:47 Jul or cancelled, based on the Secretary's 1 determination that (as applicable)\u2014 2 ''(I) additional information is 3 needed to support such certification; 4 ''(II) such assessment or certifi- 5 cation is unwarranted; or 6 ''(III) such action with regard to 7 the certification is otherwise justified 8 according to such factors and criteria 9 as the Secretary finds appropriate. 10 ''(ii) A CCEPTANCE OF CERTIFI - 11 CATION .\u2014If following action by the Sec- 12 retary under clause (i) with respect to a 13 certification, the Secretary determines that 14 such certification is acceptable, the Sec- 15 retary shall issue written notice to the ap- 16 plicable accredited person indicating such 17 acceptance. 18 ''(2) N OTIFICATIONS TO SECRETARY BY CER - 19 TIFIED REQUESTORS OR ACCREDITED PERSONS FOR 20 PROGRAM EVALUATION PURPOSES .\u2014 21 ''(A) A NNUAL SUMMARY REPORT FOR DE - 22 VICE-RELATED CHANGES OTHERWISE SUBJECT 23 TO PREMARKET NOTIFICATION .\u2014A requestor 24 whose quality system is certified under this sec- 25 VerDate Nov 24 2008 11:47 Jul 02, device-related changes with 1 respect to in-scope devices, without prior sub- 2 mission of a premarket notification, shall en- 3 sure that an annual summary report is sub- 4 mitted to the Secretary by the accredited per- 5 son which\u2014 6 ''(i) describes the changes made to the 7 in-scope device; and 8 ''(ii) indicates the effective dates of 9 such changes. 10 ''(B) P ERIODIC NOTIFICATION FOR MANU - 11 FACTURING CHANGES OTHERWISE SUBJECT TO 12 THIRTY -DAY NOTICE .\u2014A requestor whose qual- 13 ity system is certified under this section that ef- 14 fectuates device-related changes with respect to 15 in-scope devices, without prior submission of a 16 thirty-day notice, shall provide notification to 17 the Secretary of such changes in the requestor's 18 next periodic report under section 814.84(b) of 19 title 21, Code of Federal Regulations (or any 20 successor regulation). Such notification shall\u2014 21 ''(i) describe the changes made; and 22 ''(ii) indicate the effective dates of 23 such changes. 24 VerDate Nov 24 2008 11:47 Jul 02, ERIODIC NOTIFICATION FOR DE - 1 VICE-RELATED CHANGES OTHERWISE SUBJECT 2 TO SPECIAL PMA SUPPLEMENT .\u2014A requestor 3 whose quality system is certified under this sec- 4 tion that effectuates device-related changes with 5 respect to in-scope devices, without prior sub- 6 mission of a Special PMA Supplement, shall 7 provide notification to the Secretary of such 8 changes in the requestor's next periodic report 9 under section 814.84(b) of title 21, Code of 10 Federal Regulations (or any successor regula- 11 tion). Such notification shall\u2014 12 ''(i) describe the changes made, in- 13 cluding a full explanation of the basis for 14 the changes; and 15 ''(ii) indicate the effective dates of 16 such changes. 17 ''(D) U SE OF NOTIFICATIONS FOR PRO - 18 GRAM EVALUATION PURPOSES .\u2014Information 19 submitted to the Secretary under subpara- 20 graphs (A) through (C) shall be used by the 21 Secretary for purposes of the program evalua- 22 tion under subsection (d). 23 ''(c) D URATION AND EFFECT OF CERTIFICATION .\u2014 24 A certification under this section\u2014 25 VerDate Nov 24 2008 11:47 Jul ''(1) shall remain in effect for a period of 2 1 years from the date such certification is accepted by 2 the Secretary, subject to paragraph (6); 3 ''(2) may be renewed through the process de- 4 scribed in subsection (a)(3); 5 ''(3) shall continue to apply with respect to de- 6 vice-related changes made during such 2-year period, 7 provided the certification remains in effect, irrespec- 8 tive of whether such certification is renewed after 9 such 2-year period; 10 ''(4) shall have no effect on the need to comply 11 with applicable submission requirements specified in 12 subsection (a)(1)(C) with respect to any change per- 13 taining to in-scope devices which is not a device-re- 14 lated change under subsection (a)(2); 15 ''(5) shall have no effect on the authority of the 16 Secretary to conduct an inspection or otherwise de- 17 termine whether the requestor has complied with the 18 applicable requirements of this Act; and 19 ''(6) may be revoked by the Secretary upon a 20 determination that the requestor's quality system no 21 longer meets the criteria specified in the guidance 22 issued under subsection (a)(5) with respect to the 23 in-scope devices at issue. 24 VerDate Nov 24 2008 11:47 Jul 02, OTICE OF REVOCATION .\u2014The Secretary shall 1 provide written notification to the requestor of a revoca-2 tion pursuant to subsection (c)(6) not later than 10 busi-3 ness days after the determination described in such sub-4 section. Upon receipt of the written notification, the re-5 questor shall satisfy the applicable submission require-6 ments subsection (a)(1)(C) for any device-re-7 effectuated after the date of such deter-8 mination. After such revocation, such requestor is eligible 9 to seek re-certification under this section of its quality sys-10 tem. 11 ''(e) P ROGRAM EVALUATION ; SUNSET .\u2014 12 ''(1) P ROGRAM EVALUATION AND REPORT .\u2014 13 ''(A) E VALUATION .\u2014The Secretary shall 14 complete an evaluation of the third-party qual- 15 ity system assessment program under this sec- 16 tion no later than January 31, 2021, based 17 on\u2014 18 ''(i) analysis of information from a 19 representative group of device manufactur- 20 ers obtained from notifications provided by 21 certified requestors or accredited persons 22 under subsection (b)(2); and 23 VerDate Nov 24 2008 11:47 such other available information 1 and data as the Secretary determines ap- 2 propriate. 3 ''(B) R EPORT .\u2014No later than 1 year after 4 completing the evaluation under subparagraph 5 (A), the Secretary shall issue a report of the 6 evaluation's findings on the website of the Food 7 and Drug Administration, which shall include 8 the Secretary's recommendations with respect 9 to continuation and as applicable expansion of 10 the program under this section to encompass\u2014 11 ''(i) device submissions beyond those 12 identified in subsection (a)(1)(C); and 13 ''(ii) device changes beyond those in subsection (a)(2)(A). 15 ''(2) S UNSET .\u2014This section shall cease to be 16 effective October 1, 2022. 17 ''(f) R ULE OF CONSTRUCTION .\u2014Nothing in this sec- 18 tion shall be construed to limit the authority of the Sec-19 retary to request and review the complete assessment of 20 a certified requestor under this section on a for-cause 21 basis.''. 22 (b) C ONFORMING AMENDMENTS .\u2014 23 (1) R EQUIREMENTS FOR PREMARKET AP - 24 PROVAL SUPPLEMENTS .\u2014Section 515(d)(5)(A)(i) of 25 VerDate Nov 24 2008 197 the Federal Food, Drug, and Cosmetic Act (21 1 U.S.C. 360e(d)(5)(A)(i)), as redesignated by section 2 2201, is further amended by inserting '', subject to 3 section 524B'' after ''that affects safety or effective- 4 ness''. 5 (2) R EQUIREMENTS FOR THIRTY -DAY NO - 6 TICE.\u2014Section 515(d)(5)(A)(ii) of the Federal 7 Food, Drug, and Cosmetic Act (21 U.S.C. 8 360e(d)(5)(A)(ii)), as redesignated by section 2201, 9 is further amended by inserting '', subject to section 10 524B'' after ''the date on which the Secretary re- 11 ceives the notice''. 12 (3) R EQUIREMENTS FOR PREMARKET NOTIFI - 13 CATION ; TECHNICAL CORRECTION TO REFERENCE 14 TO SECTION 510(K) .\u2014Section 510(l) of the Federal 15 Food, Drug, and Cosmetic Act (21 U.S.C. 360(l)) is 16 amended by striking ''of this subsection under sub- 17 section (m)'' and inserting ''of subsection (k) under 18 subsection (m) or section 524B''. 19 (4) M ISBRANDED DEVICES .\u2014Section 502(t) of 20 the Federal Food, Drug, and Cosmetic Act (21 21 U.S.C. 352(t)) is amended by inserting ''or 524B'' 22 after ''section 519''. 23 VerDate Nov 24 2222. VALID SCIENTIFIC EVIDENCE. 1 Section 513(a)(3)(B) of the Federal Food, Drug, and 2 Cosmetic Act (21 U.S.C. 360c(a)(3)(B)) is amended\u2014 3 (1) by redesignating clauses (i) and (ii) as sub- 4 clauses (I) and (II), respectively; 5 (2) by striking ''(B) If the Secretary'' and in- 6 serting ''(B)(i) If the Secretary''; and 7 (3) by adding at the end the following: 8 ''(ii) For purposes of clause (i), valid scientific evi- 9 dence may include\u2014 10 ''(I) evidence described in well-documented case 11 histories, including registry data, that are collected 12 and monitored under a protocol determined to be ac- 13 ceptable by the Secretary; 14 ''(II) studies published in peer-reviewed jour- 15 nals; and 16 ''(III) data collected in countries other than the 17 United States so long as such data otherwise meet 18 the criteria specified in this subparagraph. 19 ''(iii) In the case of a study published in a peer-re- 20 viewed journal that is offered as valid scientific evidence 21 for purposes of clause (i), the Secretary may request data 22 underlying the study if\u2014 23 ''(I) the Secretary, in making such request, 24 complies with the requirement of subparagraph 25 (D)(ii) to consider the least burdensome appropriate 26 VerDate Nov 24 2008 11:47 Jul 02, of evaluating device effectiveness or sub- 1 section (i)(1)(D) to consider the least burdensome 2 means of determining substantial equivalence, as ap- 3 plicable; 4 ''(II) the Secretary furnishes a written rationale 5 for so requesting the underlying data together with 6 such request; and 7 ''(III) if the requested underlying data for such 8 a study are unavailable, the Secretary shall consider 9 such study to be part of the totality of the evidence 10 with respect to the device, as the Secretary deter- 11 mines appropriate.''. 12 SEC. 2223. TRAINING AND OVERSIGHT IN LEAST BURDEN-13 SOME APPROPRIATE MEANS CONCEPT. 14 (a) I NGENERAL .\u2014Section 513 of the Federal Food, 15 Drug, and Cosmetic Act (21 U.S.C. 360c) is amended by 16 adding at the end the following: 17 ''(j) T RAINING AND OVERSIGHT IN LEAST BURDEN - 18 SOME APPROPRIATE MEANS CONCEPT .\u2014 19 ''(1) T RAINING .\u2014Each employee of the Food 20 and Drug Administration who is involved in the re- 21 view of premarket submissions under section 515 or 22 section 510(k), including supervisors, shall receive 23 training regarding the meaning and implementation 24 of the least burdensome appropriate means concept 25 VerDate Nov 24 2008 11:47 Jul 02, 200 in the context of the use of that term in subsections 1 (a)(3)(D) and (i)(1)(D) of this section and in section 2 515(c)(5). 3 ''(2) G UIDANCE DOCUMENTS .\u2014 4 ''(A) D RAFT UPDATED GUIDANCE .\u2014Not 5 later than 12 months after the date of enact- 6 ment of the 21st Century Cures Act, the Sec- 7 retary shall issue a draft guidance document 8 updating the October 4, 2002, guidance docu- 9 ment entitled 'The Least Burdensome Provision 10 of the FDA Modernization Act of 1997: Con- 11 cept and Principles; Final Guidance for FDA 12 and Industry'. 13 ''(B) M EETING OF STAKEHOLDERS .\u2014In 14 developing such draft guidance document, the 15 Secretary shall convene a meeting of stake- 16 holders to ensure a full record to support the 17 publication of such document. 18 ''(3) O MBUDSMAN AUDIT .\u2014Not later than 18 19 months after the date of issuance of final version of 20 the draft guidance under paragraph (2), the om- 21 budsman for the organizational unit of the Food and 22 Drug Administration responsible for the premarket 23 review of devices shall\u2014 24 VerDate Nov 24 2008 11:47 Jul ''(A) conduct, or have conducted, an audit 1 of the training described in paragraph (1); and 2 ''(B) include in such audit interviews with 3 a representative sample of persons from indus- 4 try regarding their experience in the device pre- 5 market review process.''. 6 (b) A DDITIONAL INFORMATION REGARDING PRE- 7 MARKET APPLICATIONS .\u2014Subsection (c) of section 515 of 8 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 9 360e) is amended by adding at the end the following: 10 ''(5)(A) Whenever the Secretary requests additional 11 information from an applicant regarding an application 12 under paragraph (1), the Secretary shall consider the least 13 burdensome appropriate means necessary to demonstrate 14 device safety and effectiveness, and request information 15 accordingly. 16 ''(B) For purposes of subparagraph (A), the term 17 'necessary' means the minimum required information that 18 would support a determination by the Secretary that an 19 application provides a reasonable assurance of the safety 20 and effectiveness of the device. 21 ''(C) Nothing in this paragraph alters the standards 22 for premarket approval of a device.''. 23 VerDate Nov 24 2008 11:47 Jul 2224. RECOGNITION OF STANDARDS. 1 Section 514(c) of the Federal Food, Drug, and Cos- 2 metic Act (21 U.S.C. 360d(c)) is amended\u2014 3 (1) in paragraph (1), by inserting after sub- 4 paragraph (B) the following new subparagraphs: 5 ''(C)(i) Any person may submit a request for recogni- 6 tion under subparagraph (A) of all or part of an appro-7 priate standard established by a nationally or internation-8 ally recognized standard organization. 9 ''(ii) Not later than 60 days after the Secretary re- 10 ceives such a request, the Secretary shall\u2014 11 ''(I) make a determination to recognize all, 12 part, or none of the standard that is the subject of 13 the request; and 14 ''(II) issue to the person who submitted such 15 request a response in writing that states the Sec- 16 retary's rationale for that determination, including 17 the scientific, technical, regulatory, or other basis for 18 such determination. 19 ''(iii) The Secretary shall make a response issued 20 under clause (ii)(II) publicly available, in such manner as 21 the Secretary determines appropriate. 22 ''(iv) The Secretary shall take such actions as may 23 be necessary to implement all or part of a standard recog-24 nized under clause (i)(I), in accordance with subparagraph 25 (A). 26 VerDate Nov 24 2008 11:47 Jul ''(D) The Secretary shall make publicly available, in 1 such manner as the Secretary determines appropriate, the 2 rationale for recognition under subparagraph (A) of part 3 of a standard, including the scientific, technical, regu-4 latory, or other basis for such recognition.''; and 5 (2) by adding at the end the following new 6 paragraphs: 7 ''(4) T RAINING ON USE OF STANDARDS .\u2014The 8 Secretary shall provide to all employees of the Food 9 and Drug Administration who review premarket sub- 10 missions for devices periodic training on the concept 11 and use of recognized standards for purposes of 12 meeting a premarket submission requirement or 13 other applicable requirement under this Act, includ- 14 ing standards relevant to an employee's area of de- 15 vice review. 16 ''(5) G UIDANCE .\u2014 17 ''(A) D RAFT GUIDANCE .\u2014The Secretary 18 shall publish guidance identifying the principles 19 for recognizing standards under this section. In 20 publishing such guidance, the Secretary shall 21 consider\u2014 22 ''(i) the experience with, and reliance 23 on, a standard by other Federal regulatory 24 authorities and the device industry; and 25 VerDate Nov 24 2008 11:47 Jul recognition of a stand- 1 ard will promote harmonization among reg- 2 ulatory authorities in the regulation of de- 3 vices. 4 ''(B) T IMING .\u2014The Secretary shall pub- 5 lish\u2014 6 ''(i) draft guidance under subpara- 7 graph (A) not later than 12 months after 8 the date of the enactment of the 21st Cen- 9 tury Cures Act; and 10 ''(ii) final guidance not later than 12 11 months after the close of the public com- 12 ment period for the draft guidance under 13 clause (i).''. 14 SEC. 2225. EASING REGULATORY BURDEN WITH RESPECT 15 TO CERTAIN CLASS I AND CLASS II DEVICES. 16 (a) C LASS I DEVICES .\u2014Section 510(l) of the Federal 17 Food, Drug, and Cosmetic Act (21 U.S.C. 360(l)) is 18 amended\u2014 19 (1) by striking ''A report under subsection (k)'' 20 and inserting ''(1) A report under subsection (k)''; 21 and 22 (2) by adding at the end the following new 23 paragraph: 24 VerDate Nov 24 2008 11:47 Jul ''(2) Not later than 120 days after the date of the 1 enactment of the 21st Century Cures Act, the Secretary 2 shall identify, through publication in the Federal Register, 3 any type of class I device that the Secretary determines 4 no longer requires a report under subsection (k) to provide 5 reasonable assurance of safety and effectiveness. Upon 6 such publication\u2014 7 ''(A) each type of class I device so identified 8 shall be exempt from the requirement for a report 9 under subsection (k); and 10 ''(B) the classification regulation applicable to 11 each such type of device shall be deemed amended 12 to incorporate such exemption.''. 13 (b) C LASS II D EVICES .\u2014Section 510(m) of the Fed- 14 eral Food, Drug, and Cosmetic Act (21 U.S.C. 360(m)) 15 is amended\u2014 16 (1) by striking paragraph (1) and inserting the 17 following new paragraph: ''(1) The Secretary shall\u2014 18 ''(A) not later than 60 days after the date of 19 the enactment of the 21st Century Cures Act\u2014 20 ''(i) publish in the Federal Register a no- 21 tice that contains a list of each type of class II 22 device that the Secretary determines no longer 23 requires a report under subsection (k) to pro- 24 VerDate Nov 24 2008 11:47 Jul 02, of safety and effec- 1 tiveness; and 2 ''(ii) provide for a period of not less than 3 60 days for public comment beginning on the 4 date of the publication of such notice; and 5 ''(B) not later than 180 days after the date of 6 the enactment of 21st Century Cures Act, publish in 7 the Federal Register a list representing the Sec- 8 retary's final determination with respect to the de- 9 vices included in the list published under subpara- 10 graph (A).''; 11 (2) in paragraph (2)\u2014 12 (A) by striking ''1 day after the date of the 13 publication of a list under this subsection,'' and 14 inserting ''1 day after the date of publication of 15 the final list under paragraph (1)(B),''; and 16 (B) by striking ''30-day period'' and in- 17 serting ''60-day period''; and 18 (3) by adding at the end the following new 19 paragraph: 20 ''(3) Upon the publication of the final list under para- 21 graph (1)(B)\u2014 22 ''(A) each type of class II device so listed shall 23 be exempt from the requirement for a report under 24 subsection (k); and 25 VerDate Nov 24 2008 11:47 ''(B) the classification regulation applicable to 1 each such type of device shall be deemed amended 2 to incorporate such exemption.''. 3 SEC. 2226. ADVISORY COMMITTEE PROCESS. 4 (a) C LASSIFICATION PANELS .\u2014Paragraph (5) of sec- 5 tion 513(b) of the Federal Food, Drug, and Cosmetic Act 6 (21 U.S.C. 360c(b)) is amended\u2014 7 (1) by striking ''(5)'' and inserting ''(5)(A)''; 8 and 9 (2) by adding at the end the following: 10 ''(B) When a device is specifically the subject of re- 11 view by a classification panel, the Secretary shall\u2014 12 ''(i) ensure that adequate expertise is rep- 13 resented on the classification panel to assess\u2014 14 ''(I) the disease or condition which the de- 15 vice is intended to cure, treat, mitigate, prevent, 16 or diagnose; and 17 ''(II) the technology of the device; and 18 ''(ii) as part of the process to ensure adequate 19 expertise under clause (i), give due consideration to 20 the recommendations of the person whose premarket 21 submission is subject to panel review on the exper- 22 tise needed among the voting members of the panel. 23 ''(C) For purposes of subparagraph (B)(ii), the term 24 'adequate expertise' means, with respect to the member-25 VerDate Nov 24 2008 11:47 Jul of the classification panel reviewing a premarket sub-1 mission, that such membership includes\u2014 2 ''(i) two or more voting members, with a spe- 3 cialty or other expertise clinically relevant to the de- 4 vice under review; and 5 ''(ii) at least one voting member who is knowl- 6 edgeable about the technology of the device.''. 7 (b) P ANEL REVIEW PROCESS .\u2014Section 513(b)(6) of 8 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 9 360c(b)(6)) is amended\u2014 10 (1) in subparagraph (A)(iii), by inserting before 11 the period at the end '', including by designating a 12 representative who will be provided a time during 13 the panel meeting to address the panel individually 14 (or accompanied by experts selected by such rep- 15 resentative) for the purpose of correcting 16 misstatements of fact or providing clarifying infor- 17 mation, subject to the discretion of the panel chair- 18 person''; and 19 (2) by striking subparagraph (B) and inserting 20 the following new subparagraph: 21 ''(B)(i) Any meeting of a classification panel for a 22 device that is specifically the subject of review shall\u2014 23 ''(I) provide adequate time for initial presen- 24 tations by the person whose device is specifically the 25 VerDate Nov 24 2008 11:47 Jul 02, subject of a classification panel review and by the 1 Secretary; and 2 ''(II) encourage free and open participation by 3 all interested persons. 4 ''(ii) Following the initial presentations described in 5 clause (i), the panel may\u2014 6 ''(I) pose questions to a designated representa- 7 tive described in subparagraph (A)(iii); and 8 ''(II) consider the responses to such questions 9 in the panel's review of the device that is specifically 10 the subject of review by the panel.''. 11 SEC. 2227. HUMANITARIAN DEVICE EXEMPTION APPLICA-12 TION. 13 (a) I NGENERAL .\u2014Section 520(m) of the Federal 14 Food, Drug, and Cosmetic Act (21 U.S.C. 360j) is amend-15 ed\u2014 16 (1) in paragraph (1) by striking ''fewer than 17 4,000'' and inserting ''not more than 8,000''; 18 (2) in paragraph (2)(A) by striking ''fewer than 19 4,000'' and inserting ''not more than 8,000''; and 20 (3) in paragraph (6)(A)(ii), by striking ''4,000'' 21 and inserting ''8,000'' 22 (b) G UIDANCE DOCUMENT ON PROBABLE BEN- 23 EFIT.\u2014Not later than 18 months after the date of enact- 24 ment of this Act, the Secretary of Health and Human 25 VerDate Nov 24 2008 11:47 Jul 02, 210 Services, acting through the Commissioner of Food and 1 Drugs, shall publish a draft guidance document that de-2 fines the criteria for establishing ''probable benefit'' as 3 that term is used in section 520(m)(2)(C) of the Federal 4 Food, Drug, and Cosmetic Act (21 U.S.C. 360j(m)(2)(C)). 5 SEC. 2228. CLIA WAIVER STUDY DESIGN GUIDANCE FOR IN 6 VITRO DIAGNOSTICS. 7 (a) D RAFT REVISED GUIDANCE .\u2014Not later than 12 8 months after the date of the enactment of this Act, the 9 Secretary of Health and Human Services shall publish a 10 draft guidance that\u2014 11 (1) revises ''Section V. Demonstrating Insignifi- 12 cant Risk of an Erroneous Result\u2014'Accuracy' '' of 13 the guidance entitled ''Recommendations for Clinical 14 Laboratory Improvement Amendments of 1988 15 (CLIA) Waiver Applications for Manufacturers of In 16 Vitro Diagnostic Devices'' and dated January 30, 17 2008; and 18 (2) includes guidance on the appropriate use of 19 comparable performance between a waived user and 20 a moderately complex laboratory user to dem- 21 onstrate accuracy. 22 (b) F INAL REVISED GUIDANCE .\u2014The Secretary of 23 Health and Human Services shall finalize the draft guid-24 ance published under subsection (a) not later than 12 25 VerDate Nov 24 2008 11:47 Jul 02, 211 months after the comment period for such draft guidance 1 closes. 2 Subtitle N\u2014Sensible Oversight for 3 Technology Which Advances 4 Regulatory Efficiency 5 SEC. 2241. HEALTH SOFTWARE. 6 Section 201 of the Federal Food, Drug, and Cosmetic 7 Act (21 U.S.C. 321) is amended by adding at the end the 8 following: 9 ''(ss)(1) The term 'health software' means software 10 that does not, through use of an in vitro diagnostic device 11 or signal acquisition system, acquire, process, or analyze 12 an image or physiological signal, is not an accessory, is 13 not an integral part of a device necessary to support the 14 use of the device, is not used in the manufacture and 15 transfusion of blood and blood components to assist in the 16 prevention of disease in humans, and\u2014 17 ''(A) is intended for use for administrative or 18 operational support or the processing and mainte- 19 nance of financial records; 20 ''(B) is intended for use in clinical, laboratory, 21 or administrative workflow and related record- 22 keeping; 23 ''(C)(i) is intended for use solely in the trans- 24 fer, aggregation, conversion (in accordance with a 25 VerDate Nov 24 2008 11:47 Jul 02, present specification), storage, management, re- 1 trieval, or transmission of data or information; 2 ''(ii) utilizes a connectivity software platform, 3 electronic or electrical hardware, or a physical com- 4 munications infrastructure; and 5 ''(iii) is not intended for use\u2014 6 ''(I) in active patient monitoring; or 7 ''(II) in controlling or altering the func- 8 tions or parameters of a device that is con- 9 nected to such software; 10 ''(D) is intended for use to organize and 11 present information for health or wellness education 12 or for use in maintaining a healthy lifestyle, includ- 13 ing medication adherence and health management 14 tools; 15 ''(E) is intended for use to analyze information 16 to provide general health information that does not 17 include patient-specific recommended options to con- 18 sider in the prevention, diagnosis, treatment, cure, 19 or mitigation of a particular disease or condition; or 20 ''(F) is intended for use to analyze information 21 to provide patient-specific recommended options to 22 consider in the prevention, diagnosis, treatment, 23 cure, or mitigation of a particular disease or condi- 24 tion. 25 VerDate Nov 24 2008 11:47 'accessory' means a product that\u2014 1 ''(A) is intended for use with one or more par- 2 ent devices; 3 ''(B) is intended to support, supplement, or 4 augment the performance of one or more parent de- 5 vices; and 6 ''(C) shall be classified by the Secretary\u2014 7 ''(i) according to its intended use; and 8 ''(ii) independently of any classification of 9 any parent device with which it is used.''. 10 SEC. 2242. APPLICABILITY AND INAPPLICABILITY OF REGU-11 LATION. 12 Subchapter A of chapter V of the Federal Food, 13 Drug, and Cosmetic Act (21 U.S.C. 351 et seq.), as 14 amended by section 2221(a), is further amended by add-15 ing at the end the following: 16 ''SEC. 524C. HEALTH SOFTWARE. 17 ''(a) I NAPPLICABILITY OF REGULATION TO HEALTH 18 SOFTWARE .\u2014Except as provided in subsection (b), health 19 software shall not be subject to regulation under this Act. 20 ''(b) E XCEPTION .\u2014 21 ''(1) I N GENERAL .\u2014Subsection (a) shall not 22 apply with respect to a software product\u2014 23 ''(A) of a type described in subparagraph 24 (F) of section 201(ss)(1); and 25 VerDate Nov 24 2008 11:47 Jul ''(B) that the Secretary determines poses a 1 significant risk to patient safety. 2 ''(2) C ONSIDERATIONS .\u2014In making a deter- 3 mination under subparagraph (B) of paragraph (1) 4 with respect to a product to which such paragraph 5 applies, the Secretary shall consider the following: 6 ''(A) The likelihood and severity of patient 7 harm if the product were to not perform as in- 8 tended. 9 ''(B) The extent to which the product is 10 intended to support the clinical judgment of a 11 medical professional. 12 ''(C) Whether there is a reasonable oppor- 13 tunity for a medical professional to review the 14 basis of the information or treatment rec- 15 ommendation provided by the product. 16 ''(D) The intended user and user environ- 17 ment, such as whether a medical professional 18 will use a software product of a type described 19 in subparagraph (F) of section 201(ss)(1). 20 ''(c) D ELEGATION .\u2014The Secretary shall delegate pri- 21 mary jurisdiction for regulating a software product deter-22 mined under subsection (b) to be subject to regulation 23 under this Act to the center at the Food and Drug Admin-24 istration charged with regulating devices. 25 VerDate Nov 24 2008 11:47 Jul 02, OF SOFTWARE .\u2014 1 ''(1) I N GENERAL .\u2014The Secretary shall review 2 existing regulations and guidance regarding the reg- 3 ulation of software under this Act. The Secretary 4 may implement a new framework for the regulation 5 of software and shall, as appropriate, modify such 6 regulations and guidance or issue new regulations or 7 guidance. 8 ''(2) I SSUANCE BY ORDER .\u2014Notwithstanding 9 subchapter II of chapter 5 of title 5, United States 10 Code, the Secretary may modify or issue regulations 11 for the regulation of software under this Act by ad- 12 ministrative order published in the Federal Register 13 following the publication of a proposed order. 14 ''(3) A REAS UNDER REVIEW .\u2014The review of ex- 15 isting regulations and guidance under paragraph (1) 16 may include review of the following areas: 17 ''(A) Classification of software. 18 ''(B) Standards for development of soft- 19 ware. 20 ''(C) Standards for validation and 21 verification of software. 22 ''(D) Review of software. 23 ''(E) Modifications to software. 24 ''(F) Manufacturing of software. 25 VerDate Nov 24 2008 11:47 Jul 02, Quality systems for software. 1 ''(H) Labeling requirements for software. 2 ''(I) Postmarketing requirements for re- 3 porting of adverse events. 4 ''(4) P ROCESS FOR ISSUING PROPOSED REGU - 5 LATIONS ADMINISTRATIVE ORDER , AND GUID - 6 ANCE .\u2014Not later than 18 months after the date of 7 enactment of this section, the Secretary shall consult 8 with external stakeholders (including patients, indus- 9 try, health care providers, academia, and govern- 10 ment) to gather input before issuing regulations, an 11 administrative order, and guidance under this sub- 12 section. 13 ''(e) R ULE OF CONSTRUCTION .\u2014Nothing in this sec- 14 tion shall be construed as providing the Secretary with the 15 authority to regulate under this Act any health software 16 product of the type described in subparagraph (F) of sec-17 tion 201(ss)(1) unless and until the Secretary has made 18 a determination described in subsection (b)(1)(B) with re-19 spect to such product.''. 20 SEC. 2243. EXCLUSION FROM DEFINITION OF DEVICE. 21 Section 201(h) of the Federal Food, Drug, and Cos- 22 metic Act (21 U.S.C. 321) is amended\u2014 23 (1) in subparagraph (2), by striking ''or'' after 24 ''or other animals,''; 25 VerDate Nov 24 2008 11:47 subparagraph (3), by striking ''and'' and 1 inserting ''or''; and 2 (3) by inserting after subparagraph (3) the fol- 3 lowing: 4 ''(4) not health software (other than software 5 determined to be a risk to patient safety under sec- 6 tion 524B(b)), and''. 7 Subtitle O\u2014Streamlining Clinical 8 Trials 9 SEC. 2261. PROTECTION OF HUMAN SUBJECTS IN RE-10 SEARCH; APPLICABILITY OF RULES. 11 (a) I NGENERAL .\u2014In order to simplify and facilitate 12 compliance by researchers with applicable regulations for 13 the protection of human subjects in research, the Sec-14 retary of Health and Human Services shall, to the extent 15 possible and consistent with other statutory provisions, 16 harmonize differences between the HHS Human Subject 17 Regulations and the FDA Human Subject Regulations in 18 accordance with subsection (b). 19 (b) A VOIDING REGULATORY DUPLICATION AND UN- 20 NECESSARY DELAYS .\u2014 21 (1) I N GENERAL .\u2014The Secretary shall\u2014 22 (A) make such modifications to the provi- 23 sions of the HHS Human Subject Regulations, 24 the FDA Human Subject Regulations, and the 25 VerDate Nov 24 2008 11:47 Jul 02, as may be nec- 1 essary\u2014 2 (i) to reduce regulatory duplication 3 and unnecessary delays; 4 (ii) to modernize such provisions in 5 the context of multisite and cooperative re- 6 search projects; and 7 (iii) to incorporate local consider- 8 ations, community values, and mechanisms 9 to protect vulnerable populations; and 10 (B) ensure that human subject research 11 that is subject to the HHS Human Subject 12 Regulations or to the FDA Human Subject 13 Regulations may\u2014 14 (i) use joint or shared review; 15 (ii) rely upon the review of\u2014 16 (I) an independent institutional 17 review board; or 18 (II) an institutional review board 19 of an entity other than the sponsor of 20 the research; or 21 (iii) use similar arrangements to avoid 22 duplication of effort. 23 (2) R EGULATIONS AND GUIDANCE .\u2014Not later 24 than 36 months after the date of enactment of this 25 VerDate Nov 24 2008 11:47 Jul 02, the Secretary, acting through the relevant agen- 1 cies and offices of the Department of Health and 2 Human Services, including the Office for Human 3 Research Protections and relevant agencies and of- 4 fices of the Food and Drug Administration, shall 5 issue such regulations and guidance and take such 6 other actions as may be necessary to implement this 7 section and help to facilitate the broader use of sin- 8 gle, central, or lead institutional review boards. Such 9 regulations and guidance shall clarify the require- 10 ments and policies relating to the following: 11 (A) Arrangements to avoid duplication de- 12 scribed in paragraph (1)(A)(i), including\u2014 13 (i) delineating the roles of institu- 14 review boards in multisite or cooper- 15 ative, multisite studies where one or more 16 local institutional review boards are relied 17 upon, or similar arrangements are used; 18 (ii) the risks and benefits to human 19 subjects; 20 (iii) standardizing the informed con- 21 sent and other processes and legal docu- 22 ments; and 23 (iv) incorporating community values 24 through the use of local institutional re- 25 VerDate Nov 24 2008 11:47 Jul 02, 220 view boards while continuing to use central 1 or lead institutional review boards. 2 (B) Concerns about regulatory and legal li- 3 ability contributing to decisions by the sponsors 4 of research to rely on local institutional review 5 boards for multisite research. 6 (3) C ONSULTATION .\u2014In issuing regulations or 7 guidance under paragraph (2), the Secretary shall 8 consult with stakeholders (including researchers, 9 academic organizations, hospitals, institutional re- 10 search boards, pharmaceutical, biotechnology and 11 medical device developers, clinical research organiza- 12 tions, patient groups, and others). 13 (c) T IMING .\u2014The Secretary shall complete the har- 14 monization described in subsection (a) not later than 36 15 months after the date of enactment of this Act. 16 (d) P ROGRESS REPORT .\u2014Not later than 24 months 17 after the date of enactment of this Act, the Secretary shall 18 submit to Congress a report on the progress made toward 19 completing such harmonization. 20 (e) D RAFT NIH P OLICY .\u2014Not later than 12 months 21 after the date of enactment of this Act, the Secretary, act-22 ing through the Director of the National Institutes of 23 Health, shall finalize the draft policy entitled ''Draft NIH 24 VerDate Nov 24 2008 11:47 Jul 221 Policy on Use of a Single Institutional Review Board for 1 Multi-Site Research''. 2 (f) D EFINITIONS .\u2014 3 (1) H UMAN SUBJECT REGULATIONS .\u2014In this 4 section: 5 (A) FDA HUMAN SUBJECT REGULA - 6 TIONS .\u2014The term ''FDA Human Subject Reg- 7 ulations'' means the provisions of parts 50, 56, 8 312, and 812 of title 21, Code of Federal Regu- 9 lations (or any successor regulations). 10 (B) HHS HUMAN SUBJECT REGULA - 11 TIONS .\u2014The term ''HHS Human Subject Reg- 12 ulations'' means the provisions of subpart A of 13 part 46 of title 45, Code of Federal Regulations 14 (or any successor regulations). 15 (C) V ULNERABLE -POPULATIONS RULES .\u2014 16 The term ''vulnerable-populations rules''\u2014 17 (i) subject to clause (ii), means the 18 provisions of subparts B through D of 19 such part 46 (or any successor regula- 20 tions); or 21 (ii) as applicable to research that is 22 subject to the FDA Human Subject Regu- 23 lations, means the provisions applicable to 24 vulnerable populations under part 56 of 25 VerDate Nov 24 2008 11:47 Jul 02, 222 such title 21 (or any successor regulations) 1 and subpart D of part 50 of such title 21 2 (or any successor regulations). 3 (2) O THER DEFINITIONS .\u2014In this section: 4 (A) I NSTITUTIONAL REVIEW BOARD .\u2014The 5 term ''institutional review board'' has the mean- 6 ing that applies to the term ''institutional re- 7 view board'' under the HHS Human Subject 8 Regulations. 9 (B) L EAD INSTITUTIONAL REVIEW 10 BOARD .\u2014The term ''lead institutional review 11 board'' means an institutional review board that 12 otherwise meets the requirements of the HHS 13 Human Subject Regulations and enters into a 14 written agreement with an institution, another 15 institutional review board, a sponsor, or a prin- 16 cipal investigator to approve and oversee human 17 subject research that is conducted at multiple 18 locations. References to an institutional review 19 board include an institutional review board that 20 serves a single institution as well as a lead in- 21 stitutional review board. 22 VerDate Nov 24 2008 11:47 Jul 2262. USE OF NON-LOCAL INSTITUTIONAL REVIEW 1 BOARDS FOR REVIEW OF INVESTIGATIONAL 2 DEVICE EXEMPTIONS AND HUMAN DEVICE 3 EXEMPTIONS. 4 (a) I NGENERAL .\u2014Section 520 of the Federal Food, 5 Drug, and Cosmetic Act (21 U.S.C. 360(j)) is amended\u2014 6 (1) in subsection (g)(3)\u2014 7 (A) by striking ''local'' each place it ap- 8 pears; and 9 (B) in subparagraph (A)(i), by striking 10 ''which has been''; and 11 (2) in subsection (m)(4)\u2014 12 (A) by striking ''local'' each place it ap- 13 pears; and 14 (B) by striking subparagraph (A) and in- 15 serting the following new subparagraph: 16 ''(A) in facilities in which clinical testing of de- 17 vices is supervised by an institutional review com- 18 mittee established in accordance with the regulations 19 of the Secretary, and''. 20 (b) R EGULATIONS .\u2014Not later than 12 months after 21 the date of the enactment of this Act, the Secretary of 22 Health and Human Services shall revise or issue such reg-23 ulations or guidance as may be necessary to carry out the 24 amendments made by subsection (a). 25 VerDate Nov 24 2008 11:47 Jul 2263. ALTERATION OR WAIVER OF INFORMED CON-1 SENT FOR CLINICAL INVESTIGATIONS. 2 (a) D EVICES .\u2014Section 520(g)(3) of the Federal 3 Food, Drug, and Cosmetic Act (21 U.S.C. 360j(g)(3)) is 4 amended\u2014 5 (1) in subparagraph (D), by striking ''except 6 where subject to such conditions as the Secretary 7 may prescribe, the investigator'' and inserting the 8 following: ''except where, subject to such conditions 9 as the Secretary may prescribe\u2014 10 ''(i) the proposed clinical testing poses no 11 more than minimal risk to the human subject 12 and includes appropriate safeguards to protect 13 the rights, safety, and welfare of the human 14 subject; or 15 ''(ii) the investigator''; and 16 (2) in the matter following subparagraph (D), 17 by striking ''subparagraph (D)'' and inserting ''sub- 18 paragraph (D)(ii)''. 19 (b) D RUGS .\u2014Section 505(i)(4) of the Federal Food, 20 Drug, and Cosmetic Act (21 U.S.C. 355(i)(4)) is amended 21 by striking ''except where it is not feasible or it is contrary 22 to the best interests of such human beings'' and inserting 23 ''except where it is not feasible, it is contrary to the best 24 interests of such human beings, or the proposed clinical 25 testing poses no more than minimal risk to such human 26 VerDate Nov 24 2008 11:47 Jul 02, 225 beings and includes appropriate safeguards as prescribed 1 to protect the rights, safety, and welfare of such human 2 beings''. 3 Subtitle P\u2014Improving Scientific 4 Expertise and Outreach at FDA 5 SEC. 2281. SILVIO O. CONTE SENIOR BIOMEDICAL RE-6 SEARCH SERVICE. 7 (a) H IRING AND RETENTION AUTHORITY .\u2014Section 8 228 of the Public Health Service Act (42 U.S.C. 237) is 9 amended\u2014 10 (1) in the section heading, by inserting '' AND 11 BIOMEDICAL PRODUCT ASSESSMENT '' after '' RE- 12 SEARCH ''; 13 (2) in subsection (a)(1), by striking ''Silvio O. 14 Conte Senior Biomedical Research Service, not to 15 exceed 500 members'' and inserting ''Silvio O. Conte 16 Senior Biomedical Research and Biomedical Product 17 Assessment Service (in this section referred to as the 18 'Service'), the purpose of which is to recruit and re- 19 tain competitive and qualified scientific and tech- 20 nical experts outstanding in the field of biomedical 21 research, clinical research evaluation, and biomedical 22 product assessment''; 23 (3) by amending subsection (a)(2) to read as 24 follows: 25 VerDate Nov 24 2008 11:47 Jul ''(2) The authority established in paragraph (1) may 1 not be construed to require the Secretary to reduce the 2 number of employees serving under any other employment 3 system in order to offset the number of members serving 4 in the Service.''; 5 (4) in subsection (b)\u2014 6 (A) in the matter preceding paragraph (1), 7 by striking ''or clinical research evaluation'' and 8 inserting '', clinical research evaluation or bio- 9 medical product assessment''; and 10 (B) in paragraph (1), by inserting ''or a 11 master's level degree in engineering, 12 bioinformatics, or a related or emerging field,'' 13 after the comma; 14 (5) in subsection (d)(2), by striking ''and shall 15 not exceed the rate payable for level I of the Execu- 16 tive Schedule unless approved by the President 17 under section 5377(d)(2) of title 5, United States 18 Code'' and inserting ''and shall not exceed the rate 19 payable for the President''; 20 (6) by striking subsection (e); and 21 (7) by redesignating subsections (f) and (g) as 22 subsections (e) and (f), respectively. 23 (b) R EPORT .\u2014Not later than 3 years after the date 24 of the enactment of this Act, the Secretary of Health and 25 VerDate Nov 24 2008 11:47 Jul 02, 227 Human Services shall submit, and publish on the website 1 of the Department of Health and Human Services a report 2 on the implementation of the amendments made by sub-3 section (a), including whether the amendments have im-4 proved the ability of the Food and Drug Administration 5 to hire and retain qualified experts to fulfill obligations 6 specified under user fee agreements. 7 SEC. 2282. ENABLING FDA SCIENTIFIC ENGAGEMENT. 8 It is the sense of Congress that the participation in, 9 or sponsorship of, scientific conferences and meetings is 10 essential to the mission of the Food and Drug Administra-11 tion. 12 SEC. 2283. REAGAN-UDALL FOUNDATION FOR THE FOOD 13 AND DRUG ADMINISTRATION. 14 (a) B OARD OF DIRECTORS .\u2014 15 (1) C OMPOSITION AND SIZE .\u2014Section 16 770(d)(1)(C) of the Federal Food, Drug, and Cos- 17 metic Act (21 U.S.C. 379dd(d)(1)(C)) is amended\u2014 18 (A) by redesignating clause (ii) as clause 19 (iii); 20 (B) by inserting after clause (i) the fol- 21 lowing: 22 ''(ii) A DDITIONAL MEMBERS .\u2014The 23 Board, through amendments to the bylaws 24 of the Foundation, may provide that the 25 VerDate Nov 24 2008 11:47 Jul 02, number of voting members of the Board 1 shall be a number (to be specified in such 2 amendment) greater than 14. Any Board 3 positions that are established by any such 4 amendment shall be appointed (by majority 5 vote) by the individuals who, as of the date 6 of such amendment, are voting members of 7 the Board and persons so appointed may 8 represent any of the categories specified in 9 subclauses (I) through (V) of clause (i), so 10 long as no more than 30 percent of the 11 total voting members of the Board (includ- 12 ing members whose positions are estab- 13 lished by such amendment) are representa- 14 tives of the general pharmaceutical, device, 15 food, cosmetic, and biotechnology indus- 16 tries.''; and 17 (C) in clause (iii)(I), as redesignated by 18 subparagraph (A), by striking ''The ex officio 19 members shall ensure'' and inserting ''The ex 20 officio members, acting pursuant to clause (i), 21 and the Board, acting pursuant to clause (ii), 22 shall ensure''. 23 (2) F EDERAL EMPLOYEES ALLOWED TO SERVE 24 ON BOARD .\u2014Clause (iii)(II) of section 770(d)(1)(C) 25 VerDate Nov 24 2008 229 of the Federal Food, Drug, and Cosmetic Act (21 1 U.S.C. 379dd(d)(1)(C)), as redesignated by para- 2 graph (1)(A), is amended by adding at the end the 3 following: ''For purposes of this section, the term 4 'employee of the Federal Government' does not in- 5 clude a 'special Government employee', as that term 6 is defined in section 202(a) of title 18, United 7 States Code.''. 8 (3) S TAGGERED TERMS .\u2014Subparagraph (A) of 9 section 770(d)(3) of the Federal Food, Drug, and 10 Cosmetic Act (21 U.S.C. 379dd(d)(3)) is amended 11 to read as follows: 12 ''(A) T ERM.\u2014The term of office of each 13 member of the Board appointed under para- 14 graph (1)(C)(i), and the term of office of any 15 member of the Board whose position is estab- 16 lished pursuant to paragraph (1)(C)(ii), shall be 17 4 years, except that\u2014 18 ''(i) the terms of offices for the mem- 19 bers of the Board initially appointed under 20 paragraph (1)(C)(i) shall expire on a stag- 21 gered basis as determined by the ex officio 22 members; and 23 ''(ii) the terms of office for the per- 24 sons initially appointed to positions estab- 25 VerDate Nov 24 2008 11:47 Jul pursuant to paragraph (1)(C)(ii) 1 may be made to expire on a staggered 2 basis, as determined by the individuals 3 who, as of the date of the amendment es- 4 tablishing such positions, are members of 5 the Board.''. 6 (b) E XECUTIVE DIRECTOR COMPENSATION .\u2014Section 7 770(g)(2) of the Federal Food, Drug, and Cosmetic Act 8 (21 U.S.C. 379dd(g)(2)) is amended by striking ''but shall 9 not be greater than the compensation of the Commis-10 sioner''. 11 (c) S EPARATION OF FUNDS .\u2014Section 770(m) of the 12 Federal Food, Drug, and Cosmetic Act (21 U.S.C. 13 379dd(m)) is amended by striking ''are held in separate 14 accounts from funds received from entities under sub-15 section (i)'' and inserting ''are managed as individual pro-16 grammatic funds under subsection (i), according to best 17 accounting practices''. 18 SEC. 2284. COLLECTION OF CERTAIN VOLUNTARY INFOR-19 MATION EXEMPTED FROM PAPERWORK RE- 20 DUCTION ACT. 21 Chapter VII of the Federal Food, Drug, and Cos- 22 metic Act is amended by inserting after section 708 of 23 such Act (21 U.S.C. 379) the following: 24 VerDate Nov 24 2008 11:47 OF CERTAIN VOLUNTARY INFOR-1 MATION EXEMPTED FROM PAPERWORK RE- 2 DUCTION ACT. 3 ''Chapter 35 of title 44, United States Code, shall 4 not apply to the collection from patients, industry, aca-5 demia, and other stakeholders, of voluntary information 6 such as through voluntary surveys or questionnaires, initi-7 ated by the Secretary.''. 8 SEC. 2285. HIRING AUTHORITY FOR SCIENTIFIC, TECH-9 NICAL, AND PROFESSIONAL PERSONNEL. 10 (a) I NGENERAL .\u2014The Federal Food, Drug, and 11 Cosmetic Act is amended by inserting after section 714 12 (21 U.S.C. 379d-3) the following: 13 HIRING AUTHORITY. 14 ''(a) I NGENERAL .\u2014The Secretary may, without re- 15 gard to the provisions of title 5, United States Code, gov-16 erning appointments in the competitive service, appoint 17 qualified candidates to scientific, technical, or professional 18 positions within the following centers of the Food and 19 Drug Administration: 20 ''(1) The Center for Drug Evaluation and Re- 21 search. 22 ''(2) The Center for Biologics Evaluation and 23 Research. 24 ''(3) The Center for Devices and Radiological 25 Health. 26 VerDate Nov 24 2008 11:47 Jul 02, 232 Such positions shall be within the competitive service. 1 ''(b) C OMPENSATION .\u2014 2 ''(1) I N GENERAL .\u2014Notwithstanding any other 3 provision of law, including any requirement with re- 4 spect to General Schedule pay rates under sub- 5 chapter III of chapter 53 of title 5, United States 6 Code, and consistent with the requirements of para- 7 graph (2), the Secretary may determine and fix\u2014 8 ''(A) the annual rate of pay of any indi- 9 vidual appointed under subsection (a); and 10 ''(B) for purposes of retaining qualified 11 employees, the annual rate of pay for any high- 12 ly qualified scientific, technical, or professional 13 personnel appointed to a position at any of the 14 centers listed under subsection (a) before the 15 date of enactment of this section. 16 ''(2) L IMITATION .\u2014The annual rate of pay es- 17 tablished pursuant to paragraph (1) may not exceed 18 the annual rate of pay of the President. 19 ''(c) R EPORT .\u2014 20 ''(1) I N GENERAL .\u2014Not later than September 21 30, 2021, the Secretary shall submit a report to 22 Congress that examines the extent to which the au- 23 thority to appoint and retain personnel under this 24 section enhanced the Food and Drug Administra- 25 VerDate Nov 24 2008 11:47 Jul to meet the agency's critical need for 1 highly qualified individuals for scientific, technical, 2 or professional positions. 3 ''(2) R ECOMMENDATIONS .\u2014The report under 4 paragraph (1) shall include the recommendations of 5 the Secretary on\u2014 6 ''(A) whether the authority to appoint per- 7 sonnel under this section should be reauthor- 8 ized; and 9 ''(B) other personnel authorities that 10 would help the Food and Drug Administration 11 to better recruit and retain highly qualified in- 12 dividuals for scientific, technical, or professional 13 positions in the agency's medical product cen- 14 ters.''. 15 (b) R ULE OF CONSTRUCTION .\u2014The authority pro- 16 vided by section 714A of the Federal Food, Drug, and 17 Cosmetic Act (as added by subsection (a)) shall not be 18 construed to affect the authority provided under section 19 714 of such Act. 20 VerDate Nov 24 2008 11:47 Jul 02, Subtitle Q\u2014Exempting From 1 Sequestration Certain User Fees 2 SEC. 2301. EXEMPTING FROM SEQUESTRATION CERTAIN 3 USER FEES OF FOOD AND DRUG ADMINIS- 4 TRATION. 5 The Balanced Budget and Emergency Deficit Control 6 Act of 1985 is amended\u2014 7 (1) in section 255(g)(1)(A) (2 U.S.C. 8 905(g)(1)(A)), by inserting after the item relating to 9 ''Financial Agent Services'' the following new item: 10 ''Food and Drug Administration, Salaries 11 and Expenses, but only the portion of appro- 12 priations under such account corresponding to 13 fees collected under sections 736, 738, 740, 14 741, 744B, and 744H of the Federal Food, 15 Drug, and Cosmetic Act (75-9911-0-1-554).''; 16 and 17 (2) in section 256(h) (2 U.S.C. 906(h)), by 18 adding at the end the following new paragraph: 19 ''(5) Notwithstanding any other provision of 20 law, this subsection shall not apply with respect to 21 the portion of administrative expenses incurred by 22 the Food and Drug Administration that are funded 23 through fees collected under sections 736, 738, 740, 24 VerDate Nov 24 2008 11:47 and 744H of the Federal Food, Drug, 1 and Cosmetic Act.''. 2 TITLE III\u2014DELIVERY 3 Subtitle A\u2014Interoperability 4 SEC. 3001. ENSURING INTEROPERABILITY OF HEALTH IN-5 FORMATION TECHNOLOGY. 6 (a) I NTEROPERABILITY STANDARDS .\u2014 7 (1) I N GENERAL .\u2014Subtitle A of title XXX of 8 the Public Health Service Act (42 U.S.C. 300jj-11 9 et seq.) is amended by adding at the end the fol- 10 lowing new section: 11 ''SEC. 3010. ENSURING FORMATION 13 I NTEROPERABILITY .\u2014In order for health infor- 14 mation technology to be considered interoperable, such 15 technology must satisfy the following criteria: 16 ''(1) S ECURE TRANSFER .\u2014The technology al- 17 lows the secure transfer of all electronically acces- 18 sible health information to and from any and all 19 health information technology for authorized use 20 under applicable State or Federal law. 21 ''(2) C OMPLETE ACCESS TO HEALTH INFORMA - 22 TION .\u2014The technology allows for complete access, 23 exchange, and use of all electronically accessible 24 health information for authorized use under applica- 25 VerDate Nov 24 2008 11:47 Jul ble State or Federal law without special effort by the 1 requestor of such health information. 2 ''(3) N O INFORMATION BLOCKING .\u2014The tech- 3 nology is not configured, set up, or implemented to 4 information block, as defined in section 3010A(d). 5 ''(b) C ATEGORIES FOR INTEROPERABILITY STAND - 6 ARDS .\u2014The categories described in this subsection, with 7 respect to standards and the corresponding implementa-8 tion specifications for determining if health information 9 technology is interoperable, consistent with the criteria de-10 scribed in subsection (a), include at least categories of 11 standards and implementation specifications with respect 12 to the following: 13 ''(1) Vocabulary and terminology. 14 ''(2) Content and structure. 15 ''(3) Transport. 16 ''(4) Security. 17 ''(5) Services. 18 ''(6) Querying and requesting health informa- 19 tion for access, exchange, and use. 20 ''(c) A LLOWING FOR FLEXIBILITY .\u2014A standard and 21 implementation specification, with respect to such stand-22 ard, that is determined under section 3001(c)(5)(D) to be 23 compatible with baseline standards and implementation 24 VerDate Nov 24 2008 11:47 Jul 02, 237 specifications (as defined in clause (ii) of such section) 1 shall be treated as in compliance with this section.''. 2 (2) G UIDANCE .\u2014Not later than January 1, 3 2017, the Secretary of Health and Human Services, 4 in consultation with the National Coordinator of the 5 Office of the National Coordinator for Health Infor- 6 mation Technology, shall issue guidance with respect 7 to the implementation of section 3010 of the Public 8 Health Service Act, as added by paragraph (1), in- 9 cluding with respect to defining and providing exam- 10 ples of authorized use under applicable State or 11 Federal law of health information. 12 (b) I MPROVEMENTS TO RECOMMENDATION PROC- 13 ESS.\u2014 14 (1) HIT POLICY COMMITTEE TO INCORPORATE 15 POLICIES FOR UPDATES TO INTEROPERABILITY 16 STANDARDS .\u2014Section 3002 of the Public Health 17 Service Act (42 U.S.C. 300jj-12) is amended\u2014 18 (A) in subsection (a)\u2014 19 (i) by striking ''National Coordinator'' 20 and inserting ''Secretary, in consultation 21 with the National Coordinator,''; and 22 (ii) by adding at the end the following 23 new sentence: ''The HIT Policy Committee 24 is authorized only to provide policy and 25 VerDate Nov 24 2008 11:47 Jul 02, 238 priority recommendations to the Secretary 1 and not authorized to otherwise affect the 2 development or modification of any stand- 3 ard, implementation specification, or cer- 4 tification criterion under this title.''; and 5 (B) in subsection (b)(2)\u2014 6 (i) in subparagraph (A), in the first 7 sentence\u2014 8 (I) by striking ''The HIT Policy 9 Committee'' and inserting ''Subject to 10 subparagraph (D), the HIT Policy 11 Committee''; and 12 (II) by inserting ''(including the 13 areas in which modifications and addi- 14 tions to interoperability standards and 15 implementation specifications, with re- 16 spect to such interoperability stand- 17 ards, under section 3010 are needed 18 for the electronic access, exchange, 19 and use of health information for pur- 20 poses of adoption of such modifica- 21 tions and additions under section 22 3004)'' after ''section 3004''. 23 (ii) by adding at the end the following 24 new subparagraph: 25 VerDate Nov 24 2008 11:47 Jul RULE RELATED TO INTER - 1 OPERABILITY .\u2014Any recommendation made by 2 the HIT Policy Committee on or after the date 3 of the enactment of this subparagraph with re- 4 spect to interoperability of health information 5 technology shall be consistent with the criteria 6 described in subsection (a) of section 3010.''. 7 (2) S UNSET OF HIT STANDARDS COMMITTEE .\u2014 8 Section 3003 of the Public Health Service Act (42 9 U.S.C. 300jj-13) is amended by adding at the end 10 the following new subsection: 11 ''(f) T ERMINATION .\u2014The HIT Standards Committee 12 shall terminate on the date that is 90 days after the date 13 of the enactment of this subsection.''. 14 (3) S TANDARDS DEVELOPMENT ORGANIZA - 15 TIONS .\u2014Title XXX of the Public Health Service Act 16 is amended by inserting after section 3003 the fol- 17 lowing new section: 18 ''SEC. 3003A. RECOMMENDATIONS FOR STANDARDS 19 THROUGH CONTRACTS WITH STANDARDS DE- 20 VELOPMENT ORGANIZATIONS. 21 ''(a) C ONTRACTS .\u2014 22 ''(1) I N GENERAL .\u2014For purposes of activities 23 conducted under this title, the Secretary shall enter 24 into one or more contracts with health care stand- 25 VerDate Nov 24 2008 11:47 Jul ards development organizations accredited by the 1 American National Standards Institute (or with the 2 American National Standards Institute) to carry 3 out, directly or through contracts with subcontrac- 4 tors, the duties described in subsection (b), as appli- 5 cable. 6 ''(2) T IMING FOR FIRST CONTRACT .\u2014As soon 7 as practicable after the date of the enactment of this 8 section, the Secretary shall enter into the first con- 9 tracts under paragraph (1). 10 ''(3) P ERIOD OF CONTRACT .\u2014Each contract 11 under paragraph (1) shall be for a period deter- 12 mined necessary by the Secretary, in consultation 13 with the National Coordinator, to carry out the ap- 14 plicable duties described in subsection (b). 15 ''(4) A PPROPRIATE ENTITIES .\u2014The Secretary 16 shall ensure the most appropriate entities described 17 in paragraph (1) are selected for each contract 18 under such paragraph. 19 ''(b) D UTIES .\u2014 20 ''(1) I NITIAL CONTRACT .\u2014The Secretary shall 21 initially enter into one or more contracts under sub- 22 section (a)(1) with entities described in such sub- 23 section, under which the entities\u2014 24 ''(A) shall recommend to the Secretary\u2014 25 VerDate Nov 24 2008 11:47 Jul for adoption under section 3004, 1 an initial set of interoperability standards 2 and implementation specifications, with re- 3 spect to such standards, identified or, as 4 appropriate, developed by such entities 5 that are consistent with the criteria de- 6 scribed in subsection (a) of section 3010, 7 and with respect to the categories de- 8 scribed in subsection (b) of such section; 9 and 10 ''(ii) as applicable, for purposes of 11 section 3001(c)(5)(D), methods to test if 12 health information technology is compat- 13 ible with health information technology 14 that applies baseline standards and imple- 15 mentation specifications (as defined in 16 clause (ii) of such section); and 17 ''(B) may provide to the Secretary rec- 18 ommendations described in paragraph (2). 19 ''(2) S UBSEQUENT CONTRACTS .\u2014Under each 20 subsequent contract entered into under this section 21 with entities described in subsection (a)(1) pursuant 22 to subsection (c), the entities shall recommend to the 23 Secretary\u2014 24 VerDate Nov 24 2008 11:47 Jul under section 3004 any 1 standards (including interoperability stand- 2 ards), implementation specifications, and, to the 3 extent necessary, certification criteria (and 4 modifications, including additions, to such 5 standards, specifications, and, to the extent 6 necessary, criteria), which are in accordance 7 with the criteria described in section 3010; and 8 ''(B) as applicable, for purposes of section 9 3001(c)(5)(D), methods to test if health infor- 10 mation technology is compatible with baseline 11 standards and implementation specifications (as 12 defined in clause (ii) of such section). 13 ''(3) S UBMISSION TO NIST .\u2014Under each con- 14 tract with an entity under this section, the entity 15 shall submit to the Director of the National Institute 16 of Standards and Technology each recommendation 17 submitted to the Secretary by such entity under this 18 section. 19 ''(4) C ONSULTATION .\u2014For the purposes of de- 20 veloping methods to test interoperability standards 21 and implementation specifications with respect to 22 such standards, the entities with a contract under 23 this section may consult with the Director of the Na- 24 tional Institute of Standards and Technology. 25 VerDate Nov 24 2008 11:47 Jul 02, ODIFICATIONS AND SUBSEQUENT CON- 1 TRACTS .\u2014 2 ''(1) I N GENERAL .\u2014The Secretary, in consulta- 3 tion with the National Coordinator, shall periodically 4 conduct hearings to evaluate and review the stand- 5 ards, implementation specifications, and certification 6 criteria adopted under section 3004 for purposes of 7 determining if modifications, including any addi- 8 tions, are needed with respect to such standards, 9 specifications, and criteria. 10 ''(2) C ONTRACT TRIGGER .\u2014Based on the needs 11 for standards, implementation specifications, and 12 certification criteria (and modifications, including 13 additions, to such standards, specifications, and cri- 14 teria) under this title, as determined by the Sec- 15 retary, with due consideration to section 3010(b) 16 and in consultation with the National Coordinator, 17 the Secretary shall, as needed, enter into contracts 18 under subsection (a) to carry out the duties de- 19 scribed in subsection (b)(2) in addition to any con- 20 tract entered into to carry out the duties described 21 in subsection (b)(1). 22 ''(d) A UTHORIZATION OF APPROPRIATIONS .\u2014There 23 is authorized to be appropriated $10,000,000 for contracts 24 under subsection (a), to remain available until expended.''. 25 VerDate Nov 24 2008 11:47 Jul (4) M ODIFICATIONS TO ROLE OF THE NA - 1 TIONAL COORDINATOR .\u2014Section 3001(c)(1)(A) of 2 the Public Health Service Act (42 U.S.C. 300jj- 3 11(c)(1)(A)) is amended by inserting ''for rec- 4 ommendations made before the date of the enact- 5 ment of the 21st Century Cures Act,'' before ''review 6 and determine''. 7 (c) A DOPTION .\u2014Section 3004 of the Public Health 8 Service Act (42 U.S.C. 300jj-14) is amended\u2014 9 (1) in subsection (a)\u2014 10 (A) in paragraph (1), by inserting after 11 ''section 3001(c)'' the following: ''(or, subject to 12 subsection (c), in the case of a standard, imple- 13 mentation specification, or criterion rec- 14 ommended on or after the date of the enact- 15 ment of the 21st Century Cures Act, after the 16 date of submission of the recommendation to 17 the Secretary under section 3003A)''; and 18 (B) in paragraph (2)(B), by striking ''and 19 the HIT Standards Committee''; 20 (2) in subsection (b)\u2014 21 (A) in paragraph (3), by striking ''with the 22 schedule published under section 3003(b)(2)'' 23 and inserting ''with subsection (d)''; and 24 VerDate Nov 24 2008 245 (B) by adding at the end the following new 1 paragraph: 2 ''(4) L IMITATION .\u2014The Secretary may not 3 adopt any policies, priorities, standards, implementa- 4 tion specifications, or certification criteria under this 5 subsection or subsection (a) that are inconsistent 6 with or duplicative of an interoperability standard or 7 implementation specification with respect to such 8 standard adopted under this section, in accordance 9 with subsections (c) and (d). In the case of a stand- 10 ard, specification, or criterion that has been adopted 11 under this section and is inconsistent or duplicative 12 of such an interoperability standard or specification 13 that is subsequently adopted under this section, such 14 interoperability standard or specification shall 15 supercede such other standard, specification, or cri- 16 terion and such other standard, specification, or cri- 17 terion shall no longer be considered adopted under 18 this section beginning on the date that such inter- 19 operability standard or specification becomes effec- 20 tive.''; and 21 (3) by adding at the end the following new sub- 22 sections: 23 ''(c) A DOPTION OF INITIAL INTEROPERABILITY 24 STANDARDS AND IMPLEMENTATION SPECIFICATIONS .\u2014 25 VerDate Nov 24 2008 11:47 Jul 02, Notwithstanding the previous subsections of this section, 1 the following shall apply in the case of the initial set of 2 interoperability standards and implementation specifica-3 tions with respect to such standards recommended under 4 section 3003A: 5 ''(1) R EVIEW OF STANDARDS .\u2014Not later than 6 90 days after the date of receipt of recommendations 7 for such interoperability standards and implementa- 8 tion specifications, the Secretary, in consultation 9 with the National Coordinator and representatives of 10 other relevant Federal agencies, such as the Na- 11 tional Institute of Standards and Technology, shall 12 jointly review such standards and implementation 13 specifications and shall determine whether or not to 14 propose adoption of such standards and implementa- 15 tion specifications. 16 ''(2) D ETERMINATION TO ADOPT .\u2014If, subject 17 to subsection (d)(3), the Secretary determines\u2014 18 ''(A) to propose adoption of such standards 19 and implementation specifications, the Sec- 20 retary shall, by regulation under section 553 of 21 title 5, United States Code, determine whether 22 or not to adopt such standards and implemen- 23 tation specifications; or 24 VerDate Nov 24 2008 ''(B) not to propose adoption of such 1 standards and implementation specifications, 2 the Secretary shall notify the applicable entity 3 with a contract under section 3003A in writing 4 of such determination and the reasons for not 5 proposing the adoption of the recommendation 6 for such standards and implementation speci- 7 fications. 8 ''(3) P UBLICATION .\u2014The Secretary shall pro- 9 vide for publication in the Federal Register of all de- 10 terminations made by the Secretary under para- 11 graph (1). 12 ''(d) R ULES FOR ADOPTION .\u2014In the case of a stand- 13 ard (including interoperability standard), implementation 14 specification, or certification criterion adopted under this 15 section on or after the date of the enactment of the 21st 16 Century Cures Act, the following shall apply: 17 ''(1) I N GENERAL .\u2014Except as provided in para- 18 graphs (2) and (3), any such standard (including 19 interoperability standard), implementation specifica- 20 tion, or certification criterion shall be a standard, 21 specification, or criterion that has been rec- 22 ommended by the entities with which the Secretary 23 has entered into a contract under section 3003A. 24 VerDate Nov 24 2008 11:47 Jul SPECI - 1 FICATION , OR CRITERION RECOMMENDED .\u2014If no 2 standard, implementation specification, or, to the ex- 3 tent necessary, certification criterion is rec- 4 ommended under paragraph (1)\u2014 5 ''(A) in the case of interoperability stand- 6 ards and implementation specifications with re- 7 spect to such standards, relating to a category 8 described in section 3010(b)\u2014 9 ''(i) paragraph (1) shall not apply; 10 and 11 ''(ii) paragraph (4) shall apply; or 12 ''(B) in the case of any other standard, im- 13 plementation specification, or, to the extent nec- 14 essary, certification criterion, relating to a pol- 15 icy or priority to carry out this title, as deter- 16 mined by the Secretary, in consultation with the 17 National Coordinator\u2014 18 ''(i) paragraph (1) shall not apply; 19 and 20 ''(ii) paragraph (4) shall apply. 21 ''(3) A UTHORITY TO MODIFY IMPLEMENTATION 22 SPECIFICATIONS .\u2014If, following public comment pur- 23 suant to subsection (c), the Secretary would propose 24 adoption of interoperability standards recommended 25 VerDate Nov 24 2008 11:47 Jul under section 3003A but for the implementation 1 specifications, with respect to such standards, so 2 recommended, the Secretary may modify such imple- 3 mentation specifications and adopt such standards 4 and specifications in accordance with subsection 5 (c)(2). 6 ''(4) E FFECTIVE DATE .\u2014In the case of a 7 standard, implementation specification, or certifi- 8 cation criterion for which there is a determination to 9 adopt such standard, implementation specification, 10 or certification criterion, such standard, implementa- 11 tion specification, or certification criterion shall be 12 considered adopted under this section and shall be 13 effective beginning on the date that is 12 months 14 after the date of publication of the final rule to 15 adopt such standard, implementation specification, 16 or certification criterion. 17 ''(5) A SSISTANCE TO THE SECRETARY .\u2014In 18 complying with the requirements of this subsection, 19 the Secretary shall give due consideration to any rec- 20 ommendations of the National Committee on Vital 21 and Health Statistics established under section 22 306(k), and shall consult with appropriate Federal 23 and State agencies and private organizations. The 24 Secretary shall publish in the Federal Register any 25 VerDate Nov 24 2008 11:47 Jul 02, 250 recommendation of the National Committee on Vital 1 and Health Statistics regarding the adoption of a 2 standard, implementation specification, or certifi- 3 cation criterion under this section. Any standard, 4 implementation specification, or certification cri- 5 terion adopted pursuant to this paragraph shall be 6 promulgated in accordance with the rulemaking pro- 7 cedures of subchapter III of chapter 5 of title 5, 8 United States Code. 9 ''(e) A LLOWING FOR FLEXIBILITY THROUGH COM- 10 PATIBILITY WITH BASELINE STANDARDS AND IMPLE - 11 MENTATION SPECIFICATIONS .\u2014For purposes of this title, 12 title XVIII of the Social Security Act, title XIX of such 13 Act, and any other provision of law, a standard and imple-14 mentation specification, with respect to such standard, 15 that is determined under section 3001(c)(5)(D) to be com-16 patible with baseline standards and implementation speci-17 fications (as defined in clause (ii) of such section) shall 18 be treated as if such standard and specification were an 19 interoperability standard and implementation specifica-20 tion, with respect to such interoperability standard, adopt-21 ed under this section.''. 22 (d) R EPORTS AND NOTIFICATIONS .\u2014Section 3010 of 23 the Public Health Service Act, as added by subsection (a), 24 VerDate Nov 24 2008 11:47 Jul 251 is amended by adding at the end the following new sub-1 section: 2 ''(c) D ISSEMINATION OF INFORMATION .\u2014 3 ''(1) I NITIAL SUMMARY REPORT .\u2014Not later 4 than July 1, 2017, the Secretary, after consultation 5 with relevant stakeholders, shall submit to Congress 6 and provide for publication in the Federal Register 7 and the posting on the Internet website of the Office 8 of the National Coordinator for Health Information 9 Technology a report on the following: 10 ''(A) The initial set of interoperability 11 standards and implementation specifications 12 adopted under section 3004(c). 13 ''(B) The strategies for achieving wide- 14 spread interoperability. 15 ''(C) Any barriers that are preventing 16 widespread interoperability. 17 ''(D) The plan and milestones, including 18 specific steps, to achieve widespread interoper- 19 ability. 20 ''(2) O NGOING PUBLICATION OF RECOMMENDA - 21 TIONS .\u2014The Secretary shall provide for publication 22 in the Federal Register, and the posting on the 23 Internet website of the Office of the National Coor- 24 VerDate Nov 24 2008 11:47 Jul dinator for Health Information Technology, of all 1 recommendations made under this section.''. 2 (e) C ERTIFICATION AND OTHER ENFORCEMENT 3 PROVISIONS .\u2014 4 (1) C ERTIFICATION OF QUALIFIED ELECTRONIC 5 HEALTH RECORDS .\u2014 6 (A) I N GENERAL .\u2014Section 3007(b) of the 7 Public Health Service Act (42 U.S.C. 300jj- 8 17(b)) is amended by striking ''under section 9 3001(c)(3) to be in compliance with'' and all 10 that follows through the period at the end and 11 inserting ''under section 3001(c)(3)\u2014 12 ''(1) for certifications made before January 1, 13 2018, to be in compliance with applicable standards 14 adopted under subsections (a) and (b) of section 15 3004; and 16 ''(2) for certifications made on or after January 17 1, 2018, to be in compliance with applicable stand- 18 ards adopted under subsections (a) and (b) of sec- 19 tion 3004 and to be interoperable in accordance with 20 section 3010 and in compliance with interoperability 21 standards adopted under section 3004.''. 22 (B) R EQUIREMENTS OF SECRETARY .\u2014Sec- 23 tion 3001(c)(5) of the Public Health Service 24 Act (42 U.S.C. 300jj-11(c)(5)) is amended\u2014 25 VerDate Nov 24 2008 (i) in subparagraph (B), by inserting 1 before the period at the end the following: 2 ''and, for certifications made on or after 3 January 1, 2018, with respect to health in- 4 formation technology, additional criteria to 5 establish that the technology is interoper- 6 able, in accordance with section 3010, and 7 in compliance with interoperability stand- 8 ards and implementation specifications, 9 with respect to such standards, adopted 10 under section 3004''; and 11 (ii) by adding at the end the following 12 new subparagraphs: 13 ''(C) E NFORCEMENT ; 14 DECERTIFICATIONS .\u2014 15 ''(i) R EQUIREMENTS .\u2014Under any 16 program kept or recognized under subpara- 17 graph (A), the Secretary shall ensure that 18 any vendor of or other entity offering to 19 health care providers (as defined in section 20 3010A(g)) qualified electronic health 21 records seeking a certification of such 22 records under such program on or after 23 January 1, 2018, shall, as a condition of 24 certification (and maintenance of certifi- 25 VerDate Nov 24 2008 11:47 Jul of such a record under such pro- 1 gram\u2014 2 ''(I) provide to the Secretary an 3 attestation\u2014 4 ''(aa) the entity has imple- 5 mented interoperability standards 6 and implementation specifica- 7 tions, with respect to such stand- 8 ards, adopted under section 3004 9 (including through application of 10 subsection (e) of such section); 11 ''(bb) that the entity, unless 12 for a legitimate purpose specified 13 by the Secretary, has not taken 14 and will not take any action that 15 constitutes information blocking 16 (as defined in section 3010A(d)), 17 with respect to such qualified 18 electronic health records; 19 ''(cc) that includes the pric- 20 ing information described in 21 clause (iii) for purposes of inclu- 22 sion under subsection (f) of such 23 information on the Internet 24 website of the Department of 25 VerDate Nov 24 2008 11:47 Jul 02, Health and Human Services; that 1 such information will be available 2 on a public Internet website of 3 such entity; and that the entity 4 will voluntarily provide such in- 5 formation to customers prior to 6 offering any qualified electronic 7 health records or related product 8 or service (including subsequent 9 updates, add-ons, or additional 10 products or services to be pro- 11 vided during the course of an on- 12 going contract), prospective cus- 13 tomers (such as persons who re- 14 quest or receive a quotation or 15 estimate), and other persons who 16 request such information; 17 ''(dd) that the technology 18 with respect to such records has 19 published application program- 20 ming interfaces, with respect to 21 health information within such 22 records, for search and indexing, 23 semantic harmonization and vo- 24 VerDate Nov 24 2008 and user 1 interface applications; 2 ''(ee) that the entity has 3 successfully and rigorously tested 4 the real world use of the record 5 in the type of setting in which it 6 would be marketed; and 7 ''(ff) that the entity has in 8 place data sharing programs or 9 capabilities based on common 10 data elements through such 11 mechanisms as application pro- 12 gramming interfaces without the 13 requirement for vendor-specific 14 interfaces; 15 ''(II) publish application pro- 16 gramming interfaces and associated 17 documentation, with respect to health 18 information within such records, for 19 search and indexing, semantic harmo- 20 nization and vocabulary translation, 21 and user interface applications; and 22 ''(III) demonstrate to the satis- 23 faction of the Secretary that health 24 information from such records are 25 VerDate Nov 24 2008 11:47 Jul 02, able to be exchanged, accessed, and 1 used through the use of application 2 programming interfaces without spe- 3 cial effort, as authorized under appli- 4 cable law. 5 ''(ii) D ECERTIFICATION .\u2014Under any 6 program kept or recognized under subpara- 7 graph (A), the Secretary shall ensure that 8 beginning January 1, 2019, any qualified 9 electronic health records that do not sat- 10 isfy the certification criteria described in 11 subparagraph (B) or with respect to which 12 the vendor or other entity described in 13 clause (i) does not satisfy the requirements 14 under such clause (or is determined to be 15 in violation of the terms of the attestation 16 or other requirements under such clause) 17 shall no longer be considered as certified 18 under such program. 19 ''(iii) P RICING INFORMATION .\u2014For 20 purposes of clause (i)(I)(cc), the pricing in- 21 formation described in this clause, with re- 22 spect to a vendor of or other entity offer- 23 ing a qualified electronic health record, is 24 the following: 25 VerDate Nov 24 2008 11:47 Jul ''(I) Additional types of costs or 1 fees (whether fixed, recurring, trans- 2 action based, or otherwise) imposed by 3 the entity (or any third-party from 4 whom the entity purchases, licenses, 5 or obtains any technology, products, 6 or services in connection with the 7 qualified electronic health record) to 8 purchase, license, implement, main- 9 tain, upgrade, use, or otherwise enable 10 and support the use of capabilities to 11 which such record is to be certified 12 under this section; or in connection 13 with any health information generated 14 in the course of using any capability 15 to which the record is to be so cer- 16 tified. 17 ''(II) Limitations, whether by 18 contract or otherwise, on the use of 19 any capability to which the record is 20 to be certified under this section for 21 any purpose within the scope of the 22 record's certification; or in connection 23 with any health information generated 24 in the course of using any capability 25 VerDate Nov 24 2008 11:47 Jul 02, 259 to which the record is to be certified 1 under this section. 2 ''(III) Limitations, including 3 technical or practical limitations of 4 technology or its capabilities, that 5 could prevent or impair the successful 6 implementation, configuration, 7 customization, maintenance, support, 8 or use of any capabilities to which the 9 record is to be certified under this 10 section; or that could prevent or limit 11 the access, use, exchange, or port- 12 ability of any health information gen- 13 erated in the course of using any ca- 14 pability to which the record is to be so 15 certified. 16 ''(D) F LEXIBILITY THROUGH COMPAT - 17 IBILITY .\u2014 18 ''(i) I N GENERAL .\u2014Under any pro- 19 gram kept or recognized under subpara- 20 graph (A), the Secretary shall provide for 21 a method and process by which a vendor of 22 or other entity offering to health care pro- 23 viders (as defined in section 3010A(g)) 24 qualified electronic health records seeking 25 VerDate Nov 24 2008 11:47 Jul 02, 260 a certification of such records under such 1 program on or after January 1, 2018, may 2 demonstrate, using such mechanisms as a 3 reference implementation model or other 4 means, that the standards and implemen- 5 tation specifications applied by such entity 6 with respect to such records are compatible 7 with baseline standards and implementa- 8 tion specifications, including by dem- 9 onstrating such records are able to trans- 10 mit information that is compatible with 11 qualified electronic health records that 12 would receive such information and that 13 apply the baseline standards and imple- 14 mentation specifications. Such a method 15 and process shall ensure that any such en- 16 tity using a standard or implementation 17 specification other than a baseline stand- 18 ard or implementation specification dem- 19 onstrates, through testing, compatibility 20 with the baseline standard and implemen- 21 tation specification with respect to receiv- 22 ing information. 23 ''(ii) B ASELINE STANDARDS AND IM - 24 PLEMENTATION SPECIFICATIONS .\u2014For 25 VerDate Nov 24 2008 11:47 purposes of clause (i), the term 'baseline 1 standards and implementation specifica- 2 tions' means the interoperability standards 3 and implementation specifications, with re- 4 spect to such standards, adopted under 5 section 3004 (without application of sub- 6 section (e) of such section).''. 7 (2) A DDITIONAL ENFORCEMENT PROVISIONS 8 UNDER THE PUBLIC HEALTH SERVICE ACT .\u2014Sub- 9 title A of title XXX of the Public Health Service Act 10 (42 U.S.C. 300jj-11 et seq.), as amended by sub- 11 sections (a)(1) and (d), is further amended by add- 12 ing at the end the following new section: 13 ''SEC. 3010A. ENFORCEMENT MECHANISMS. 14 ''(a) I NSPECTOR GENERAL AUTHORITY .\u2014The In- 15 spector General of the Department of Health and Human 16 Services shall have the authority to investigate claims of\u2014 17 ''(1)(A) vendors of, or other entities offering to 18 health care providers (as defined in subsection (g)), 19 qualified electronic health records (as defined in sec- 20 tion 3000(13)) being in violation of an attestation 21 (whether providing false information at the time of 22 such attestation or by act or practice conducted 23 after such attestation) made under section 24 3001(c)(5)(C)(i)(I), with respect to the use of such 25 VerDate Nov 24 2008 11:47 Jul 02, 262 records by a health care provider with respect to 1 items and services furnished under the Medicare 2 program under title XVIII of the Social Security Act 3 or Medicaid program under title XIX of such Act; 4 and 5 ''(B) vendors of, or other entities offering to 6 health care providers (as defined in subsection (g)), 7 health information technology having engaged in in- 8 formation blocking (as defined in subsection (d)), 9 unless for a legitimate purpose specified by the Sec- 10 retary, with respect to the use of such technology by 11 a health care provider with respect to items and 12 services furnished under such a program; 13 ''(2) health care providers having engaged in in- 14 formation blocking (as so defined), with respect to 15 the use of health information technology with re- 16 spect to items and services furnished under such a 17 program, unless for a legitimate purpose specified by 18 the Secretary; and 19 ''(3) health information system providers (such 20 as operators of health information exchanges, clin- 21 ical data registries, and other systems that facilitate 22 the exchange of information) having engaged in in- 23 formation blocking (as so defined), unless for a le- 24 gitimate purpose specified by the Secretary, with re- 25 VerDate Nov 24 2008 11:47 Jul 02, spect to the use of health information technology 1 with respect to items and services furnished under 2 such a program. 3 ''(b) I NFORMATION SHARING PROVISIONS .\u2014 4 ''(1) I N GENERAL .\u2014The National Coordinator 5 may serve as a technical consultant to the Inspector 6 General of the Department of Health and Human 7 Services and the Federal Trade Commission for pur- 8 poses of carrying out this section. As such technical 9 consultant, the National Coordinator may, notwith- 10 standing any other provision of law, share informa- 11 tion related to claims or investigations under sub- 12 section (a) with the Federal Trade Commission for 13 purposes of such investigations and shall share in- 14 formation with the Inspector General, as required by 15 law. 16 ''(2) P ROTECTION FROM DISCLOSURE OF IN - 17 FORMATION .\u2014Any information that is received by 18 the National Coordinator in connection with a claim 19 or suggestion of possible information blocking and 20 that could reasonably be expected to facilitate identi- 21 fication of the source of the information\u2014 22 ''(A) shall not be disclosed by the National 23 Coordinator except as may be necessary to 24 carry out the purpose of this section; and 25 VerDate Nov 24 2008 11:47 Jul shall be exempt from mandatory dis- 1 closure under section 552 of title 5, United 2 States Code, as provided by subsection (b)(3) of 3 such section. 4 Such information may be used by the Inspector Gen- 5 eral of the Department of Health and Human Serv- 6 ices or Federal Trade Commission for reporting pur- 7 poses to the extent that such information could not 8 reasonably be expected to facilitate identification of 9 the source of such information. 10 ''(3) N ON-APPLICATION OF PAPERWORK REDUC - 11 TION ACT .\u2014Chapter 35 of title 44, United States 12 Code (commonly referred to as the Paperwork Re- 13 duction Act of 1995) shall not apply to the National 14 Coordinator or to the Office of the National Coordi- 15 nator for Health Information Technology with re- 16 spect to the collection of complaints relating to 17 claims described in subsection (a). 18 ''(4) S TANDARDIZED PROCESS .\u2014The National 19 Coordinator shall implement a standardized process 20 for the public to submit reports on claims of\u2014 21 ''(A) health information technology prod- 22 ucts of vendors (or other entities offering such 23 products to health care providers (as defined in 24 VerDate Nov 24 2008 11:47 Jul 02, being interoperable or re- 1 sulting in information blocking; or 2 ''(B) actions by such entities, health care 3 providers, or health information system pro- 4 viders that result in such technology not being 5 interoperable or in information blocking with 6 respect to such technology; and 7 ''(C) any other act described in subsection 8 (a). 9 The standardized process shall provide for the collec- 10 tion of such information as the originating institu- 11 tion, location, type of transaction, system and 12 version, timestamp, terminating institution, loca- 13 tions, system and version, failure notice, and other 14 related information. 15 ''(c) P ENALTY .\u2014 16 ''(1) I N GENERAL .\u2014Any person or entity de- 17 scribed in paragraph (1), (2), or (3) of subsection 18 (a) determined to have committed on or after Janu- 19 ary 1, 2018, an act described in such respective 20 paragraph with respect to the use of a qualified elec- 21 tronic health record or health information tech- 22 nology, as applicable under such respective para- 23 graph, with respect to items and services furnished 24 under the Medicare program under title XVIII of 25 VerDate Nov 24 2008 11:47 Jul 266 the Social Security Act or the Medicaid program 1 under title XIX of such Act, shall be subject to a 2 civil monetary penalty in such amount as determined 3 appropriate by the Secretary through rulemaking. 4 ''(2) A PPLICATION .\u2014Subject to paragraph (3), 5 the provisions of section 1128A (other than sub- 6 sections (a) and (b)) of such Act (42 U.S.C. 1320a- 7 7a) shall apply to a civil money penalty applied 8 under this subsection in the same manner as they 9 apply to a civil money penalty or proceeding under 10 subsection (a) of such section 1128A. 11 ''(3) R ECOVERY OF FUNDS .\u2014Notwithstanding 12 section 3302 of title 31, United States Code, or any 13 other provision of law affecting the crediting of col- 14 lections, the Inspector General of the Department of 15 Health and Human Services may receive and retain 16 for current use any amounts recovered under this 17 subsection. In addition to amounts otherwise avail- 18 able to the Inspector General, funds received by the 19 Inspector General under this paragraph shall be de- 20 posited, as an offsetting collection, to the credit of 21 any appropriation available for purposes of carrying 22 out this subsection and subsection (a) and shall be 23 available without fiscal year limitation and without 24 further appropriation. 25 VerDate Nov 24 2008 11:47 Jul 02, BLOCKING .\u2014 1 ''(1) I N GENERAL .\u2014For purposes of this sec- 2 tion and section 3010, subject to paragraph (3), the 3 term 'information blocking' means, with respect to 4 the access, use, and exchange of qualified electronic 5 health records and other health information tech- 6 nology, business, technical, and organizational prac- 7 tices, including practices described in paragraph (2), 8 that\u2014 9 ''(A) prevent or materially discourage the 10 access, exchange, or use of electronic health in- 11 formation; and 12 ''(B) the actor knows or should know (as 13 defined in section 1128A(i)(7) of the Social Se- 14 curity Act) are likely to interfere with the ac- 15 cess, exchange, or use of electronic health infor- 16 mation. 17 ''(2) P RACTICES DESCRIBED .\u2014For purposes of 18 paragraph (1), the practices described in this para- 19 graph shall include the following: 20 ''(A) Contract terms, policies, or business 21 or organizational practices that restrict author- 22 ized use under applicable State or Federal law 23 of electronic health information or restrict the 24 authorized exchange under applicable State or 25 VerDate Nov 24 2008 11:47 Jul 02, 268 Federal law of such information for treatment 1 and other permitted purposes under such appli- 2 cable law, including transitions between cer- 3 tified EHR technologies. 4 ''(B) Charging unreasonable prices or fees 5 (such as for health information exchange, port- 6 ability, interfaces, and full export of health in- 7 formation) that make accessing, exchanging, or 8 using electronic health information cost prohibi- 9 tive. 10 ''(C) Developing or implementing health 11 information technology in nonstandard ways 12 that are likely to substantially increase the 13 costs, complexity, or burden of sharing elec- 14 tronic health information, especially in cases in 15 which relevant interoperability standards or 16 methods to measure interoperability have been 17 adopted by the Secretary. 18 ''(D) Developing or implementing health 19 information technology in ways that are likely 20 to lock in users or electronic health information, 21 such as not allowing for the full export of 22 health information; lead to fraud, waste, or 23 abuse; or impede innovations and advancements 24 in health information access, exchange, and use, 25 VerDate Nov 24 2008 11:47 Jul 02, technology-enabled 1 care delivery. 2 ''(3) E XCEPTIONS .\u2014 3 ''(A) I N GENERAL .\u2014The term 'information 4 blocking' shall not include practices that\u2014 5 ''(i) are required by applicable law; or 6 ''(ii) that the Secretary, through regu- 7 lation, identifies as necessary to protect 8 patient safety, to maintain the privacy or 9 security of individuals' health information, 10 or to promote competition and consumer 11 welfare. 12 ''(B) P ROCESS .\u2014For purposes of subpara- 13 graph (A)(ii), not later than 12 months after 14 the date of the enactment of this section, the 15 Secretary shall issue regulations following the 16 notice and comment procedures of section 553 17 of title 5, United States Code, except that the 18 Secretary may issue the first such regulation as 19 an interim final regulation. 20 ''(C) N O ENFORCEMENT BEFORE EXCEP - 21 TIONS IDENTIFIED .\u2014The term 'information 22 blocking' shall not include any practice or con- 23 duct occurring before the date that is 30 days 24 after the date on which the first regulation (as 25 VerDate Nov 24 2008 11:47 Jul 02, in subparagraph (B)) is issued under 1 such subparagraph. 2 ''(D) C ONSULTATION .\u2014To the extent that 3 regulations issued under this paragraph define 4 practices that are necessary to promote com- 5 petition and consumer welfare, the Secretary 6 may consult with the Federal Trade Commis- 7 sion in issuing such regulations. 8 ''(E) A PPLICATION .\u2014The term 'informa- 9 tion blocking', with respect to an individual or 10 entity, shall not include an act or practice other 11 than an act or practice committed by such indi- 12 vidual or entity. 13 ''(e) T REATMENT OF VENDORS WITH RESPECT TO 14 PATIENT SAFETY ORGANIZATIONS .\u2014In applying part C 15 of title IX\u2014 16 ''(1) vendors shall be treated as a provider (as 17 defined in section 921) for purposes of reporting re- 18 quirements under such part, to the extent that such 19 reports are related to attestation requirements under 20 section 3001(c)(5)(C)(i)(I); 21 ''(2) claims of information blocking described in 22 subsection (a) shall be treated as a patient safety ac- 23 tivity under such part for purposes of reporting re- 24 quirements under such part; and 25 VerDate Nov 24 2008 11:47 Jul care providers that are not mem- 1 bers of patient safety organizations shall be treated 2 in the same manner as health care providers that 3 are such members for purposes of such reporting re- 4 quirements with respect to claims of information 5 blocking described in subsection (a). 6 ''(f) R ULEMAKING AND GUIDANCE .\u2014 7 ''(1) I N GENERAL .\u2014Not later than 12 months 8 after the date of the enactment of this section, the 9 Secretary, in consultation with the National Coordi- 10 nator and the Inspector General of the Department 11 of Health and Human Services, shall, through rule- 12 making, implement the provisions of section 3001 of 13 the 21st Century Cures Act, including amendments 14 made by such section, relating to information block- 15 ing. 16 ''(2) N ON-DUPLICATION OF PENALTY STRUC - 17 TURES .\u2014In carrying out paragraph (1), in deter- 18 mining the scope of penalties, assessments, or exclu- 19 sions under such section 3001, including amend- 20 ments made by such section, relating to information 21 blocking, the Secretary shall ensure to the extent 22 possible that such penalties, assessments, and exclu- 23 sions do not duplicate penalty, assessment, and ex- 24 clusion structures that would otherwise apply with 25 VerDate Nov 24 2008 11:47 Jul 02, respect to information blocking and the type of indi- 1 vidual or entity involved as of the day before the 2 date of the enactment of this section. 3 ''(3) C LARIFICATION .\u2014In carrying out para- 4 graph (1), the Secretary shall ensure that health 5 care providers are not penalized for actions of ven- 6 dor of, and other entities offering to such providers, 7 health information technology for the failure of such 8 technology to meet requirements for such technology 9 to be certified under this title. 10 ''(4) G UIDANCE RELATING TO HIPAA .\u2014Not 11 later than January 1, 2017, the National Coordi- 12 nator shall publish guidance to clarify the relation- 13 ship of the provisions of the HIPAA privacy and se- 14 curity law, as defined in section 3009(a)(2) to infor- 15 mation blocking, including\u2014 16 ''(A) examples of how such provisions may 17 result in information blocking; and 18 ''(B) clarifying that a health care provider 19 (as defined in subsection (g)) who discloses 20 health information as allowed under applicable 21 State and Federal law is not liable for unlawful 22 actions, including breaches that occur in the 23 custody of the recipient unless the disclosure 24 proximately cause the breach. 25 VerDate Nov 24 2008 11:47 Jul 02, CARE PROVIDER DEFINED .\u2014For pur- 1 poses of this section, the term 'health care provider' means 2 a provider of services under subsection (u) of section 1861 3 of the Social Security Act and a supplier under subsection 4 (d) of such section. 5 ''(h) A UTHORIZATION OF APPROPRIATIONS .\u2014In ad- 6 dition to amounts made available under subsection (c)(3), 7 there is authorized to be appropriated $10,000,000 for fis-8 cal year 2017 to carry out subsection (a), to remain avail-9 able until expended.''. 10 (3) P OSTINGS RELATING TO ENFORCEMENT ON 11 HHS INTERNET WEBSITE .\u2014Section 3001 of the 12 Public Health Service Act (42 U.S.C. 300jj-11) is 13 amended by adding at the end the following new 14 subsection: 15 ''(f) E NFORCEMENT INFORMATION POSTED ON HHS 16 INTERNET WEBSITE .\u2014 17 ''(1) P RICING INFORMATION .\u2014Not later than 18 January 1, 2019, the National Coordinator shall 19 post the information described in subsection 20 (c)(5)(C)(I)(i)(cc) on the public Internet website of 21 the Office of the National Coordinator for Health 22 Information Technology in a manner that allows for 23 comparison of functionality, price information, and 24 other features among health information technology 25 VerDate Nov 24 2008 11:47 Jul 02, 274 products that aids in making informed decisions for 1 purchasing such a product. 2 ''(2) A NNUAL POSTING .\u2014For 2019 and each 3 subsequent year, the Secretary shall post on the 4 public Internet website of the Department of Health 5 and Human Services a list of any qualified electronic 6 health records with respect to which certification has 7 been withdrawn under subsection (c)(5)(C)(ii) dur- 8 ing such year and the vendor of or other entity of- 9 fering to health care providers (as defined in section 10 3010A(g)) such qualified electronic health records. 11 ''(3) P ERIODIC REVIEW .\u2014The Secretary shall 12 periodically review and confirm that vendors of and 13 other entities offering to health care providers (as 14 defined in section 3010A(g)) qualified electronic 15 health records have publicly published application 16 programming interfaces and associated documenta- 17 tion as required by subsection (c)(5)(C)(i)(II) for 18 purposes of certification and maintaining certifi- 19 cation under any program kept or recognized under 20 subsection (c)(5)(A).''. 21 (4) D EMONSTRATION REQUIRED FOR MEANING - 22 FUL EHR USE UNDER MEDICARE .\u2014 23 (A) E LIGIBLE PROFESSIONALS .\u2014 24 VerDate Nov 24 2008 11:47 Jul I N GENERAL .\u2014Section 1 1848(o)(2)(A) of the Social Security Act 2 (42 U.S.C. 1395w-4(o)(2)(A)) is amended 3 by inserting after clause (iii) the following 4 new clause: 5 ''(iv) I NTEROPERABILITY .\u2014With re- 6 spect to EHR reporting periods for pay- 7 ment years beginning with 2020, the eligi- 8 ble professional demonstrates to the satis- 9 faction of the Secretary, in accordance 10 with subparagraph (C)(i), that during such 11 period the professional has not taken any 12 action described in subsection (a)(2) of 13 section 3010A of the Public Health Service 14 Act, with respect to the use of any certified 15 EHR technology.''. 16 (ii) H ARDSHIP EXEMPTION IN CASE 17 OF DECERTIFIED EHR .\u2014Subparagraph (B) 18 of section 1848(a)(7) of the Social Security 19 Act (42 U.S.C. 1395w-4(a)(7)) is amend- 20 ed to read as follows: 21 ''(B) S IGNIFICANT HARDSHIP EXCEP - 22 TION .\u2014 23 ''(i) I N GENERAL .\u2014The Secretary 24 may, on a case-by-case basis, exempt an el- 25 VerDate Nov 24 2008 11:47 Jul 02, igible professional from the application of 1 the payment adjustment under subpara- 2 graph (A) if the Secretary determines, sub- 3 ject to annual renewal, that compliance 4 with the requirement for being a meaning- 5 ful EHR user would result in a significant 6 hardship, such as in the case of an eligible 7 professional who practices in a rural area 8 without sufficient Internet access. 9 ''(ii) D ECERTIFICATION .\u2014The Sec- 10 retary shall exempt an eligible professional 11 from the application of the payment ad- 12 justment under subparagraph (A) if the 13 Secretary determines that such profes- 14 sional was determined to not be a mean- 15 ingful EHR user because the certified 16 EHR technology used by such professional 17 is decertified under section 3001(c)(5)(C) 18 of the Public Health Service Act. An ex- 19 emption under the previous sentence may 20 be applied to an eligible professional only, 21 subject to clause (iii), during the first pay- 22 ment year with respect to the first EHR 23 reporting period to which such decertifica- 24 tion applies. 25 VerDate Nov 24 2008 11:47 DECERTIFICA TION .\u2014 2 ''(I) I N GENERAL .\u2014Notwith- 3 standing clause (iv)(I), in no case 4 shall an exemption by reason of clause 5 (ii) be for a period of less than 12 6 months. 7 ''(II) E XTENSION .\u2014An exemp- 8 tion under clause (ii) may be ex- 9 tended, on a case-by-case basis, for a 10 period of an additional 12 months 11 subject to the limitation described in 12 clause (iv)(I). 13 ''(iv) L IMITATION .\u2014 14 ''(I) I N GENERAL .\u2014Subject to 15 subclause (II), in no case may an eli- 16 gible professional be granted an ex- 17 emption under this subparagraph for 18 more than 5 years. 19 ''(II) E XCEPTION .\u2014Subclause (I) 20 shall not apply to an exemption by 21 reason of clause (ii) to the extent nec- 22 essary to satisfy clause (iii)(I).''. 23 (iii) F URTHER APPLICATION .\u2014Section 24 1848(o)(2) of the Social Security Act (42 25 VerDate Nov 24 2008 11:47 Jul 02, is amended by add- 1 ing at the end the following new subpara- 2 graph: 3 ''(E) H ARDSHIP EXEMPTION IN CASE OF 4 DECERTIFIED EHR .\u2014In the case of certified 5 EHR technology used by an eligible profes- 6 sional that is decertified under section 7 3001(c)(5)(C), during the first payment year 8 with respect to the first EHR reporting period 9 to which such decertification applies, the Sec- 10 retary shall not treat the professional as not 11 being a meaningful EHR user solely because 12 the technology used by such professional was so 13 decertified. The treatment of a professional 14 under the previous sentence shall be for a pe- 15 riod of at least 12 months and may, on a case- 16 by-case basis, be for a period of an additional 17 12 months.''. 18 (B) E LIGIBLE HOSPITALS .\u2014 19 (i) I N GENERAL .\u2014Section 20 1886(n)(3)(A) of the Social Security Act 21 (42 U.S.C. 1395ww(n)(3)(A)) is amended 22 by inserting after clause (iii) the following 23 new clause: 24 VerDate Nov 24 2008 11:47 Jul re- 1 spect to EHR reporting periods for pay- 2 ment years beginning with 2020, the hos- 3 pital demonstrates to the satisfaction of 4 the Secretary, in accordance with subpara- 5 graph (C)(i), that during such period the 6 hospital has not taken any action described 7 in subsection (a)(2) of section 3010A of 8 the Public Health Service Act, with respect 9 to the use of any certified EHR tech- 10 nology.''. 11 (ii) H ARDSHIP EXEMPTION IN CASE 12 OF DECERTIFIED EHR .\u2014Subclause (II) of 13 section 1886(b)(3)(B)(ix) of the Social Se- 14 curity Act (42 U.S.C. 15 1395ww(b)(3)(B)(ix)) is amended to read 16 as follows: 17 ''(II)(aa) The Secretary may, on a 18 case-by-case basis, exempt a subsection (d) 19 hospital from the application of subclause 20 (I) with respect to a fiscal year if the Sec- 21 retary determines, subject to annual re- 22 newal, that requiring such hospital to be a 23 meaningful EHR user during such fiscal 24 year would result in a significant hardship, 25 VerDate Nov 24 2008 11:47 Jul 02, 280 such as in the case of a hospital in a rural 1 area without sufficient Internet access. 2 ''(bb) The Secretary shall exempt a 3 subsection (d) hospital from the applica- 4 tion of subclause (I) with respect to a fis- 5 cal year if the Secretary determines that 6 such hospital was determined to not be a 7 meaningful EHR user because the certified 8 EHR technology used by such hospital is 9 decertified under section 3001(c)(5)(C) of 10 the Public Health Service Act. An exemp- 11 tion under the previous sentence may be 12 applied to a subsection (d) hospital only, 13 subject to items (cc) and (dd), during the 14 first payment year with respect to the first 15 EHR reporting period to which such decer- 16 tification applies. 17 ''(cc) Notwithstanding item (ee), in no 18 case shall an exemption by reason of item 19 (bb) be for a period of less than 12 20 months. 21 ''(dd) An exemption under item (bb) 22 may, on a case-by-case basis, be extended 23 for a period of an additional 12 months 24 VerDate Nov 24 2008 11:47 Jul 02, 281 subject to the limitation described in item 1 (ee). 2 ''(ee) Subject to item (ff), in no case 3 may a hospital be granted an exemption 4 under this subclause for more than 5 5 years. 6 ''(ff) Item (ee) shall not apply to an 7 exemption by reason of item (bb) to the ex- 8 tent necessary to satisfy item (cc).''. 9 (C) D EMONSTRATION REQUIRED FOR 10 MEANINGFUL EHR USE UNDER MEDICAID .\u2014 11 Section 1903(t)(2) of the Social Security Act 12 (42 U.S.C. 1396b(t)(2)) is amended by adding 13 at the end the following: ''An eligible profes- 14 sional shall not qualify as a Medicaid provider 15 under this subsection, with respect to a year be- 16 ginning with 2020, unless such provider dem- 17 onstrates to the Secretary, through means such 18 as an attestation, that the provider has not 19 taken any action described in subsection (a)(2) 20 of section 3010A of the Public Health Service 21 Act, with respect to the use of any certified 22 EHR technology.''. 23 (5) G UIDANCE .\u2014Not later than January 1, 24 2018, the Secretary of Health and Human Services 25 VerDate Nov 24 2008 11:47 Jul 02, issue guidance to further the voluntary transi- 1 tion of health care providers between different cer- 2 tified EHR technology (as defined in section 3 3000(1) of the Public Health Service Act (42 U.S.C. 4 300jj(1)) by removing disincentives to such transi- 5 tion, which may include applying to instances of 6 such a transition the hardship exemption authority 7 under section 1848(a)(7) of the Social Security Act 8 (42 U.S.C. 1395w-4(a)(7)), section 9 1886(b)(3)(B)(ix) of such Act (42 U.S.C. 10 1395ww(b)(3)(B)(ix)), and other provisions of law in 11 existence as of the date of the enactment of this Act. 12 In developing such guidance, the Secretary may con- 13 sult with the relevant Federal agencies. 14 (f) D EFINITIONS .\u2014 15 (1) C ERTIFIED EHR TECHNOLOGY .\u2014Paragraph 16 (1) of section 3000 of the Public Health Service Act 17 (42 U.S.C. 300jj) is amended to read as follows: 18 ''(1) C ERTIFIED EHR TECHNOLOGY .\u2014The term 19 'certified EHR technology' means a qualified elec- 20 tronic health record that is certified pursuant to sec- 21 tion 3001(c)(5) as meeting the certification criteria 22 defined in subparagraph (B) of such section that are 23 applicable to the type of record involved (as deter- 24 mined by the Secretary, such as an ambulatory elec- 25 VerDate Nov 24 2008 11:47 Jul record for office-based physicians or an 1 inpatient hospital electronic health record for hos- 2 pitals) including, beginning January 1, 2018, with 3 respect to which the vendor or other entity offering 4 such technology is in compliance with the require- 5 ments under section 3001(c)(5)(C)(i).''. 6 (2) W IDESPREAD INTEROPERABILITY .\u2014Section 7 3000 of the Public Health Service Act (42 U.S.C. 8 300jj) is amended by adding at the end the following 9 new paragraph: 10 ''(15) W IDESPREAD INTEROPERABILITY .\u2014The 11 term 'widespread means that, on a 12 nationwide basis\u2014 13 ''(A) health information technology is 14 interoperable, in accordance with section 3010; 15 and 16 ''(B) such technology is employed by mean- 17 ingful EHR users under the Medicare program 18 under title XVIII of the Social Security Act and 19 the Medicaid program under title XIX of such 20 Act and by other clinicians and health care pro- 21 viders.''. 22 (g) C ONFORMING AMENDMENTS .\u2014 23 VerDate Nov 24 2008 11:47 Jul OLUNTARY USE OF STANDARDS .\u2014Section 1 3006 of the Public Health Service Act (42 U.S.C. 2 300jj-16) is amended\u2014 3 (A) in subsection (a)(1), by inserting '', in- 4 cluding an interoperability standard or imple- 5 mentation specification, with respect to such 6 interoperability standard, adopted under such 7 section'' after ''section 3004''. 8 (B) in subsection (b), by inserting '', in- 9 cluding the interoperability standards and im- 10 plementation specifications, with respect to such 11 interoperability standards, adopted under such 12 section'' after ''section 3004''. 13 (2) HIPAA PRIVACY AND SECURITY LAW DEFI - 14 NITION CORRECTION .\u2014Section 3009(a)(2)(A) of the 15 Public Health Service Act (42 U.S.C. 300jj- 16 19(a)(2)(A)) is amended by striking ''title IV'' and 17 inserting ''title XIII''. 18 (3) C OORDINATION OF FEDERAL ACTIVITIES .\u2014 19 Section 13111 of the HITECH Act is amended\u2014 20 (A) in subsection (a), by inserting before 21 the period at the end the following: ''(and, be- 22 ginning on January 1, 2018, that are also 23 interoperable under section 3010 of such Act 24 and in compliance with interoperability stand- 25 VerDate Nov 24 2008 11:47 implementation specifications, with re- 1 spect to such interoperability standards, adopt- 2 ed under section 3004 of such Act )''; and 3 (B) in subsection (b), by inserting ''(and, 4 beginning on January 1, 2018, including an 5 interoperability standard or implementation 6 specification, with respect to such interoper- 7 ability standard, adopted under section 3004 of 8 such Act)'' before ''the President''. 9 (4) A PPLICATION TO PRIVATE ENTITIES .\u2014Sec- 10 tion 13112 of the HITECH Act is amended by in- 11 serting before the period at the end the following: 12 ''(and, beginning on January 1, 2018, that are also 13 interoperable under section 3010 of such Act and in 14 compliance with interoperability standards and im- 15 plementation specifications, with respect to such 16 interoperability standards, adopted under section 17 3004 of such Act)''. 18 (5) NIST TESTING .\u2014Section 13201 the 19 HITECH Act (42 U.S.C. 17911) is amended\u2014 20 (A) in subsection (a), by inserting ''(or, be- 21 ginning January 1, 2018, in coordination with 22 the entities with contracts under section 3003A, 23 with respect to standards, and implementation 24 VerDate Nov 24 2008 11:47 Jul 02, under section 3004)'' before '', 1 the Director''; and 2 (B) in subsection (b), by inserting ''(or, be- 3 ginning January 1, 2018, in coordination with 4 the entities with contracts under section 3003A, 5 with respect to standards and implementation 6 specifications under section 3004)'' before '', 7 the Director''; and 8 (C) by adding at the end the following new 9 subsection: 10 ''(c) F UNDING .\u2014For purposes of carrying out this 11 section, in addition to any other funds made available to 12 carry out this section, there is authorized to be appro-13 priated $15,000,000, to remain available until expended.''. 14 (6) C OORDINATION WITH RECOMMENDATIONS 15 FOR ACHIEVING WIDESPREAD EHR INTEROPER - 16 ABILITY .\u2014Section 106 of the Medicare Access and 17 CHIP Reauthorization Act of 2015 (Public Law 18 114-10) is amended by striking subsection (b).''. 19 (h) P ATIENT ENGAGEMENT AND EMPOWERMENT .\u2014 20 It is the sense of Congress that\u2014 21 (1) if the strategic goals that Congress set forth 22 in the HITECH Act are to be achieved, interoper- 23 ability is best achieved with individuals and author- 24 ized representatives having equal access to the 25 VerDate Nov 24 2008 11:47 Jul 02, health information of such individuals in electronic 1 format; 2 (2) patients have the right to the entirety of the 3 health information of such individuals, including 4 such information contained in an electronic health 5 record of such individuals; 6 (3) such right extends to both structured and 7 unstructured data; 8 (4) such right extends to authorized representa- 9 tives of the individual involved, such as care takers 10 of such individual, family members of such indi- 11 vidual, and guardians of such individual; and 12 (5) to further facilitate access of an individual 13 to health information of such individual\u2014 14 (A) health care providers should not have 15 the ability to deny a request of the individual 16 for access to the entirety of such health infor- 17 mation of such individual; 18 (B) health care providers do not need the 19 consent of individuals to share personal health 20 information of such individuals with other cov- 21 ered entities, in compliance with the HIPAA 22 privacy regulations promulgated pursuant to 23 section 264(c) of the Health Insurance Port- 24 ability and Accountability Act of 1996 for the 25 VerDate Nov 24 2008 11:47 Jul 02, 288 purposes of supporting patient care, except in 1 situations where consent is specifically required 2 under such regulations, such as in cases related 3 to the psychiatric records of the individual in- 4 volved; 5 (C) mechanisms should be utilized that 6 allow for the bidirectional exchange of informa- 7 tion through such mechanisms as web portals, 8 appointments, and prescription refills, for the 9 purpose of patients partnering with providers to 10 assist in managing health and care; 11 (D) mechanisms described in subparagraph 12 (C) should allow for connecting individuals 13 across the continuum of care; 14 (E) an individual has the right to access 15 the health information of the individual without 16 cost to the individual; 17 (F) mechanisms described in subparagraph 18 (C) should allow for data of an individual gen- 19 erated by the individual to be integrated into 20 such platforms as electronic health records; 21 (G) such access should be timely, in ac- 22 cordance with the HIPAA privacy regulations 23 described in subparagraph (B), and take into 24 VerDate Nov 24 2008 11:47 Jul 02, of the indi- 1 vidual involved; 2 (H) an individual should have the right to 3 be confident that the data in the electronic 4 health record of the individual pertains to such 5 individual; and 6 (I) the right described in subparagraph 7 (H) will promote safety and care coordination 8 for individuals. 9 Subtitle B\u2014Telehealth 10 SEC. 3021. TELEHEALTH SERVICES UNDER THE MEDICARE 11 PROGRAM. 12 (a) P ROVISION OF INFORMATION BY CENTERS FOR 13 MEDICARE & M EDICAID SERVICES .\u2014Not later than 1 14 year after the date of the enactment of this Act, the Ad-15 ministrator of the Centers for Medicare & Medicaid Serv-16 ices shall provide to the committees of jurisdiction of the 17 House of Representatives and the Senate information on 18 the following: 19 (1) The populations of Medicare beneficiaries, 20 such as those who are dually eligible for the Medi- 21 care program under title XVIII of the Social Secu- 22 rity Act (42 U.S.C. 1395 et seq.) and the Medicaid 23 program under title XIX of such Act (42 U.S.C. 24 1396 et seq.) and those with chronic conditions, 25 VerDate Nov 24 2008 11:47 Jul 02, 290 whose care may be improved most in terms of qual- 1 ity and efficiency by the expansion, in a manner that 2 meets or exceeds the existing in-person standard of 3 care under the Medicare program under title XVIII 4 of such Act, of telehealth services under section 5 1834(m)(4) of such Act (42 U.S.C. 1395m(m)(4)). 6 (2) Activities by the Center for Medicare and 7 Medicaid Innovation which examine the use of tele- 8 health services in models, projects, or initiatives 9 funded through section 1115A of the Social Security 10 Act (42 U.S.C. 1315a). 11 (3) The types of high volume services (and re- 12 lated diagnoses) under such title XVIII which might 13 be suitable to the furnishing of services via tele- 14 health. 15 (4) Barriers that might prevent the expansion 16 of telehealth services under section 1834(m)(4) of 17 the Social Security Act (42 U.S.C. 1395m(m)(4)) 18 beyond such services that are in effect as of the date 19 of the enactment of this Act. 20 (b) P ROVISION OF INFORMATION BY MEDPAC.\u2014Not 21 later than March 15, 2017, the Medicare Payment Advi-22 sory Commission established under section 1805 of the So-23 Security Act (42 U.S.C. 1395b-6) shall, using quan-24 titative and qualitative research methods, provide informa-25 VerDate Nov 24 2008 11:47 Jul tion to the committees of jurisdiction of the House of Rep-1 resentatives and the Senate that identifies\u2014 2 (1) the telehealth services for which payment 3 can be made, as of the date of the enactment of this 4 Act, under the fee-for-service program under parts A 5 and B of title XVIII of such Act; 6 (2) the telehealth services for which payment 7 can be made, as of such date, under private health 8 insurance plans; 9 (3) with respect to services identified under 10 paragraph (2) but not under paragraph (1), ways in 11 which payment for such services might be incor- 12 porated into such fee-for-service program (including 13 any recommendations for ways to accomplish this in- 14 corporation). 15 (c) S ENSE OF CONGRESS .\u2014It is the sense of Con- 16 gress that\u2014 17 (1) eligible originating sites should be expanded 18 beyond those originating sites described in section 19 1834(m)(4)(C) of the Social Security Act (42 U.S.C. 20 1395m(m)(4)(C)); and 21 (2) any expansion of telehealth services under 22 the Medicare program should\u2014 23 (A) recognize that telemedicine is the deliv- 24 ery of safe, effective, quality health care serv- 25 VerDate Nov 24 2008 11:47 Jul ices, by a health care provider, using technology 1 as the mode of care delivery; 2 (B) meet or exceed the conditions of cov- 3 erage and payment with respect to the Medicare 4 program under title XVIII unless specifically 5 address in subsequent statute, of such Act if 6 the service were furnished in person, including 7 standards of care; and 8 (C) involve clinically appropriate means to 9 furnish such services. 10 Subtitle C\u2014Encouraging Con-11 tinuing Medical Education for 12 Physicians 13 SEC. 3041. EXEMPTING FROM MANUFACTURER TRANS-14 PARENCY REPORTING CERTAIN TRANSFERS 15 USED FOR EDUCATIONAL PURPOSES. 16 (a) I NGENERAL .\u2014Section 1128G(e)(10)(B) of the 17 Social Security Act (42 U.S.C. 1320a-7h(e)(10)(B)) is 18 amended\u2014 19 (1) in clause (iii), by inserting '', including 20 peer-reviewed journals, journal reprints, journal sup- 21 plements, medical conference reports, and medical 22 textbooks'' after ''patient use''; and 23 (2) by adding at the end the following new 24 clause: 25 VerDate Nov 24 2008 11:47 Jul the case of a covered recipi- 1 ent who is a physician, an indirect pay- 2 ment or transfer of value to the covered re- 3 cipient\u2014 4 ''(I) for speaking at, or preparing 5 educational materials for, an edu- 6 cational event for physicians or other 7 health care professionals that does not 8 commercially promote a covered drug, 9 device, biological, or medical supply; 10 or 11 ''(II) that serves the sole purpose 12 of providing the covered recipient with 13 medical education, such as by pro- 14 viding the covered recipient with the 15 tuition required to attend an edu- 16 cational event or with materials pro- 17 vided to physicians at an educational 18 event.''. 19 (b) E FFECTIVE DATE.\u2014The amendments made by 20 this section shall apply with respect to transfers of value 21 made on or after the date of the enactment of this Act. 22 VerDate Nov 24 2008 11:47 Jul 02, D\u2014Disposable Medical 1 Technologies 2 SEC. 3061. TREATMENT OF CERTAIN ITEMS AND DEVICES. 3 (a) I NGENERAL .\u2014Section 1834 of the Social Secu- 4 rity Act (42 U.S.C. 1395m) is amended by adding at the 5 end the following new subsection: 6 ''(r) P AYMENT FOR CERTAIN DISPOSABLE DE- 7 VICES .\u2014 8 ''(1) I N GENERAL .\u2014The Secretary shall make 9 separate payment in the amount established under 10 paragraph (3) to a home health agency for a device 11 described in paragraph (2) when furnished to an in- 12 dividual who receives home health services for which 13 payment is made under section 1895(b). 14 ''(2) D EVICE DESCRIBED .\u2014For purposes of 15 paragraph (1), a device described in this paragraph 16 is a disposable device for which, as of January 1, 17 2015, there is\u2014 18 ''(A) a Level I Healthcare Common Proce- 19 dure Coding System (HCPCS) code for which 20 the description for a professional service in- 21 cludes the furnishing of such device; and 22 ''(B) a separate Level I HCPCS code for 23 a professional service that uses durable medical 24 equipment instead of such device. 25 VerDate Nov 24 2008 11:47 Jul 02, AYMENT AMOUNT .\u2014The Secretary shall 1 establish the separate payment amount for such a 2 device such that such amount does not exceed the 3 payment that would be made for the HCPCS code 4 described in paragraph (2)(A) under section 1833(t) 5 (relating to payment for covered OPD services).''. 6 (b) C ONFORMING AMENDMENT .\u2014Section 7 1861(m)(5) of the Social Security Act (42 U.S.C. 8 1395x(m)(5)) is amended by inserting ''and devices de-9 scribed in section 1834(r)(2)'' after ''durable medical 10 equipment''. 11 (c) E FFECTIVE DATE.\u2014The amendments made by 12 this section shall apply to devices furnished on or after 13 January 1, 2017. 14 Subtitle E\u2014Local Coverage 15 Decision Reforms 16 SEC. 3081. IMPROVEMENTS IN THE MEDICARE LOCAL COV-17 ERAGE DETERMINATION (LCD) PROCESS. 18 (a) I NGENERAL .\u2014Section 1862(l)(5) of the Social 19 Security Act (42 U.S.C. 1395y(l)(5)) is amended by add-20 ing at the end the following new subparagraph: 21 ''(D) L OCAL COVERAGE DETERMINA - 22 TIONS .\u2014The Secretary shall require each medi- 23 care administrative contractor that develops a 24 local coverage determination to make available 25 VerDate Nov 24 2008 11:47 Jul 02, on the website of such contractor and on the 1 Medicare website, at least 45 days before the 2 effective date of such determination, the fol- 3 lowing information: 4 ''(i) Such determination in its en- 5 tirety. 6 ''(ii) Where and when the proposed 7 determination was first made public. 8 ''(iii) Hyperlinks to the proposed de- 9 termination and a response to comments 10 submitted to the contractor with respect to 11 such proposed determination. 12 ''(iv) A summary of evidence that was 13 considered by the contractor during the de- 14 velopment of such determination and a list 15 of the sources of such evidence. 16 ''(v) An explanation of the rationale 17 that supports such determination.''. 18 (b) E FFECTIVE DATE.\u2014The amendment made by 19 subsection (a) shall apply with respect to local coverage 20 determinations that are proposed or revised on or after 21 the date that is 180 days after the date of the enactment 22 of this Act. 23 VerDate Nov 24 2008 11:47 Jul 02, 3 SEC. 3101. MEDICARE PHARMACEUTICAL AND TECH-4 NOLOGY OMBUDSMAN. 5 Section 1808(c) of the Social Security Act (42 U.S.C. 6 1395b-9(c)) is amended by adding at the end the fol-7 lowing new paragraph: 8 ''(4) P HARMACEUTICAL AND TECHNOLOGY OM - 9 BUDSMAN .\u2014Not later than 12 months after the date 10 of the enactment of this paragraph, the Secretary 11 shall provide for a pharmaceutical and technology 12 ombudsman within the Centers for Medicare & Med- 13 icaid Services who shall receive and respond to com- 14 plaints, grievances, and requests that\u2014 15 ''(A) are from entities that manufacture 16 pharmaceutical, biotechnology, medical device, 17 or diagnostic products that are covered or for 18 which coverage is being sought under this title; 19 and 20 ''(B) are with respect to coverage, coding, 21 or payment under this title for such products. 22 The second sentence of paragraph (2) shall apply to 23 this paragraph in the same manner as such sentence 24 applies to paragraph (2).''. 25 VerDate Nov 24 2008 11:47 Jul 1 Service 2 SEC. 3121. MEDICARE SITE-OF-SERVICE PRICE TRANS-3 PARENCY. 4 Section 1834 of the Social Security Act (42 U.S.C. 5 1395m), as amended by section 3061, is further amended 6 by adding at the end the following new subsection: 7 ''(s) S ITE-OF-SERVICE PRICE TRANSPARENCY .\u2014 8 ''(1) I N GENERAL .\u2014In order to facilitate price 9 transparency with respect to items and services for 10 which payment may be made either to a hospital 11 outpatient department or to an ambulatory surgical 12 center under this title, the Secretary shall, for 2017 13 and each year thereafter, make available to the pub- 14 lic via a searchable website, with respect to an ap- 15 propriate number of such items and services\u2014 16 ''(A) the estimated payment amount for 17 the item or service under the outpatient depart- 18 ment fee schedule under subsection (t) of sec- 19 tion 1833 and the ambulatory surgical center 20 payment system under subsection (i) of such 21 section; and 22 ''(B) the estimated amount of beneficiary 23 liability applicable to the item or service. 24 VerDate Nov 24 2008 11:47 Jul 02, ESTIMATED BENE 1 FICIARY LIABILITY .\u2014For purposes of paragraph 2 (1)(B), the estimated amount of beneficiary liability, 3 with respect to an item or service, is the amount for 4 such item or service for which an individual who 5 does not have coverage under a medicare supple- 6 mental policy certified under section 1882 or any 7 other supplemental insurance coverage is respon- 8 sible. 9 ''(3) I MPLEMENTATION .\u2014In carrying out this 10 subsection, the Secretary\u2014 11 ''(A) shall include in the notice described 12 in section 1804(a) a notification of the avail- 13 ability of the estimated amounts made available 14 under paragraph (1); and 15 ''(B) may utilize mechanisms in existence 16 on the date of the enactment of this subsection, 17 such as the portion of the website of the Cen- 18 ters for Medicare & Medicaid Services on which 19 information comparing physician performance is 20 posted (commonly referred to as the Physician 21 Compare website), to make available such esti- 22 mated amounts under such paragraph. 23 ''(4) F UNDING .\u2014For purposes of implementing 24 this subsection, the Secretary shall provide for the 25 VerDate Nov 24 2008 11:47 Jul 02, 300 transfer, from the Supplemental Medical Insurance 1 Trust Fund under section 1841 to the Centers for 2 Medicare & Medicaid Services Program Management 3 Account, of $6,000,000 for fiscal year 2015, to re- 4 main available until expended.''. 5 Subtitle H\u2014Medicare Part D Pa-6 tient Safety and Drug Abuse 7 Prevention 8 SEC. 3141. PROGRAMS TO PREVENT PRESCRIPTION DRUG 9 ABUSE UNDER MEDICARE PARTS C AND D. 10 (a) D RUG MANAGEMENT PROGRAM FOR AT-RISK 11 BENEFICIARIES .\u2014 12 (1) I N GENERAL .\u2014Section 1860D-4(c) of the 13 Social Security Act (42 U.S.C. 1395w-10(c)) is 14 amended by adding at the end the following: 15 ''(5) D RUG MANAGEMENT PROGRAM FOR AT - 16 RISK BENEFICIARIES .\u2014 17 ''(A) A UTHORITY TO ESTABLISH .\u2014A PDP 18 sponsor may establish a drug management pro- 19 gram for at-risk beneficiaries under which, sub- 20 ject to subparagraph (B), the PDP sponsor 21 may, in the case of an at-risk beneficiary for 22 prescription drug abuse who is an enrollee in a 23 prescription drug plan of such PDP sponsor, 24 limit such beneficiary's access to coverage for 25 VerDate Nov 24 2008 11:47 Jul 02, 301 frequently abused drugs under such plan to fre- 1 quently abused drugs that are prescribed for 2 such beneficiary by one or more prescribers se- 3 lected under subparagraph (D), and dispensed 4 for such beneficiary by one or more pharmacies 5 selected under such subparagraph. 6 ''(B) R EQUIREMENT FOR NOTICES .\u2014 7 ''(i) I N GENERAL .\u2014A PDP sponsor 8 may not limit the access of an at-risk ben- 9 eficiary for prescription drug abuse to cov- 10 erage for frequently abused drugs under a 11 prescription drug plan until such spon- 12 sor\u2014 13 ''(I) provides to the beneficiary 14 an initial notice described in clause 15 (ii) and a second notice described in 16 clause (iii); and 17 ''(II) verifies with the providers 18 of the beneficiary that the beneficiary 19 is an at-risk beneficiary for prescrip- 20 tion drug abuse. 21 ''(ii) I NITIAL NOTICE .\u2014An initial no- 22 tice described in this clause is a notice that 23 provides to the beneficiary\u2014 24 VerDate Nov 24 2008 11:47 Jul notice that the PDP sponsor 1 has identified the beneficiary as po- 2 tentially being an at-risk beneficiary 3 for prescription drug abuse; 4 ''(II) information describing all 5 State and Federal public health re- 6 sources that are designed to address 7 prescription drug abuse to which the 8 beneficiary has access, including men- 9 tal health services and other coun- 10 seling services; 11 ''(III) notice of, and information 12 about, the right of the beneficiary to 13 appeal such identification under sub- 14 section (h) and the option of an auto- 15 matic escalation to external review; 16 ''(IV) a request for the bene- 17 ficiary to submit to the PDP sponsor 18 preferences for which prescribers and 19 pharmacies the beneficiary would pre- 20 fer the PDP sponsor to select under 21 subparagraph (D) in the case that the 22 beneficiary is identified as an at-risk 23 beneficiary for prescription drug 24 abuse as described in clause (iii)(I); 25 VerDate Nov 24 2008 11:47 Jul an explanation of the mean- 1 ing and consequences of the identi- 2 fication of the beneficiary as poten- 3 tially being an at-risk beneficiary for 4 prescription drug abuse, including an 5 explanation of the drug management 6 program established by the PDP 7 sponsor pursuant to subparagraph 8 (A); 9 ''(VI) clear instructions that ex- 10 plain how the beneficiary can contact 11 the PDP sponsor in order to submit 12 to the PDP sponsor the preferences 13 described in subclause (IV) and any 14 other communications relating to the 15 drug management program for at-risk 16 beneficiaries established by the PDP 17 sponsor; and 18 ''(VII) contact information for 19 other organizations that can provide 20 the beneficiary with assistance regard- 21 ing such drug management program 22 (similar to the information provided 23 by the Secretary in other standardized 24 notices provided to part D eligible in- 25 VerDate Nov 24 2008 11:47 Jul 02, dividuals enrolled in prescription drug 1 plans under this part). 2 ''(iii) S ECOND NOTICE .\u2014A second no- 3 tice described in this clause is a notice that 4 provides to the beneficiary notice\u2014 5 ''(I) that the PDP sponsor has 6 identified the beneficiary as an at-risk 7 beneficiary for prescription drug 8 abuse; 9 ''(II) that such beneficiary is 10 subject to the requirements of the 11 drug management program for at-risk 12 beneficiaries established by such PDP 13 sponsor for such plan; 14 ''(III) of the prescriber (or pre- 15 scribers) and pharmacy (or phar- 16 macies) selected for such individual 17 under subparagraph (D); 18 ''(IV) of, and information about, 19 the beneficiary's right to appeal such 20 identification under subsection (h) 21 and the option of an automatic esca- 22 lation to external review; 23 ''(V) that the beneficiary can, in 24 the case that the beneficiary has not 25 VerDate Nov 24 2008 11:47 Jul 02, previously submitted to the PDP 1 sponsor preferences for which pre- 2 scribers and pharmacies the bene- 3 ficiary would prefer the PDP sponsor 4 select under subparagraph (D), sub- 5 mit such preferences to the PDP 6 sponsor; and 7 ''(VI) that includes clear instruc- 8 tions that explain how the beneficiary 9 can contact the PDP sponsor. 10 ''(iv) T IMING OF NOTICES .\u2014 11 ''(I) I N GENERAL .\u2014Subject to 12 subclause (II), a second notice de- 13 scribed in clause (iii) shall be provided 14 to the beneficiary on a date that is 15 not less than 60 days after an initial 16 notice described in clause (ii) is pro- 17 vided to the beneficiary. 18 ''(II) E XCEPTION .\u2014In the case 19 that the PDP sponsor, in conjunction 20 with the Secretary, determines that 21 concerns identified through rule- 22 making by the Secretary regarding 23 the health or safety of the beneficiary 24 or regarding significant drug diversion 25 VerDate Nov 24 2008 11:47 Jul 02, require the PDP sponsor to 1 provide a second notice described in 2 clause (iii) to the beneficiary on a 3 date that is earlier than the date de- 4 scribed in subclause (I), the PDP 5 sponsor may provide such second no- 6 tice on such earlier date. 7 ''(C) A T-RISK BENEFICIARY FOR PRE - 8 SCRIPTION DRUG ABUSE .\u2014 9 ''(i) I N GENERAL .\u2014For purposes of 10 this paragraph, the term 'at-risk bene- 11 ficiary for prescription drug abuse' means 12 a part D eligible individual who is not an 13 exempted individual described in clause (ii) 14 and\u2014 15 ''(I) who is identified as such an 16 at-risk beneficiary through the use of 17 clinical guidelines developed by the 18 Secretary in consultation with PDP 19 sponsors and other stakeholders de- 20 scribed in section 3141(f)(2)(A) of the 21 21st Century Cures Act; or 22 ''(II) with respect to whom the 23 PDP sponsor of a prescription drug 24 plan, upon enrolling such individual in 25 VerDate Nov 24 2008 11:47 Jul 02, 307 such plan, received notice from the 1 Secretary that such individual was 2 identified under this paragraph to be 3 an at-risk beneficiary for prescription 4 drug abuse under the prescription 5 drug plan in which such individual 6 was most recently previously enrolled 7 and such identification has not been 8 terminated under subparagraph (F). 9 ''(ii) E XEMPTED INDIVIDUAL DE - 10 SCRIBED .\u2014An exempted individual de- 11 scribed in this clause is an individual 12 who\u2014 13 ''(I) receives hospice care under 14 this title; 15 ''(II) is a resident of a long-term 16 care facility, of an intermediate care 17 facility for the mentally retarded, or 18 of another facility for which fre- 19 quently abused drugs are dispensed 20 for residents through a contract with 21 a single pharmacy; or 22 ''(III) the Secretary elects to 23 treat as an exempted individual for 24 purposes of clause (i). 25 VerDate Nov 24 2008 11:47 Jul 02, ELECTION OF PRESCRIBERS AND 1 PHARMACIES .\u2014 2 ''(i) I N GENERAL .\u2014With respect to 3 each at-risk beneficiary for prescription 4 drug abuse enrolled in a prescription drug 5 plan offered by such sponsor, a PDP spon- 6 sor shall, based on the preferences sub- 7 mitted to the PDP sponsor by the bene- 8 ficiary pursuant to clauses (ii)(IV) and 9 (iii)(V) of subparagraph (B) (except as 10 otherwise provided in this subparagraph), 11 select\u2014 12 ''(I) one or more individuals who 13 are authorized to prescribe frequently 14 abused drugs (referred to in this 15 paragraph as 'prescribers') who may 16 write prescriptions for such drugs for 17 such beneficiary; and 18 ''(II) one or more pharmacies 19 that may dispense such drugs to such 20 beneficiary. 21 ''(ii) R EASONABLE ACCESS .\u2014In mak- 22 ing the selections under this subpara- 23 graph\u2014 24 VerDate Nov 24 2008 11:47 a PDP sponsor shall ensure 1 that the beneficiary continues to have 2 reasonable access to frequently abused 3 drugs (as defined in subparagraph 4 (G)), taking into account geographic 5 location, beneficiary preference, im- 6 pact on costsharing, and reasonable 7 travel time; and 8 ''(II) a PDP sponsor shall ensure 9 such access (including access to pre- 10 scribers and pharmacies with respect 11 to frequently abused drugs) in the 12 case of individuals with multiple resi- 13 dences and in the case of natural dis- 14 asters and similar emergency situa- 15 tions. 16 ''(iii) B ENEFICIARY PREFERENCES .\u2014 17 If an at-risk beneficiary for prescription 18 drug abuse submits preferences for which 19 in-network prescribers and pharmacies the 20 beneficiary would prefer the PDP sponsor 21 select in response to a notice under sub- 22 paragraph (B), the PDP sponsor shall\u2014 23 ''(I) review such preferences; 24 VerDate Nov 24 2008 11:47 change the selec- 1 tion of prescribers and pharmacies for 2 the beneficiary based on such pref- 3 erences; and 4 ''(III) inform the beneficiary of 5 such selection or change of selection. 6 ''(iv) E XCEPTION REGARDING BENE - 7 FICIARY PREFERENCES .\u2014In the case that 8 the PDP sponsor determines that a change 9 to the selection of prescriber or pharmacy 10 under clause (iii)(II) by the PDP sponsor 11 is contributing or would contribute to pre- 12 scription drug abuse or drug diversion by 13 the beneficiary, the PDP sponsor may 14 change the selection of prescriber or phar- 15 macy for the beneficiary without regard to 16 the preferences of the beneficiary described 17 in clause (iii). 18 ''(v) C ONFIRMATION .\u2014Before select- 19 ing a prescriber (or prescribers) or phar- 20 macy (or pharmacies) under this subpara- 21 graph, a PDP sponsor must request and 22 receive confirmation from such a prescriber 23 or pharmacy acknowledging and accepting 24 that the beneficiary involved is in the drug 25 VerDate Nov 24 2008 11:47 Jul 02, 2 ''(E) T ERMINATIONS AND APPEALS .\u2014The 3 identification of an individual as an at-risk ben- 4 eficiary for prescription drug abuse under this 5 paragraph, a coverage determination made 6 under a drug management program for at-risk 7 beneficiaries, and the selection of prescriber or 8 pharmacy under subparagraph (D) with respect 9 to such individual shall be subject to reconsider- 10 ation and appeal under subsection (h) and the 11 option of an automatic escalation to external re- 12 view to the extent provided by the Secretary. 13 ''(F) T ERMINATION OF IDENTIFICATION .\u2014 14 ''(i) I N GENERAL .\u2014The Secretary 15 shall develop standards for the termination 16 of identification of an individual as an at- 17 risk beneficiary for prescription drug abuse 18 under this paragraph. Under such stand- 19 ards such identification shall terminate as 20 of the earlier of\u2014 21 ''(I) the date the individual dem- 22 onstrates that the individual is no 23 longer likely, in the absence of the re- 24 strictions under this paragraph, to be 25 VerDate Nov 24 2008 11:47 Jul 02, an at-risk beneficiary for prescription 1 drug abuse described in subparagraph 2 (C)(i); and 3 ''(II) the end of such maximum 4 period of identification as the Sec- 5 retary may specify. 6 ''(ii) R ULE OF CONSTRUCTION .\u2014 7 Nothing in clause (i) shall be construed as 8 preventing a plan from identifying an indi- 9 vidual as an at-risk beneficiary for pre- 10 scription drug abuse under subparagraph 11 (C)(i) after such termination on the basis 12 of additional information on drug use oc- 13 curring after the date of notice of such ter- 14 mination. 15 ''(G) F REQUENTLY ABUSED DRUG .\u2014For 16 purposes of this subsection, the term 'frequently 17 abused drug' means a drug that is a controlled 18 substance that the Secretary determines to be 19 frequently abused or diverted. 20 ''(H) D ATA DISCLOSURE .\u2014In the case of 21 an at-risk beneficiary for prescription drug 22 abuse whose access to coverage for frequently 23 abused drugs under a prescription drug plan 24 has been limited by a PDP sponsor under this 25 VerDate Nov 24 2008 11:47 Jul 02, paragraph, such PDP sponsor shall disclose 1 data, including any necessary individually iden- 2 tifiable health information, in a form and man- 3 ner specified by the Secretary, about the deci- 4 sion to impose such limitations and the limita- 5 tions imposed by the sponsor under this part to 6 other PDP sponsors that request such data. 7 ''(I) E DUCATION .\u2014The Secretary shall 8 provide education to enrollees in prescription 9 drug plans of PDP sponsors and providers re- 10 garding the drug management program for at- 11 risk beneficiaries described in this paragraph, 12 including education\u2014 13 ''(i) provided by medicare administra- 14 tive contractors through the improper pay- 15 ment outreach and education program de- 16 scribed in section 1874A(h); and 17 ''(ii) through current education efforts 18 (such as State health insurance assistance 19 programs described in subsection (a)(1)(A) 20 of section 119 of the Medicare Improve- 21 ments for Patients and Providers Act of 22 2008 (42 U.S.C. 1395b-3 note)) and ma- 23 terials directed toward such enrollees. 24 VerDate Nov 24 2008 11:47 Jul 02, PLANS .\u2014Pursuant to section 1860D\u201421(c)(1), 2 the provisions of this paragraph apply under 3 part D to MA organizations offering MA-PD 4 plans to MA eligible individuals in the same 5 manner as such provisions apply under this 6 part to a PDP sponsor offering a prescription 7 drug plan to a part D eligible individual.''. 8 (2) I NFORMATION FOR CONSUMERS .\u2014Section 9 1860D-4(a)(1)(B) of the Social Security Act (42 10 U.S.C. 1395w-104(a)(1)(B)) is amended by adding 11 at the end the following: 12 ''(v) The drug management program 13 for at-risk beneficiaries under subsection 14 (c)(5).''. 15 (b) U TILIZATION MANAGEMENT PROGRAMS .\u2014Sec- 16 tion 1860D-4(c) of the Social Security Act (42 U.S.C. 17 as amended by subsection (a)(1), is fur-18 ther amended\u2014 19 (1) in paragraph (1), by inserting after sub- 20 paragraph (D) the following new subparagraph: 21 ''(E) A utilization management tool to pre- 22 vent drug abuse (as described in paragraph 23 (6)(A)).''; and 24 VerDate Nov 24 2008 11:47 Jul 315 (2) by adding at the end the following new 1 paragraph: 2 ''(6) U TILIZATION MANAGEMENT TOOL TO PRE - 3 VENT DRUG ABUSE .\u2014 4 ''(A) I N GENERAL .\u2014A tool described in 5 this paragraph is any of the following: 6 ''(i) A utilization tool designed to pre- 7 vent the abuse of frequently abused drugs 8 by individuals and to prevent the diversion 9 of such drugs at pharmacies. 10 ''(ii) Retrospective utilization review 11 to identify\u2014 12 ''(I) individuals that receive fre- 13 quently abused drugs at a frequency 14 or in amounts that are not clinically 15 appropriate; and 16 ''(II) providers of services or sup- 17 pliers that may facilitate the abuse or 18 diversion of frequently abused drugs 19 by beneficiaries. 20 ''(iii) Consultation with the contractor 21 described in subparagraph (B) to verify if 22 an individual enrolling in a prescription 23 drug plan offered by a PDP sponsor has 24 been previously identified by another PDP 25 VerDate Nov 24 2008 11:47 Jul sponsor as an individual described in 1 clause (ii)(I). 2 ''(B) R EPORTING .\u2014A PDP sponsor offer- 3 ing a prescription drug plan (and an MA orga- 4 nization offering an MA-PD plan) in a State 5 shall submit to the Secretary and the Medicare 6 drug integrity contractor with which the Sec- 7 retary has entered into a contract under section 8 1893 with respect to such State a report, on a 9 monthly basis, containing information on\u2014 10 ''(i) any provider of services or sup- 11 plier described in subparagraph (A)(ii)(II) 12 that is identified by such plan sponsor (or 13 organization) during the 30-day period be- 14 fore such report is submitted; and 15 ''(ii) the name and prescription 16 records of individuals described in para- 17 graph (5)(C).''. 18 (c) E XPANDING ACTIVITIES OF MEDICARE DRUG IN- 19 TEGRITY CONTRACTORS (MEDIC S).\u2014 20 (1) I N GENERAL .\u2014Section 1893 of the Social 21 Security Act (42 U.S.C. 1395ddd) is amended by 22 adding at the end the following new subsection: 23 ''(j) E XPANDING ACTIVITIES OF MEDICARE DRUG 24 INTEGRITY CONTRACTORS (MEDIC S).\u2014 25 VerDate Nov 24 2008 11:47 CCESS TO INFORMATION .\u2014Under con- 1 tracts entered into under this section with Medicare 2 drug integrity contractors (including any successor 3 entity to a Medicare drug integrity contractor), the 4 Secretary shall authorize such contractors to directly 5 accept prescription and necessary medical records 6 from entities such as pharmacies, prescription drug 7 plans, MA-PD plans, and physicians with respect to 8 an individual in order for such contractors to pro- 9 vide information relevant to the determination of 10 whether such individual is an at-risk beneficiary for 11 prescription drug abuse, as defined in section 12 1860D-4(c)(5)(C). 13 ''(2) R EQUIREMENT FOR ACKNOWLEDGMENT 14 OF REFERRALS .\u2014If a PDP sponsor or MA organiza- 15 tion refers information to a contractor described in 16 paragraph (1) in order for such contractor to assist 17 in the determination described in such paragraph, 18 the contractor shall\u2014 19 ''(A) acknowledge to the sponsor or organi- 20 zation receipt of the referral; and 21 ''(B) in the case that any PDP sponsor or 22 MA organization contacts the contractor re- 23 questing to know the determination by the con- 24 tractor of whether or not an individual has been 25 VerDate Nov 24 2008 11:47 Jul 02, 318 determined to be an individual described such 1 paragraph, shall inform such sponsor or organi- 2 zation of such determination on a date that is 3 not later than 15 days after the date on which 4 the sponsor or organization contacts the con- 5 tractor. 6 ''(3) M AKING DATA AVAILABLE TO OTHER EN - 7 TITIES .\u2014 8 ''(A) I N GENERAL .\u2014For purposes of car- 9 rying out this subsection, subject to subpara- 10 graph (B), the Secretary shall authorize MED- 11 ICs to respond to requests for information from 12 PDP sponsors and MA organizations, State 13 prescription drug monitoring programs, and 14 other entities delegated by such sponsors or or- 15 ganizations using available programs and sys- 16 tems in the effort to prevent fraud, waste, and 17 abuse. 18 ''(B) HIPAA COMPLIANT INFORMATION 19 ONLY .\u2014Information may only be disclosed by a 20 MEDIC under subparagraph (A) if the disclo- 21 sure of such information is permitted under the 22 Federal regulations (concerning the privacy of 23 individually identifiable health information) pro- 24 mulgated under section 264(c) of the Health 25 VerDate Nov 24 2008 11:47 Jul 02, Accountability Act of 1 1996 (42 U.S.C. 1320d-2 note).''. 2 (2) OIG STUDY AND REPORT ON EFFECTIVE - 3 NESS OF MEDICS .\u2014 4 (A) S TUDY .\u2014The Inspector General of the 5 Department of Health and Human Services 6 shall conduct a study on the effectiveness of 7 Medicare drug integrity contractors with which 8 the Secretary of Health and Human Services 9 has entered into a contract under section 1893 10 of the Social Security Act (42 U.S.C. 1395ddd) 11 in identifying, combating, and preventing fraud 12 under the Medicare program, including under 13 the authority provided under section 1893(j) of 14 the Social Security Act, added by paragraph 15 (1). 16 (B) R EPORT .\u2014Not later than 1 year after 17 the date of the enactment of this Act, the In- 18 spector General shall submit to Congress a re- 19 port on the study conducted under subpara- 20 graph (A). Such report shall include such rec- 21 ommendations for improvements in the effec- 22 tiveness of such contractors as the Inspector 23 General determines appropriate. 24 VerDate Nov 24 2008 11:47 Jul 02, T REATMENT OF CERTAIN COMPLAINTS FOR PUR- 1 POSES OF QUALITY OR PERFORMANCE ASSESSMENT .\u2014 2 Section 1860D-42 of the Social Security Act (42 U.S.C. 3 1395w-152) is amended by adding at the end the fol-4 lowing new subsection: 5 ''(d) T REATMENT OF CERTAIN COMPLAINTS FOR 6 PURPOSES OF QUALITY OR PERFORMANCE ASSESS - 7 MENT .\u2014In conducting a quality or performance assess- 8 ment of a PDP sponsor, the Secretary shall develop or 9 utilize existing screening methods for reviewing and con-10 sidering complaints that are received from enrollees in a 11 prescription drug plan offered by such PDP sponsor and 12 that are complaints regarding the lack of access by the 13 individual to prescription drugs due to a drug manage-14 ment program for at-risk beneficiaries.''. 15 (e) S ENSE OF CONGRESS REGARDING USE OF TECH- 16 NOLOGY TOOLS TOCOMBAT FRAUD .\u2014It is the sense of 17 Congress that MA organizations and PDP sponsors 18 should consider using e-prescribing and other health infor-19 mation technology tools to support combating fraud under 20 MA-PD plans and prescription drug plans under parts C 21 and D of the Medicare program. 22 (f) E FFECTIVE DATE.\u2014 23 (1) I N GENERAL .\u2014The amendments made by 24 this section shall apply to prescription drug plans 25 VerDate Nov 24 2008 11:47 Jul 02, (and MA-PD plans) for plan years beginning more 1 than 1 year after the date of the enactment of this 2 Act. 3 (2) S TAKEHOLDER MEETINGS PRIOR TO EFFEC - 4 TIVE DATE .\u2014 5 (A) I N GENERAL .\u2014Not later than January 6 1, 2016, the Secretary of Health and Human 7 Services shall convene stakeholders, including 8 individuals entitled to benefits under part A of 9 title XVIII of the Social Security Act or en- 10 rolled under part B of such title of such Act, 11 advocacy groups representing such individuals, 12 physicians, pharmacists, and other clinicians, 13 retail pharmacies, plan sponsors, entities dele- 14 gated by plan sponsors, and biopharmaceutical 15 manufacturers for input regarding the topics 16 described in subparagraph (B). 17 (B) T OPICS DESCRIBED .\u2014The topics de- 18 scribed in this subparagraph are the topics of\u2014 19 (i) the anticipated impact of drug 20 management programs for at-risk bene- 21 ficiaries under paragraph (5) of section 22 1860D-4(c) of the Social Security Act (42 23 U.S.C. 1395w-104(c)) on cost-sharing and 24 ensuring accessibility to prescription drugs 25 VerDate Nov 24 2008 11:47 Jul 02, for enrollees in prescription drug plans of 1 PDP sponsors, and enrollees in MA-PD 2 plans, who are at-risk beneficiaries for pre- 3 scription drug abuse (as defined in sub- 4 paragraph (C) of such paragraph); 5 (ii) the use of an expedited appeals 6 process under which such an enrollee may 7 appeal an identification of such enrollee as 8 an at-risk beneficiary for prescription drug 9 abuse under such paragraph (similar to the 10 processes established under the Medicare 11 Advantage program under part C of title 12 XVIII of the Social Security Act that allow 13 an automatic escalation to external review 14 of claims submitted under such part); 15 (iii) the types of enrollees that should 16 be treated as exempted individuals, as de- 17 scribed in subparagraph (C)(ii) of such 18 paragraph; 19 (iv) the manner in which terms and 20 definitions in such paragraph should be ap- 21 plied, such as the use of clinical appro- 22 priateness in determining whether an en- 23 rollee is an at-risk beneficiary for prescrip- 24 VerDate Nov 24 2008 11:47 drug abuse as defined in subpara- 1 graph (C) of such paragraph; 2 (v) the information to be included in 3 the notices described in subparagraph (B) 4 of such paragraph and the standardization 5 of such notices; and 6 (vi) with respect to a PDP sponsor 7 (or Medicare Advantage organization) that 8 establishes a drug management program 9 for at-risk beneficiaries under such para- 10 graph, the responsibilities of such PDP 11 sponsor (or organization) with respect to 12 the implementation of such program. 13 (g) R ULEMAKING .\u2014The Secretary of Health and 14 Human Services shall promulgate regulations based on the 15 input gathered pursuant to subsection (f)(2)(A). 16 TITLE IV\u2014MEDICAID, MEDI-17 CARE, AND OTHER REFORMS 18 Subtitle A\u2014Medicaid and Medicare 19 Reforms 20 SEC. 4001. LIMITING FEDERAL MEDICAID REIMBURSEMENT 21 TO STATES FOR DURABLE MEDICAL EQUIP- 22 MENT (DME) TO MEDICARE PAYMENT RATES. 23 (a) M EDICAID REIMBURSEMENT .\u2014 24 VerDate Nov 24 2008 11:47 Jul I N GENERAL .\u2014Section 1903(i) of the Social 1 Security Act (42 U.S.C. 1396b(i)) is amended\u2014 2 (A) in paragraph (25), by striking ''or'' at 3 the end; 4 (B) in paragraph (26), by striking the pe- 5 riod at the end and inserting ''; or''; and 6 (C) by inserting after paragraph (26) the 7 following new paragraph: 8 ''(27) with respect to any amounts expended by 9 the State on the basis of a fee schedule for items de- 10 scribed in section 1861(n), as determined in the ag- 11 gregate with respect to each class of such items as 12 defined by the Secretary, in excess of the aggregate 13 amount, if any, that would be paid for such items 14 within such class on a fee-for-service basis under the 15 program under part B of title XVIII, including, as 16 applicable, under a competitive acquisition program 17 under section 1847 in an area of the State.''. 18 (2) E FFECTIVE DATE .\u2014The amendments made 19 by this subsection shall be effective with respect to 20 payments for items furnished on or after January 1, 21 2020. 22 (b) M EDICARE OMBUDSMAN .\u2014Section 1808(c) of the 23 Social Security Act (42 U.S.C. 1395b(c)), as amended by 24 VerDate Nov 24 2008 11:47 Jul 02, section 3101, is further amended by adding at the end 1 the following new paragraph: 2 ''(5) M ONITORING DME REIMBURSEMENT 3 UNDER MEDICAID .\u2014The ombudsmen under each of 4 paragraphs (1) and (4) shall evaluate the impact of 5 the competitive acquisition program under section 6 1847, including as applied under section 7 1903(i)(27), on beneficiary health status and health 8 outcomes.''. 9 SEC. 4002. EXCLUDING AUTHORIZED GENERICS FROM CAL-10 CULATION OF AVERAGE MANUFACTURER 11 PRICE. 12 (a) I NGENERAL .\u2014Subparagraph (C) of section 13 1927(k)(1) of the Social Security Act (42 U.S.C. 1396r- 14 8(k)(1)) is amended\u2014 15 (1) in the subparagraph heading, by striking 16 ''INCLUSION '' and inserting ''E XCLUSION ''; 17 (2) by striking ''a new drug application'' and 18 inserting ''the manufacturer's new drug applica- 19 tion''; and 20 (3) by striking ''inclusive'' and inserting ''exclu- 21 sive''. 22 (b) E FFECTIVE DATE.\u2014The amendments made by 23 this section take effect on October 1, 2015. 24 VerDate Nov 24 2008 11:47 Jul 02, MEDICARE PAYMENT INCENTIVE FOR THE TRAN-1 SITION FROM TRADITIONAL X-RAY IMAGING 2 TO DIGITAL RADIOGRAPHY AND OTHER 3 MEDICARE IMAGING PAYMENT PROVISION. 4 (a) P HYSICIAN FEESCHEDULE .\u2014 5 (1) P AYMENT INCENTIVE FOR TRANSITION .\u2014 6 (A) I N GENERAL .\u2014Section 1848(b) of the 7 Social Security Act (42 U.S.C. 1395w-4(b)) is 8 amended by adding at the end the following 9 new paragraph: 10 ''(9) S PECIAL RULE TO INCENTIVIZE TRANSI - 11 TION FROM TRADITIONAL X -RAY IMAGING TO DIG - 12 ITAL RADIOGRAPHY .\u2014 13 ''(A) L IMITATION ON PAYMENT FOR FILM 14 X-RAY IMAGING SERVICES .\u2014In the case of an 15 imaging service (including the imaging portion 16 of a service) that is an X-ray taken using film 17 and that is furnished during 2017 or a subse- 18 quent year, the payment amount for the tech- 19 nical component (including the technical compo- 20 nent portion of a global service) of such service 21 that would otherwise be determined under this 22 section (without application of this paragraph 23 and before application of any other adjustment 24 under this section) for such year shall be re- 25 duced by 20 percent. 26 VerDate Nov 24 2008 11:47 Jul 02, FOR COMPUTED RADIOGRAPHY IMAGING SERV - 2 ICES.\u2014In the case of an imaging service (in- 3 cluding the imaging portion of a service) that is 4 an X-ray taken using computed radiography 5 technology\u2014 6 ''(i) in the case of such a service fur- 7 nished during 2018, 2019, 2020, 2021, or 8 2022, the payment amount for the tech- 9 nical component (including the technical 10 component portion of a global service) of 11 such service that would otherwise be deter- 12 mined under this section (without applica- 13 tion of this paragraph and before applica- 14 tion of any other adjustment under this 15 section) for such year shall be reduced by 16 7 percent; and 17 ''(ii) in the case of such a service fur- 18 nished during 2023 or a subsequent year, 19 the payment amount for the technical com- 20 ponent (including the technical component 21 portion of a global service) of such service 22 that would otherwise be determined under 23 this section (without application of this 24 paragraph and before application of any 25 VerDate Nov 24 2008 11:47 Jul 02, 328 other adjustment under this section) for 1 such year shall be reduced by 10 percent. 2 ''(C) C OMPUTED RADIOGRAPHY TECH - 3 NOLOGY DEFINED .\u2014For purposes of this para- 4 graph, the term 'computed radiography tech- 5 nology' means cassette-based imaging which 6 utilizes an imaging plate to create the image in- 7 volved. 8 ''(D) I MPLEMENTATION .\u2014In order to im- 9 plement this paragraph, the Secretary shall 10 adopt appropriate mechanisms which may in- 11 clude use of modifiers.''. 12 (B) E XEMPTION FROM BUDGET NEU - 13 TRALITY .\u2014Section 1848(c)(2)(B)(v) of the So- 14 cial Security Act (42 U.S.C. 1395w- 15 4(c)(2)(B)(v)) is amended by adding at the end 16 the following new subclause: 17 ''(X) R EDUCED EXPENDITURES 18 ATTRIBUTABLE TO INCENTIVES TO 19 TRANSITION TO DIGITAL RADIOG - 20 RAPHY .\u2014Effective for fee schedules 21 established beginning with 2017, re- 22 duced expenditures attributable to 23 subparagraph (A) of subsection (b)(9) 24 and effective for fee schedules estab- 25 VerDate Nov 24 2008 11:47 Jul beginning with 2018, reduced 1 expenditures attributable to subpara- 2 graph (B) of such subsection.''. 3 (2) E LIMINATION OF APPLICATION OF MUL - 4 TIPLE PROCEDURE PAYMENT REDUCTION .\u2014 5 (A) I N GENERAL .\u2014Section 1848(b)(4) of 6 the Social Security Act (42 U.S.C. 1395w- 7 4(b)(4)) is amended by adding at the end the 8 following new subparagraph: 9 ''(E) E LIMINATION OF APPLICATION OF 10 MULTIPLE PROCEDURE PAYMENT REDUC - 11 TION .\u2014 12 ''(i) I N GENERAL .\u2014For services fur- 13 nished on or after January 1, 2017, the 14 Secretary shall not apply a multiple proce- 15 dure payment reduction to the professional 16 component of imaging services unless the 17 Secretary has published as part of a Medi- 18 care Physician Fee Schedule Proposed 19 Rule the empirical analysis described in 20 clause (ii) with tables made available on 21 the website of the Centers for Medicare & 22 Medicaid Services. 23 ''(ii) E MPIRICAL ANALYSIS DE - 24 SCRIBED .\u2014The empirical analysis de- 25 VerDate Nov 24 2008 scribed in this clause is an analysis of the 1 Resource-Based Relative Value Scale Data 2 Manager information or other information 3 that is used to determine what, if any, effi- 4 ciencies exist within the professional com- 5 ponent of imaging services when two or 6 more studies are furnished to the same in- 7 dividual on the same day. Such empirical 8 analysis shall include\u2014 9 ''(I) information detailing which 10 physician work activities overlap and 11 the reductions applicable to such over- 12 lap; 13 ''(II) a discussion of the clinical 14 aspects that informed the assignment 15 of the reduction percentages described 16 in subclause (I); 17 ''(III) to the extent that such re- 18 ductions are used for proposed pay- 19 ment reductions, an explanation of 20 how the percentage reductions for pre- 21 service, intra-service, and post-service 22 work were determined and calculated; 23 ''(IV) other data used to deter- 24 mine a reduction; and 25 VerDate Nov 24 2008 11:47 Jul ''(V) a demonstration that the 1 Secretary has consulted with prac- 2 ticing radiologists to gain knowledge 3 of how radiologists interpret studies of 4 multiple body parts on the same indi- 5 vidual on the same day.''. 6 (B) C ONFORMING AMENDMENT .\u2014Section 7 220(i) of the Protecting Access to Medicare Act 8 of 2014 (42 U.S.C. 1395w-4 note) is repealed. 9 (b) P AYMENT INCENTIVE FOR TRANSITION UNDER 10 HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYS- 11 TEM.\u2014Section 1833(t)(16) of the Social Security Act (42 12 U.S.C. 1395(t)(16)) is amended by adding at the end the 13 following new subparagraph: 14 ''(F) P AYMENT INCENTIVE FOR THE TRAN - 15 SITION FROM TRADITIONAL X -RAY IMAGING TO 16 DIGITAL RADIOGRAPHY .\u2014Notwithstanding the 17 previous provisions of this subsection: 18 ''(i) L IMITATION ON PAYMENT FOR 19 FILM X -RAY IMAGING SERVICES .\u2014In the 20 case of an imaging service that is an X-ray 21 taken using film and that is furnished dur- 22 ing 2017 or a subsequent year, the pay- 23 ment amount for such service (including 24 the X-ray component of a packaged serv- 25 VerDate Nov 24 2008 11:47 Jul ice) that would otherwise be determined 1 under this section (without application of 2 this paragraph and before application of 3 any other adjustment under this sub- 4 section) for such year shall be reduced by 5 20 percent. 6 ''(ii) P HASED -IN LIMITATION ON PAY - 7 MENT FOR COMPUTED RADIOGRAPHY IM - 8 AGING SERVICES .\u2014In the case of an imag- 9 ing service that is an X-ray taken using 10 computed radiography technology (as de- 11 fined in section 1848(b)(9)(C))\u2014 12 ''(I) in the case of such a service 13 furnished during 2018, 2019, 2020, 14 2021, or 2022, the payment amount 15 for such service (including the X-ray 16 component of a packaged service) that 17 would otherwise be determined under 18 this section (without application of 19 this paragraph and before application 20 of any other adjustment under this 21 subsection) for such year shall be re- 22 duced by 7 percent; and 23 ''(II) in the case of such a service 24 furnished during 2023 or a subse- 25 VerDate Nov 24 2008 11:47 Jul quent year, the payment amount for 1 such service (including the X-ray com- 2 ponent of a packaged service) that 3 would otherwise be determined under 4 this section (without application of 5 this paragraph and before application 6 of any other adjustment under this 7 subsection) for such year shall be re- 8 duced by 10 percent. 9 ''(iii) A PPLICATION WITHOUT REGARD 10 TO BUDGET NEUTRALITY .\u2014The reductions 11 made under this paragraph\u2014 12 ''(I) shall not be considered an 13 adjustment under paragraph (2)(E); 14 and 15 ''(II) shall not be implemented in 16 a budget neutral manner. 17 ''(iv) I MPLEMENTATION .\u2014In order to 18 implement this subparagraph, the Sec- 19 retary shall adopt appropriate mechanisms 20 which may include use of modifiers.''. 21 SEC. 4004. TREATMENT OF INFUSION DRUGS FURNISHED 22 THROUGH DURABLE MEDICAL EQUIPMENT. 23 Section 1842(o)(1) of the Social Security Act (42 24 U.S.C. 1395u(o)(1)) is amended\u2014 25 VerDate Nov 24 2008 subparagraph (C), by inserting ''(and in- 1 cluding a drug or biological described in subpara- 2 graph (D)(i) furnished on or after January 1, 3 2017)'' after ''2005''; and 4 (2) in subparagraph (D)\u2014 5 (A) by striking ''infusion drugs'' and in- 6 serting ''infusion drugs or biologicals'' each 7 place it appears; and 8 (B) in clause (i)\u2014 9 (i) by striking ''2004'' and inserting 10 ''2004, and before January 1, 2017''; and 11 (ii) by striking ''for such drug''. 12 SEC. 4005. EXTENSION AND EXPANSION OF PRIOR AUTHOR-13 IZATION FOR POWER MOBILITY DEVICES 14 (PMDS) AND ACCESSORIES AND PRIOR AU- 15 THORIZATION AUDIT LIMITATIONS. 16 Section 1834(a) of the Social Security Act (42 U.S.C. 17 1395m(a)) is amended\u2014 18 (1) in paragraph (15), by adding at the end the 19 following new subparagraph: 20 ''(D) L IMITATION ON AUDITS AFTER AD - 21 VANCE DETERMINATION .\u2014A claim for an item 22 that has received a provisional affirmation 23 under an advance determination under this 24 paragraph or a prior authorization under para- 25 VerDate Nov 24 2008 11:47 Jul 335 graph (23) shall not be subject to review under 1 section 1893(h) but may be subject to audits 2 for potential fraud, inappropriate utilization, 3 changes in billing patterns, or information that 4 could not have been considered during the ad- 5 vance determination (such as proof of item de- 6 livery).''; and 7 (2) by adding at the end the following new 8 paragraph: 9 ''(23) P RIOR AUTHORIZATION FOR POWER MO - 10 BILITY DEVICES (PMDS) AND ACCESSORIES .\u2014Not 11 later than 90 days after the date of the enactment 12 of this paragraph, the Secretary shall, using funds 13 provided under paragraph (2) of section 402(a) of 14 the Social Security Amendments of 1967 and other 15 funds available to the Secretary\u2014 16 ''(A) extend at least through August 31, 17 2018, the PMD Prior Authorization Dem- 18 onstration (being conducted under paragraph 19 (1)(J) of such section); 20 ''(B) begin to expand, as appropriate, such 21 demonstration to include additional power mo- 22 bility devices and accessories as part of initial 23 claims for payment under this part for such de- 24 vices; and 25 VerDate Nov 24 2008 11:47 ''(C) begin to expand such demonstration 1 to such additional States or geographic areas as 2 may be appropriate.''. 3 SEC. 4006. CIVIL MONETARY PENALTIES FOR VIOLATIONS 4 RELATED TO GRANTS, CONTRACTS, AND 5 OTHER AGREEMENTS. 6 (a) I NGENERAL .\u2014Section 1128A of the Social Secu- 7 rity Act (42 U.S.C. 1320a-7a) is amended by adding at 8 the end the following new subsection: 9 ''(o) Any person (including an organization, agency, 10 or other entity, but excluding a program beneficiary, as 11 defined in subsection (r)(4)) that, with respect to a grant, 12 contract, or other agreement for which the Secretary of 13 Health and Human Services provides funding\u2014 14 ''(1) knowingly presents or causes to be pre- 15 sented a specified claim (as defined in subsection 16 (r)(6)) under such grant, contract, or other agree- 17 ment that the person knows or should know is false 18 or fraudulent; 19 ''(2) knowingly makes, uses, or causes to be 20 made or used any false statement, omission, or mis- 21 representation of a material fact in any application, 22 proposal, bid, progress report, or other document 23 that is required to be submitted in order to directly 24 or indirectly receive or retain funds provided in 25 VerDate Nov 24 2008 11:47 Jul 02, 337 whole or in part by such Secretary pursuant to such 1 grant, contract, or other agreement; 2 ''(3) knowingly makes, uses, or causes to be 3 made or used, a false record or statement material 4 to a false or fraudulent specified claim under such 5 grant, contract, or other agreement; 6 ''(4) knowingly makes, uses, or causes to be 7 made or used, a false record or statement material 8 to an obligation to pay or transmit funds or property 9 to such Secretary with respect to such grant, con- 10 tract, or other agreement, or knowingly conceals or 11 knowingly and improperly avoids or decreases an ob- 12 ligation to pay or transmit funds or property to such 13 Secretary with respect to such grant, contract, or 14 other agreement; or 15 ''(5) fails to grant timely access, upon reason- 16 able request (as defined by such Secretary in regula- 17 tions), to the Inspector General of the Department, 18 for the purpose of audits, investigations, evaluations, 19 or other statutory functions of such Inspector Gen- 20 eral in matters involving such grants, contracts, or 21 other agreements; 22 shall be subject, in addition to any other penalties that 23 may be prescribed by law, to a civil money penalty in cases 24 under paragraph (1), of not more than $10,000 for each 25 VerDate Nov 24 2008 11:47 Jul specified claim; in cases under paragraph (2), not more 1 than $50,000 for each false statement, omission, or mis-2 representation of a material fact; in cases under para-3 graph (3), not more than $50,000 for each false record 4 or statement; in cases under paragraph (4), not more than 5 $50,000 for each false record or statement or $10,000 for 6 each day that the person knowingly conceals or knowingly 7 and improperly avoids or decreases an obligation to pay; 8 or in cases under paragraph (5), not more than $15,000 9 for each day of the failure described in such paragraph. 10 In addition, in cases under paragraphs (1) and (3), such 11 a person shall be subject to an assessment of not more 12 than 3 times the amount claimed in the specified claim 13 described in such paragraph in lieu of damages sustained 14 by the United States or a specified State agency because 15 of such specified claim, and in cases under paragraphs (2) 16 and (4), such a person shall be subject to an assessment 17 of not more than 3 times the total amount of the funds 18 described in paragraph (2) or (4), respectively (or, in the 19 case of an obligation to transmit property to the Secretary 20 Health and Human Services described in paragraph (4), 21 of the value of the property described in such paragraph) 22 in lieu of damages sustained by the United States or a 23 specified State agency because of such case. In addition, 24 the Secretary of Health and Human Services may make 25 VerDate Nov 24 2008 11:47 Jul 02, 339 a determination in the same proceeding to exclude the per-1 son from participation in the Federal health care pro-2 grams (as defined in section 1128B(f)(1)) and to direct 3 the appropriate State agency to exclude the person from 4 participation in any State health care program. 5 ''(p) The provisions of subsections (c), (d), and (g) 6 shall apply to a civil money penalty or assessment under 7 subsection (o) in the same manner as such provisions 8 apply to a penalty, assessment, or proceeding under sub-9 section (a). 10 ''(q) With respect to a penalty or assessment under 11 subsection (o), the Inspector General of the Department 12 is authorized to receive, and to retain for current use, such 13 amounts of such penalty or assessment as are necessary 14 to provide reimbursement for the costs of conducting in-15 vestigations and audits with respect to such subsection 16 and for monitoring compliance plans with respect to such 17 subsection when such penalty or assessment is ordered by 18 a court, voluntarily agreed to by the payor, or otherwise. 19 Funds received by such Inspector General as reimburse-20 ment under the preceding sentence shall be deposited to 21 the credit of the appropriations from which initially paid, 22 or to appropriations for similar purposes currently avail-23 able at the time of deposit, and shall remain available for 24 VerDate Nov 24 2008 11:47 Jul 02, 340 obligation for 1 year from the date of the deposit of such 1 funds. 2 ''(r) For purposes of this subsection and subsections 3 (o), (p), and (q): 4 ''(1) The term 'Department' means the Depart- 5 ment of Health and Human Services. 6 ''(2) The term 'material' means having a nat- 7 ural tendency to influence, or be capable of influ- 8 encing, the payment or receipt of money or property. 9 ''(3) The term 'other agreement' includes a co- 10 operative agreement, scholarship, fellowship, loan, 11 subsidy, payment for a specified use, donation agree- 12 ment, award, or sub-award (regardless of whether 13 one or more of the persons entering into the agree- 14 ment is a contractor or sub-contractor). 15 ''(4) The term 'program beneficiary' means, in 16 the case of a grant, contract, or other agreement de- 17 signed to accomplish the objective of awarding or 18 otherwise furnishing benefits or assistance to indi- 19 viduals and for which the Secretary of Health and 20 Human Services provides funding, an individual who 21 applies for, or who receives, such benefits or assist- 22 ance from such grant, contract, or other agreement. 23 Such term does not include, with respect to such 24 grant, contract, or other agreement, an officer, em- 25 VerDate Nov 24 2008 11:47 Jul agent of a person or entity that receives 1 such grant or that enters into such contract or other 2 agreement. 3 ''(5) The term 'recipient' includes a sub-recipi- 4 ent or subcontractor. 5 ''(6) The term 'specified claim' means any ap- 6 plication, request, or demand under a grant, con- 7 tract, or other agreement for money or property, 8 whether or not the United States or a specified 9 State agency has title to the money or property, that 10 is not a claim (as defined in subsection (i)(2)) and 11 that\u2014 12 ''(A) is presented or caused to be pre- 13 sented to an officer, employee, or agent of the 14 Department or agency thereof, or of any speci- 15 fied State agency; or 16 ''(B) is made to a contractor, grantee, or 17 any other recipient if the money or property is 18 to be spent or used on the Department's behalf 19 or to advance a Department program or inter- 20 est, and if the Department\u2014 21 ''(i) provides or has provided any por- 22 tion of the money or property requested or 23 demanded; or 24 VerDate Nov 24 2008 11:47 Jul will reimburse such contractor, 1 grantee or other recipient for any portion 2 of the money or property which is re- 3 quested or demanded. 4 ''(7) The term 'specified State agency' means 5 an agency of a State government established or des- 6 ignated to administer or supervise the administra- 7 tion of a grant, contract, or other agreement funded 8 in whole or in part by the Secretary of Health and 9 Human Services. 10 ''(s) For purposes of subsection (o), the term 'obliga- 11 tion' means an established duty, whether or not fixed, aris-12 ing from an express or implied contractual, grantor-grant-13 ee, or licensor-licensee relationship, for a fee-based or 14 similar relationship, from statute or regulation, or from 15 the retention of any overpayment.''. 16 (b) C ONFORMING AMENDMENTS .\u2014Section 1128A of 17 the Social Security Act (42 U.S.C. 1320a-7a) is amend-18 ed\u2014 19 (1) in subsection (d)\u2014 20 (A) in paragraph (1), by inserting ''or 21 specified claims'' after ''claims''; 22 (B) in paragraph (2), by inserting ''or 23 specified claims'' after ''claims''; 24 VerDate Nov 24 2008 11:47 (e), by inserting ''or specified 1 claim'' after ''claim''; and 2 (3) in subsection (f)\u2014 3 (A) by inserting ''or specified claim (as de- 4 fined in subsection (r)(6))'' after ''district 5 where the claim''; 6 (B) by inserting ''(or, with respect to a 7 person described in subsection (o), the person)'' 8 after ''claimant''; 9 (C) by inserting ''that are not received by 10 the Inspector General of the Department of 11 Health and Human Services under subsection 12 (q) as reimbursement'' after ''amounts recov- 13 ered''; and 14 (D) by inserting ''(or, in the case of a pen- 15 alty or assessment under subsection (o), by a 16 specified State agency (as defined in subsection 17 (r)(7))'' after ''or a State agency''. 18 Subtitle B\u2014Other Reforms 19 SEC. 4041. SPR DRAWDOWN. 20 (a) D RAWDOWN AND SALE.\u2014Notwithstanding sec- 21 tion 161 of the Energy Policy and Conservation Act (42 22 U.S.C. 6241), except as provided in subsection (b) the 23 Secretary of Energy shall draw down and sell\u2014 24 VerDate Nov 24 2008 11:47 Jul (1) 4,000,000 barrels of crude oil from the 1 Strategic Petroleum Reserve during fiscal year 2 2018; 3 (2) 5,000,000 barrels of crude oil from the 4 Strategic Petroleum Reserve during fiscal year 5 2019; 6 (3) 8,000,000 barrels of crude oil from the 7 Strategic Petroleum Reserve during fiscal year 8 2020; 9 (4) 8,000,000 barrels of crude oil from the 10 Strategic Petroleum Reserve during fiscal year 11 2021; 12 (5) 10,000,000 barrels of crude oil from the 13 Strategic Petroleum Reserve during fiscal year 14 2022; 15 (6) 15,000,000 barrels of crude oil from the 16 Strategic Petroleum Reserve during fiscal year 17 2023; 18 (7) 15,000,000 barrels of crude oil from the 19 Strategic Petroleum Reserve during fiscal year 20 2024; and 21 (8) 15,000,000 barrels of crude oil from the 22 Strategic Petroleum Reserve during fiscal year 23 2025. 24 VerDate Nov 24 2008 11:47 Jul Amounts received for a sale under this subsection shall 1 be deposited in the General Fund of the Treasury during 2 the fiscal year in which the sale occurs. 3 (b) E MERGENCY PROTECTION .\u2014The Secretary shall 4 not draw down and sell crude oil under this section in 5 amounts that would result in a Strategic Petroleum Re-6 serve that contains an inventory of petroleum products 7 representing less than 90 days of emergency reserves, 8 based on the average daily level of net imports of crude 9 oil and petroleum products in the previous calendar year. 10 (c) P ROCEEDS .\u2014Proceeds from a sale under this sec- 11 tion shall be deposited into the general fund of the Treas-12 ury of the United States. 13 Subtitle C\u2014Miscellaneous 14 SEC. 4061. LYME DISEASE AND OTHER TICK-BORNE DIS-15 EASES. 16 (a) I NGENERAL .\u2014Title III of the Public Health 17 Service Act (42 U.S.C. 241 et seq.) is amended by adding 18 at the end the following new part: 19 ''PART W\u2014LYME DISEASE AND OTHER TICK- 20 BORNE 21 ''SEC. 399OO. RESEARCH. 22 ''(a) I NGENERAL .\u2014The Secretary shall conduct or 23 support epidemiological, basic, translational, and clinical 24 VerDate Nov 24 2008 11:47 Jul Lyme disease and other tick-borne dis-1 eases. 2 ''(b) B IENNIAL REPORTS .\u2014The Secretary shall en- 3 sure that each biennial report under section 403 includes 4 information on actions undertaken by the National Insti-5 tutes of Health to carry out subsection (a) with respect 6 to Lyme disease and other tick-borne diseases, including 7 an assessment of the progress made in improving the out-8 comes of Lyme disease and such other tick-borne diseases. 9 ''SEC. 399OO-1. WORKING GROUP. 10 ''(a) E STABLISHMENT .\u2014The Secretary shall estab- 11 lish a permanent working group, to be known as the Inter-12 agency Lyme and Tick-Borne Disease Working Group (in 13 this section and section 399OO-2 referred to as the 14 'Working Group'), to review all efforts within the Depart-15 ment of Health and Human Services concerning Lyme dis-16 ease and other tick-borne diseases to ensure interagency 17 coordination, minimize overlap, and examine research pri-18 orities. 19 ''(b) R ESPONSIBILITIES .\u2014The Working Group 20 shall\u2014 21 ''(1) not later than 24 months after the date of 22 enactment of this part, and every 24 months there- 23 after, develop or update a summary of\u2014 24 VerDate Nov 24 2008 11:47 Jul ongoing Lyme disease and other tick- 1 borne disease research related to causes, pre- 2 vention, treatment, surveillance, diagnosis, 3 diagnostics, duration of illness, intervention, 4 and access to services and supports for individ- 5 uals with Lyme disease or other tick-borne dis- 6 eases; 7 ''(B) advances made pursuant to such re- 8 search; 9 ''(C) the engagement of the Department of 10 Health and Human Services with persons that 11 participate at the public meetings required by 12 paragraph (5); and 13 ''(D) the comments received by the Work- 14 ing Group at such public meetings and the Sec- 15 retary's response to such comments; 16 ''(2) ensure that a broad spectrum of scientific 17 viewpoints is represented in each such summary; 18 ''(3) monitor Federal activities with respect to 19 Lyme disease and other tick-borne diseases; 20 ''(4) make recommendations to the Secretary 21 regarding any appropriate changes to such activities; 22 and 23 ''(5) ensure public input by holding annual pub- 24 lic meetings that address scientific advances, re- 25 VerDate Nov 24 2008 11:47 Jul 02, search questions, surveillance activities, and emerg- 1 ing strains in species of pathogenic organisms. 2 ''(c) M EMBERSHIP .\u2014 3 ''(1) I N GENERAL .\u2014The Working Group shall 4 be composed of a total of 14 members as follows: 5 ''(A) F EDERAL MEMBERS .\u2014Seven Federal 6 members, consisting of one or more representa- 7 tives of each of\u2014 8 ''(i) the Office of the Assistant Sec- 9 retary for Health; 10 ''(ii) the Food and Drug Administra- 11 tion; 12 ''(iii) the Centers for Disease Control 13 and Prevention; 14 ''(iv) the National Institutes of 15 Health; and 16 ''(v) such other agencies and offices of 17 the Department of Health and Human 18 Services as the Secretary determines ap- 19 propriate. 20 ''(B) N ON-FEDERAL PUBLIC MEMBERS .\u2014 21 Seven non-Federal public members, consisting 22 of representatives of the following categories: 23 ''(i) Physicians and other medical pro- 24 viders with experience in diagnosing and 25 VerDate Nov 24 2008 11:47 Jul 02, Lyme disease and other tick-borne 1 diseases. 2 ''(ii) Scientists or researchers with ex- 3 pertise. 4 ''(iii) Patients and their family mem- 5 bers. 6 ''(iv) Nonprofit organizations that ad- 7 vocate for patients with respect to Lyme 8 disease and other tick-borne diseases. 9 ''(v) Other individuals whose expertise 10 is determined by the Secretary to be bene- 11 ficial to the functioning of the Working 12 Group. 13 ''(2) A PPOINTMENT .\u2014The members of the 14 Working Group shall be appointed by the Secretary, 15 except that of the non-Federal public members 16 under paragraph (1)(B)\u2014 17 ''(A) one shall be appointed by the Speaker 18 of the House of Representatives; and 19 ''(B) one shall be appointed by the major- 20 ity leader of the Senate. 21 ''(3) D IVERSITY OF SCIENTIFIC PERSPEC - 22 TIVES .\u2014In making appointments under paragraph 23 (2), the Secretary, the Speaker of the House of Rep- 24 resentatives, and the majority leader of the Senate 25 VerDate Nov 24 2008 11:47 Jul 02, shall ensure that the non-Federal public members of 1 the Working Group represent a diversity of scientific 2 perspectives. 3 ''(4) T ERMS .\u2014The non-Federal public members 4 of the Working Group shall each be appointed to 5 serve a 4-year term and may be reappointed at the 6 end of such term. 7 ''(d) M EETINGS .\u2014The Working Group shall meet as 8 often as necessary, as determined by the Secretary, but 9 not less than twice each year. 10 ''(e) A PPLICABILITY OF FACA.\u2014The Working Group 11 shall be treated as an advisory committee subject to the 12 Federal Advisory Committee Act. 13 ''(f) R EPORTING .\u2014Not later than 24 months after 14 the date of enactment of this part, and every 24 months 15 thereafter, the Working Group\u2014 16 ''(1) shall submit a report on its activities, in- 17 cluding an up-to-date summary under subsection 18 (b)(1) and any recommendations under subsection 19 (b)(4), to the Secretary, the Committee on Energy 20 and Commerce of the House of Representatives, and 21 the Committee on Health, Education, Labor and 22 Pensions of the Senate; 23 VerDate Nov 24 2008 11:47 Jul shall make each such report publicly avail- 1 able on the website of the Department of Health and 2 Human Services; and 3 ''(3) shall allow any member of the Working 4 Group to include in any such report minority views. 5 ''SEC. 399OO-2. STRATEGIC PLAN. 6 ''Not later than 3 years after the date of enactment 7 of this section, and every 5 years thereafter, the Secretary 8 shall submit to the Congress a strategic plan, informed 9 by the most recent summary under section 399OO- 10 1(b)(1), for the conduct and support of Lyme disease and 11 tick-borne disease research, including\u2014 12 ''(1) proposed budgetary requirements; 13 ''(2) a plan for improving outcomes of Lyme 14 disease and other tick-borne diseases, including 15 progress related to chronic or persistent symptoms 16 and chronic or persistent infection and co-infections; 17 ''(3) a plan for improving diagnosis, treatment, 18 and prevention; 19 ''(4) appropriate benchmarks to measure 20 progress on achieving the improvements described in 21 paragraphs (2) and (3); and 22 ''(5) a plan to disseminate each summary under 23 section 399OO-1(b)(1) and other relevant informa- 24 tion developed by the Working Group to the public, 25 VerDate Nov 24 2008 11:47 Jul 02, health care providers, public health depart- 1 ments, and other relevant medical groups.''. 2 (b) N OADDITIONAL AUTHORIZATION OF APPRO - 3 PRIATIONS .\u2014No additional funds are authorized to be ap- 4 propriated for the purpose of carrying out this section and 5 the amendment made by this section, and this section and 6 such amendment shall be carried out using amounts other-7 wise available for such purpose. 8 VerDate Nov 24 2008 11:47 Jul 02, "}